llIIlIlllIlIlIllIlIllIllIllIIlIlllIllIIlllIIlIlllIlIIlllIIlllllIIlIIllIllIlIIIIIIIIIIIIIII 
US 20100166768A1 
119) United States 
112) Patent Application Publication 110) Pub. No. : US 2010/0166768 A1 
Sleeman et al. 143) Pub. Date: Jul. 1, 2010 
154) HIGH AFFINITY HUMAN ANTIBODIES TO 
PCSK9 
175) Inventors: Mark W. Sleeman, Mahopac, NY 
1US); Joel H. Martin, Putnam 
Valley, NY 1US); Tammy T. 
Huang, Goldens Bridge, NY 1US); 
Douglas MacDonald, New York, 
NY (US) 
122) Filed: Dec. 15, 2009 
Related U. S. Application Data 
160) Provisional application No. 61/122, 482, filed on Dec. 
15, 2008, provisional application No. 61/210, 566, 
filed on Mar. 18, 2009, provisional application No. 
Correspondence Address: 
REGENERON PHARMACEUTICALS, INC 
777 OLD SAW MILL RIVER ROAD 
TARRYTOWN, NY 10591 (US) 
173) Assignee: Regeneron Pharmaceuticals, Inc. , 
Tarrytown, NY 1US) 
121) Appl. No. : 12/637, 942 
61/168, 753, filed on Apr. 13, 2009, provisional appli- 
cation No. 61/218, 136, filed on Jun. 18, 2009, provi- 
sional application No. 61/249, 135, filed on Oct. 6, 
2009, provisional application No. 61/261, 776, filed on 
Nov. 17, 2009. 
Publication Classification 
151) Int. Cl. 
261K 39/395 
C07K 16/40 
C07H 21/04 
C12N 15/63 
C12P 21/06 
152) U. S. Cl. . . . . . . . . . . . . 
12006. 01) 
12006. 01) 
12006. 01) 
12006. 01) 
12006. 01) 
. . . 424/158. 1; 530/387. 1; 530/387. 9; 
536/23. 53; 435/320. 1; 435/69. 6 
157) ABSTRACT 
An human antibody or antigen-binding fragment of a human 
antibody that specifically binds and inhibits human propro- 
tein convertase subtilisin/kexin type 9 1hPCSK9) character- 
ized by the ability to reduce serum LDL cholesterol by 
40-80'/0 over a 24, 60 or 90 day period relative to predose 
levels, with little or no reduction in serum HDL cholesterol 
and/or with little or no measurable effect on liver function, as 
determined by ALT and AST measurements. 
Patent Application Publication Jul. 1, 2010 Sheet 1 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 2 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 3 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 4 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 5 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 6 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 7 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 8 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 9 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 10 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 11 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 12 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 13 of 14 US 2010/0166768 A1 
Patent Application Publication Jul. 1, 2010 Sheet 14 of 14 US 2010/0166768 A1 
US 2010/0166768 A1 JU1. 1, 2010 
HIGH AFFINITY HUMAN ANTIBODIES TO 
PCSK9 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
[0001] This application claims the benefit under 35 USC 
)119(e) of U. S. Provisional 61/261, 776 filed 17 Nov. 2009, 
61/249, 135 filed 6 Oct. 2009, 61/218, 136 filed 18 Jun. 2009, 
61/168, 753 filed 13 Apr. 2009, 61/210, 566 filed 18 Mar. 2009 
and 61/1229, 482 filed 15 Dec. 2008, which applications are 
herein specifically incorporated by reference in their entirety. 
FIELD OF THE INVENTION 
[0002] The present invention is related to human antibodies 
and antigen-binding fragments of human antibodies that spe- 
cifically bind human proprotein convertase subtilisin/kexin 
type 9 (PCSK9), and therapeutic methods of using those 
antibodies. 
SEQUENCE LISTING 
[0003] An ASCII compliant text file of the sequence listing 
is filed concurrently with the present specification (37 CFR 
)1. 52(e) and 37 CFR )1. 821). The contents of the text file are 
herein incorporated by reference. The text file containing the 
sequence listing is named "PCSK9 SeqList", was created on 
11 Dec. 2009, and contains approximately 418 kilobytes. 
STATEMENT OF RELATED ART 
[0004] Proprotein convertase subtilisin/kexin type 9 
(PCSK9) is a proprotein convertase belonging to the protein- 
ase K subfamily of the secretory subtilase family. The 
encoded protein is synthesized as a soluble zymogen that 
undergoes autocatalytic intramolecular processing in the 
endoplasmic reticulum. Evidence suggest that PCSK9 
increases plasma LDL cholesterol by promoting degradation 
of the LDL receptor, which mediates LDL endocytosis in the 
liver, the major route of LDL clearance from circulation. The 
structure of PCSK9 protein shows that it has a signal 
sequence, followed by a prodomain, a catalytic domain that 
contains a conserved triad of residues (D186, H226 and 
S386), and a C-terminal domain. It is synthesized as a soluble 
74-kDa precursor that undergoes autocatalytic cleavage in the 
ER, generating a 14-kDa prodomain and 60-kDa catalytic 
fragment. The autocatalytic activity has been shown to be 
required for secretion. After cleavage the prodomain remains 
tightly associated with the catalytic domain. 
[0005] Antibodies to PCSK9 are described in, for example, 
WO 2008/057457, WO 2008/057458, WO 2008/057459, 
WO 2008/063382, WO 2008/125623, and US 2008/0008697. 
BRIEF SUMMARY OF THE INVENTION 
[0006] In a first aspect, the invention provides fully human 
monoclonal antibodies (mAbs) and antigen-binding frag- 
ments thereof that specifically bind and neutralize human 
PCSK9 (hPCSK9) activity. 
[0007] In one embodiment, the invention comprises an 
antibody or antigen-binding fragment of an antibody that 
specifically binds hPCSK9 and is characterized by at least 
one of: 
[000S] (I) capable of reducing serum total cholesterol at 
least about 25-35% and sustaining the reduction over at least 
a 24 day period relative to a predose level, preferably the 
reduction in serum total cholesterol is at least about 30-40%; 
[0009] (ii) capable of reducing serum LDL cholesterol at 
least about 65-80% and sustaining the reduction over at least 
a 24 day period relative to a predose level; 
[0010] (fii) capable of reducing serum triglyceride at least 
about 25-40% relative to predose level; 
[0011] (iv) does not reduce serum HDL cholesterol or 
reduces serum HDL cholesterol no more than 5% relative to 
predose level. 
[0012] In one embodiment, the invention comprises an 
antibody or antigen-binding fragment of an antibody that 
specifically binds hPCSK9 and is characterized by at least 
one of: 
[0013] (I) capable of reducing serum LDL cholesterol at 
least about 40-70% and sustaining the reduction over at least 
a 60 or 90 day period relative to a predose level; 
[0014] (ii) capable of reducing serum triglyceride at least 
about 25-40% relative to predose level; 
[0015] (iii) does not reduce serum HDL cholesterol or 
reduces serum HDL cholesterol no more than 5% relative to 
predose level. 
[0016] In one embodiment, the antibody or antigen-binding 
fragment is characterized as binding an epitope comprising 
amino acid residue 238 of hPCSK9 (SEQ ID NO:755). In a 
more specific embodiment, the antibody or antigen-binding 
fragment binds an epitope comprising one or more of amino 
acid residue 238, 153, 159 and 343 of hPCSK9 (SEQ ID 
NO:755). ). In a more specific embodiment, the antibody or 
fragment thereof is characterized as binding an epitope which 
does not comprise an amino acid residue at position 192, 194, 
197 and/or 237 of SEQ ID NO:755. 
[0017] In one embodiment, the antibody or antigen-binding 
fragment is characterized as binding an epitope comprising 
amino acid residue 366 of hPCSK9 (SEQ ID NO:755). In a 
more specific embodiment, the antibody or antigen-binding 
fragment binds an epitope comprising one or more of amino 
acid residue at position 147, 366 and 380 of SEQ ID NO:755. 
In a more specific embodiment, the antibody or antigen- 
binding fragment of an antibody is characterized as binding 
an epitope which does not comprise an amino acid residue at 
position 215 or 238 of SEQ ID NO:755. 
[001S] In one embodiment, the antibody or antigen-binding 
fragment is characterized as exhibiting an enhanced binding 
affinity (K~) for hPCSK9 at pH 5. 5 relative to the K~ at pH 
7. 4, as measured by plasmon surface resonance. In a specific 
embodiment, the antibody or fragment thereof exhibits at 
least a 20- fold, at least a 40- fold or at least a 50-fold enhanced 
affinity for PCSK9 at an acidic pH relative to a neutral pH, as 
measured by surface plasmon resonance. 
[0019] In one embodiment, the antibody or antigen-binding 
fragment is characterized as not exhibiting an enhanced bind- 
ing affinity for PCSK9 at an acidic pH relative to a neutral pH, 
as measured by surface plasmon resonance. In a specific 
embodiment, the antibody or fragment thereof exhibits a 
decreased binding affinity at an acidic pH. 
[0020] In another embodiment, the antibody or antigen- 
binding fragment binds human, human GOF mutation 
D374Y, cynomolgus monkey, rhesus monkey, mouse, rat and 
hamster PCSK9. 
[0021] In one embodiment, the antibody or antigen-binding 
fragment binds human and monkey PCSK9, but does not bind 
mouse, rat or hamster PCSK9. 
US 2010/0166768 A1 JU1. 1, 2010 
[0022] The mAbs can be full-length (e. g. , an IgGI or IgG4 
antibody) or may comprise only an antigen-binding portion 
(e. g. , a Fab, F(ab')~ or scFv fragment), and may be modified 
to affect functionality, e. g. , to eliminate residual effector 
functions (Reddy et al. (2000) J. Immunol. 164:1925-1933). 
[0023] In one embodiment, the invention comprises an 
antibody or antigen-binding fragment of an antibody com- 
prising a heavy chain variable region (HCVR) selected from 
the group consisting of SEQ ID NO:2, 18, 22, 26, 42, 46, 50, 
66, 70, 74, 90, 94, 98, 114, 118, 122, 138, 142, 146, 162, 166, 
170, 186, 190, 194, 210, 214, 218, 234, 238, 242, 258, 262, 
266, 282, 286, 290, 306, 310, 314, 330, 334, 338, 354, 358, 
362, 378, 382, 386, 402, 406, 410, 426, 430, 434, 450, 454, 
458, 474, 478, 482, 498, 502, 506, 522, 526, 530, 546, 550, 
554, 570, 574, 578, 594, 598, 602, 618, 622, 626, 642, 646, 
650, 666, 670, 674, 690, 694, 698, 714, 718, 722, 7388nd742, 
or a substantially similar sequence thereof having at least 
90%, at least 95%, at least 98% or at least 99% sequence 
identity. In one embodiment, the HCVR comprises an amino 
acid sequence selected from the group consisting of SEQ ID 
NO:50, 66, 70, 74, 90, 94, 122, 138, 142, 218, 234, 238, 242, 
258, 262, 314, 330 and 334. In a more specific embodiment, 
the HCVR comprises SEQ ID NO:90 or 218. 
[0024] In one embodiment, the antibody or fragment 
thereof further comprises a light chain variable region 
(LCVR) selected from the group consisting of SEQ ID 
NO:10, 20, 24, 34, 44, 48, 58, 68, 72, 82, 92, 96, 106, 116, 
120, 130, 140, 144, 154, 164, 168, 178, 188, 192, 202, 212, 
216, 226, 236, 240, 250, 260, 264, 274, 284, 288, 298, 308, 
312, 322, 332, 336, 346, 356, 360, 370, 380, 384, 394, 404, 
408, 418, 428, 432, 442, 452, 456, 466, 476, 480, 490, 500, 
504, 514, 524, 528, 538, 548, 552, 562, 572, 576, 586, 596, 
600, 610, 620, 624, 634, 644, 648, 658, 668, 672, 682, 692, 
696, 706, 716, 720, 730, 740 and 744, or a substantially 
similar sequence thereof having at least 90%, at least 95%, at 
least 98% or at least 99% sequence identity. In one embodi- 
ment, the LCVR comprises an amino acid sequence selected 
from the group consisting of SEQ ID NO: 58, 68, 72, 82, 92, 
96, 130, 140, 144, 226, 236, 240, 250, 260, 264, 322, 332 and 
336. In a more specific embodiment, the LCVR comprises 
SEQ ID NO:92 or 226. 
[0025] In specific embodiments, the antibody or fragment 
thereof comprises a HCVR and LCVR (HCVR/LCVR) 
sequence pair selected from the group consisting of SEQ ID 
NO: 2/10, 18/20, 22/24, 26/34, 42/44, 46/48, 50/58, 66/68, 
70/72, 74/82, 90/92, 94/96, 98/106, 114/116, 118/120, 122/ 
130, 138/140, 142/144, 146/154, 162/164, 166/168, 170/178, 
186/188, 190/192, 194/202, 210/212, 214/216, 218/226, 234/ 
236, 238/240, 242/250, 258/260, 262/264, 266/274, 282/284, 
286/288, 290/298, 306/308, 310/312, 314/322, 330/332, 334/ 
336, 338/346, 354/356, 358/360, 362/370, 378/380, 382/384, 
386/394, 402/404, 406/408, 410/418, 426/428, 430/432, 434/ 
442, 450/452, 454/456, 458/466, 474/476, 478/480, 482/490, 
498/500, 502/504, 506/514, 522/524, 526/528, 530/538, 546/ 
548, 550/552, 554/562, 570/572, 574/576, 578/586, 594/596, 
598/600, 602/610, 618/620, 622/624, 626/634, 642/644, 646/ 
648, 650/658, 666/668, 670/672, 674/682, 690/692, 694/696, 
698/706, 714/716, 718/720, 722/730, 738/740 Bnd 742/744. 
In one embodiment, the HCVR and LCVR sequence pair 
comprises one of SEQ ID NO: 50/58, 66/68, 70/72, 74/82, 
90/92, 94/96, 122/130, 138/140, 142/144, 218/226, 234/236, 
238/240, 242/250, 258/260, 262/264, 314/322, 330/332 and 
334/336. In a more specific embodiment, the HCVR/LCVR 
pair comprises SEQ ID NO:90/92 or 218/226. 
[0026] In a second aspect, the invention features an anti- 
body or antigen-binding fragment of an antibody comprising 
a heavy chain CDR3 (HCDR3) domain selected from the 
group consisting of SEQ ID NO:8, 32, 56, 80, 104, 128, 152, 
176, 200, 224, 248, 272, 296, 320, 344, 368, 392, 416, 440, 
464, 488, 512, 536, 560, 584, 608, 632, 656, 680, 704 Bnd728, 
or a substantially similar sequence thereof having at least 
90%, at least 95%, at least 98% or at least 99% sequence 
identity; and a light chain CDR3 (LCDR3) domain selected 
from the group consisting of SEQ ID NO:16, 40, 64, 88, 112, 
136, 160, 184, 208, 232, 256, 280, 304, 328, 352, 376, 400, 
424, 448, 472, 496, 520, 544, 568, 592, 616, 640, 664, 688, 
712 and 736, or substantially similar sequences thereof hav- 
ing at least 90%, at least 95%, at least 98% or at least 99% 
sequence identity. In one embodiment, the HCDR3/LCDR3 
sequence pair is selected from the group consisting of SEQ ID 
NO:56/64, 80/88, 128/136, 224/232, 248/256 and 320/328. In 
a more specific embodiment, the HCDR3/LCDR3 sequence 
pair comprises SEQ ID NO: 80/88 or 224/232. 
[0027] In a further embodiment, the invention comprising 
an antibody or fragment thereof further comprising a heavy 
chain CDRI (HCDRI) domain selected from the group con- 
sisting of SEQ ID NO:4, 28, 52, 76, 100, 124, 148, 172, 196, 
220, 244, 268, 292, 316, 340, 364, 388, 412, 436, 460, 484, 
508, 532, 556, 580, 604, 628, 652, 676, 700 and 724, or a 
substantially similar sequence thereof having at least 90%, at 
least 95%, at least 98% or at least 99% sequence identity; a 
heavy chain CDR2 (HCDR2) domain selected from the group 
consisting of SEQ ID NO:6, 30, 54, 78, 102, 126, 150, 174, 
198, 222, 246, 270, 294, 318, 342, 366, 390, 414, 438, 462, 
486, 510, 534, 558, 582, 606, 630, 654, 678, 702 and 726, or 
a substantially similar sequence thereof having at least 90%, 
at least 95%, at least 98% or at least 99% sequence identity; a 
light chain CDRI (LCDRI) domain selected from the group 
consisting of SEQ ID NO:12, 36, 60, 84, 108, 132, 156, 180, 
204, 228, 252, 276, 300, 324, 348, 372, 396, 420, 444, 468, 
492, 516, 540, 564, 588, 612, 636, 660, 684, 708 and 732, or 
a substantially similar sequence thereof having at least 90%, 
at least 95%, at least 98% or at least 99% sequence identity; 
and a light chain CDR2 (LCDR2) domain selected from the 
group consisting of SEQ ID NO:14, 38, 62, 86, 110, 134, 158, 
182, 206, 230, 254, 278, 302, 326, 350, 374, 398, 422, 446, 
470, 494, 518, 542, 566, 590, 614, 638, 662, 686, 7108nd734, 
or a substantially similar sequence thereof having at least 
90%, at least 95%, at least 98% or at least 99% sequence 
identity. In one embodiment, the heavy and light chain CDR 
sequences comprise a sequence selected from the group con- 
sisting of SEQ ID NO:52, 54, 56, 60, 62, 64; 76, 78, 80, 84, 86, 
88; 124, 126, 128, 132, 134, 136; 220, 222, 224, 228, 230, 
232; 244, 246, 248, 252, 254, 256; and 316, 318, 320, 324, 
326, 328. In more specific embodiments, the CDR sequences 
comprise SEQ ID NO: 76, 78, 80, 84, 86, 88; or 220, 222, 224, 
228, 230, 232. 
[002S] In a related embodiment, the invention comprises an 
antibody or antigen-binding fragment of an antibody which 
specifically binds hPCSK9, wherein the antibody or fragment 
comprises heavy and light chain CDR domains contained 
within heavy and light chain sequence pairs selected from the 
group consisting of SEQ ID NO: 2/10, 18/20, 22/24, 26/34, 
42/44, 46/48, 50/58, 66/68, 70/72, 74/82, 90/92, 94/96, 
98/106, 114/116, 118/120, 122/130, 138/140, 142/144, 146/ 
154, 162/164, 166/168, 170/178, 186/188, 190/192, 194/202, 
210/212, 214/216, 218/226, 234/236, 238/240, 242/250, 258/ 
260, 262/264, 266/274, 282/284, 286/288, 290/298, 306/308, 
US 2010/0166768 A1 JU1. 1, 2010 
310/312, 314/322, 330/332, 334/336, 338/346, 354/356, 358/ 
360, 362/370, 378/380, 382/384, 386/394, 402/404, 406/408, 
410/418, 426/428, 430/432, 434/442, 450/452, 454/456, 458/ 
466, 474/476, 478/480, 482/490, 498/500, 502/504, 506/514, 
522/524, 526/528, 530/538, 546/548, 550/552, 554/562, 570/ 
572, 574/576, 578/586, 594/596, 598/600, 602/610, 618/620, 
622/624, 626/634, 642/644, 646/648, 650/658, 666/668, 670/ 
672, 674/682, 690/692, 694/696, 698/706, 714/716, 718/720, 
722/730, 738/740 and 742/744. In one embodiment, the CDR 
sequences are contained within HCVR and LCVR selected 
from the amino acid sequence pairs of SEQ ID NO: 50/58, 
66/68, 70/72, 74/82, 90/92, 94/96, 122/130, 138/140, 142/ 
144, 218/226, 234/236, 238/240, 242/250, 258/260, 262/264, 
314/322, 330/332 and 334/336. In more specific embodi- 
ments, the CDR sequences are comprised within HCVR/ 
LCVR sequences selected from SEQ ID NO: 90/92 or 218/ 
226. 
[0029] In one embodiment, the invention provides fully 
human monoclonal antibody or antigen-binding fragment 
thereof that specifically bind hPCSK9 and neutralize PCSK9 
activity, wherein the antibody or fragment thereof exhibits 
one or more of the following characteristics: (I) capable of 
reducing serum total cholesterol at least about 25-35% and 
sustaining the reduction over at least a 24 day period relative 
to a predose level, preferably the reduction in serum total 
cholesterol is at least about 30-40%; (ii) capable of reducing 
serum LDL cholesterol at least about 65-80% and sustaining 
the reduction over at least a 24 day period relative to a predo se 
level; (iii) capable of reducing serum triglyceride at least 
about 25-40% relative to predose level; (iv) does not reduce 
serum HDL cholesterol or reduces serum HDL cholesterol no 
more than 5% relative to predose level; (v) binds an epitope 
comprising amino acid residue 238 of hPCSK9 (SEQ ID 
NO:755); (vi) exhibits an enhanced binding affinity (K~) for 
hPCSK9 at p H 5. 5 relative to the K~ at p H 7. 4, as measured by 
plasmon surface resonance, wherein the enhanced affinity is 
at least about a 20- to 50-fold increase in affinity; (vii) binds 
human, human GOF mutation D374Y, cynomolgus monkey, 
rhesus monkey, mouse, rat and hamster PCSK9; (viii) com- 
prises heavy and light chain CDR3 sequences comprising 
SEQ ID NO:80 and 88; and (ix) comprises CDR sequences 
from SEQ ID NO:90 and 92. 
[0030] In one embodiment, the invention provides fully 
human monoclonal antibody or antigen-binding fragment 
thereof that specifically bind human PCSK9 (hPCSK9) and 
neutralize PCSK9 activity, wherein the antibody or fragment 
thereof exhibits one or more of the following characteristics: 
(I) capable of reducing serum LDL cholesterol at least about 
40-70% and sustaining the reduction over at least a 60 or 90 
day period relative to a predose level; (ii) capable of reducing 
serum triglyceride at least about 25-40% relative to predose 
level; (iii) does not reduce serum HDL cholesterol or reduces 
serum HDL cholesterol no more than 5% relative to predose 
level; (iv) binds an epitope comprising amino acid residue 
366 of hPCSK9 (SEQ ID NO:755); (v) does not exhibit an 
enhanced binding affinity for PCSK9 at an acidic pH relative 
to a neutral pH, as measured by surface plasmon resonance; 
(vi) binds human and monkey PCSK9, but does not bind 
mouse, rat or hamster PCSK9; (vii) comprises heavy and light 
chain CDR3 sequences comprising SEQ ID NO:224 and 232; 
and (viii) comprises CDR sequences from SEQ ID NO:218 
and 226. 
[0031] In a third aspect, the invention provides nucleic acid 
molecules encoding anti-PCSK9 antibodies or fragments 
thereof. Recombinant expression vectors carrying the nucleic 
acids of the invention, and host cells into which such vectors 
have been introduced, are also encompassed by the invention, 
as are methods of producing the antibodies by culturing the 
host cells under conditions permitting production of the anti- 
bodies, and recovering the antibodies produced. 
[0032] In one embodiment, the invention provides an anti- 
body or fragment thereof comprising a HCVR encoded by a 
nucleic acid sequence selected from the group consisting of 
SEQ ID NO: I, 17, 21, 25, 41, 45, 49, 65, 69, 73, 89, 93, 97, 
113, 117, 121, 137, 141, 145, 161, 165, 169, 185, 189, 193, 
209, 213, 217, 233, 237, 241, 257, 261, 265, 281, 285, 289, 
305, 309, 313, 329, 333, 337, 353, 357, 361, 377, 381, 385, 
401, 405, 409, 425, 429, 433, 449, 453, 457, 473, 477, 481, 
497, 501, 505, 521, 525, 529, 545, 549, 553, 569, 573, 577, 
593, 597, 601, 617, 621, 625, 641, 645, 649, 665, 669, 673, 
689, 693, 697, 713, 717, 721, 737 and 741, or a substantially 
identical sequence having at least 90%, at least 95%, at least 
98%, or at least 99% homology thereof. In one embodiment, 
the HCVR is encoded by a nucleic acid sequence selected 
from the group consisting of SEQ ID NO: 49, 65, 69, 73, 89, 
93, 121, 137, 141, 217, 233, 237, 241, 257, 261, 313, 329 and 
333. In more specific embodiments, the HCVR is encoded by 
a nucleic acid sequence selected from the group consisting of 
SEQ ID NO: 89 and 217. 
[0033] In one embodiment, the antibody or fragment 
thereof further comprises a LCVR encoded by a nucleic acid 
sequence selected from the group consisting of SEQ ID NO: 
9, 19, 23, 33, 43, 47, 57, 67, 71, 81, 91, 95, 105, 115, 119, 129, 
139, 143, 153, 163, 167, 177, 187, 191, 201, 211, 215, 225, 
235, 239, 249, 259, 263, 273, 283, 287, 297, 307, 311, 321, 
331, 335, 345, 355, 359, 369, 379, 383, 393, 403, 407, 417, 
427, 431, 441, 451, 455, 465, 475, 479, 489, 499, 503, 513, 
523, 527, 537, 547, 551, 561, 571, 575, 585, 595, 599, 609, 
619, 623, 633, 643, 647, 657, 667, 671, 681, 691, 695, 705, 
715, 719, 729, 739 and 743, or a substantially identical 
sequence having at least 90%, at least 95%, at least 98%, or at 
least 99% homology thereof. In one embodiment, the LCVR 
is encoded by a nucleic acid sequence selected from the group 
consisting of SEQ ID NO: 57, 67, 71, 81, 91, 95, 129, 139, 
143, 225, 235, 239, 249, 259, 263, 321, 331 and 335. In more 
specific embodiments, the LCVR is encoded by a nucleic acid 
sequence selected from the group consisting of SEQ ID NO: 
91 and 225. 
[0034] In one embodiment, the invention features an anti- 
body or antigen-binding fragment of an antibody comprising 
a HCDR3 domain encoded by a nucleotide sequence selected 
from the group consisting of SEQ ID NO:7, 31, 55, 79, 103, 
127, 151, 175, 199, 223, 247, 271, 295, 319, 343, 367, 391, 
415, 439, 463, 487, 511, 535, 559, 583, 607, 631, 655, 679, 
703 and 727, or a substantially identical sequence having at 
least 90%, at least 95%, at least 98%, or at least 99% homol- 
ogy thereof; and a LCDR3 domain encoded by a nucleotide 
sequence selected from the group consisting of SEQ ID NO: 
15, 39, 63, 87, 111, 135, 159, 183, 207, 231, 255, 279, 303, 
327, 351, 375, 399, 423, 447, 471, 495, 519, 543, 567, 591, 
615, 639, 663, 687, 711 and 735, or a substantially identical 
sequence having at least 90%, at least 95%, at least 98%, or at 
least 99% homology thereof. In one embodiment, the 
HCDR3 and LCDR3 comprise a sequence pair encoded by 
the nucleic acid sequence of SEQ ID NO: 55/63, 79/87, 
127/135, 223/231, 247/255 and 319/327, respectively. In 
more specific embodiments, the HCDR3 and LCDR3 com- 
US 2010/0166768 A1 JU1. 1, 2010 
prise a sequence pair encoded by the nucleic acid sequence of 
SEQ ID NO: 79/87 and 223/231. 
[0035] In a further embodiment, the antibody or fragment 
thereof further comprises, a HCDRI domain encoded by a 
nucleotide sequence selected from the group consisting of 
SEQ ID NO: 3, 27, 51, 75, 99, 123, 147, 171, 195, 219, 243, 
267, 291, 315, 339, 363, 387, 411, 435, 459, 483, 507, 531, 
555, 579, 603, 627, 651, 675, 699 and 723, or a substantially 
identical sequence having at least 90%, at least 95%, at least 
98%, or at least 99% homology thereof; a HCDR2 domain 
encoded by a nucleotide sequence selected from the group 
consisting of SEQ ID NO:5, 29, 53, 77, 101, 125, 149, 173, 
197, 221, 245, 269, 293, 317, 341, 365, 389, 413, 437, 461, 
485, 509, 533, 557, 581, 605, 629, 653, 677, 701 and 725, or 
a substantially identical sequence having at least 90%, at least 
95%, at least 98%, or at least 99% homology thereof; a 
LCDRI domain encoded by a nucleotide sequence selected 
from the group consisting of SEQ ID NO: 11, 35, 59, 83, 107, 
131, 155, 179, 203, 227, 251, 275, 299, 323, 347, 371, 395, 
419, 443, 467, 491, 515, 539, 563, 587, 611, 635, 659, 683, 
707 and 731, or a substantially identical sequence having at 
least 90%, at least 95%, at least 98%, or at least 99% homol- 
ogy thereof; and a LCDR2 domain encoded by a nucleotide 
sequence selected from the group consisting of SEQ ID NO: 
13, 37, 61, 85, 109, 133, 157, 181, 205, 229, 253, 277, 301, 
325, 349, 373, 397, 421, 445, 469, 493, 517, 541, 565, 589, 
613, 637, 661, 685, 709 and 733, or a substantially identical 
sequence having at least 90%, at least 95%, at least 98%, or at 
least 99% homology thereof. In one embodiment, the heavy 
and light chain CDR sequences are encoded by the nucleic 
acid sequences of SEQ ID NO: 51, 53, 55, 59, 61, 63; 75, 77, 
79, 83, 85, 87; 123, 125, 127, 131, 133, 135; 219, 221, 223, 
227, 229, 231; 243, 245, 247, 251, 253, 255; and 315, 317, 
319, 323, 325, 327. In more specific embodiments, the heavy 
and light chain CDR sequences are encoded by the nucleic 
acid sequences of SEQ ID NO: 75, 77, 79, 83, 85, 87; and 219, 
221, 223, 227, 229, 231. 
[0036] In a fourth aspect, the invention features an isolated 
antibody or antigen-binding fragment thereof that specifi- 
cally binds hPCSK9, comprising a HCDR3 and a LCDR3, 
wherein HCDR3 comprises an amino acid sequence of the 
formula X X X X X X X X X 
X' X" X' X' X' X' X' X' X' 
X' X (SEQ ID NO:747), wherein X' is Ala, X is Arg or 
Lys, X is Asp, X is Ser or Ile, X is Asn or Val, X is Leu or 
Trp, X is Gly or Met, X is Asn or Val, X is Phe or Tyr, X' 
is Asp, X" is Leu or Met, X' is Asp or absent, X' is Tyr or 
absent, X' is Tyr or absent, X' is Tyr or absent, X' is Tyr or 
absent, X' is Glyorabsent, X' is Metorabsent, X' isAsp 
or absent, and X is Val or absent; and LCDR3 comprises an 
amino acid sequence of the formula X' X X X 
X X X X X (SEQ ID NO:750), wherein X' is 
Glnor Met, X is Gln, X is Tyror Thr, X is TyrorLeu, X 
is ThrorGln, X is Thr, X is Pro, X is TyrorLeu, andX is 
Thr. 
[0037] In a further embodiment, the antibody or fragment 
thereof further comprise a HCDRI sequence of the formula 
X' X X X X X X X (SEQ ID NO:745), 
wherein X' is Gly, X is Phe, X is Thr, X is Phe, X is Ser or 
Asn, X is Ser or Asn, X is Tyr or H is, and X is Ala or Trp; 
a HCDR2 sequence of the formula X' X X X 
X X X X (SEQ IDNO:746), whereinX'is Ile, X is 
Ser orAsn, X is Gly or Gln, X is Asp or Ser, X is Gly, X is 
SerorGly, X is ThrorGlu, andX is ThrorLys; a LCDRI 
sequence of the formula X' X X X X X 
X X X X X X (SEQ ID NO:748) wherein 
X' is Gln, X is Ser, X isVal orLeu, X is Leu, X is His or 
Tyr, X is Arg or Ser, X is Ser or Asn, X is Asn or Gly, X is 
Asn, X' is Arg or Asn, X" is Asn or Tyr, and X' is Phe or 
absent; a LCDR2 sequence of the formula X' X X 
(SEQ ID NO:749) whereinX' is Trp orLeu, X is Ala or Gly, 
and X is Ser. FIG. 1 shows the sequence alignment of heavy 
and light chain variable regions for 316P and 300N mAbs. 
[0038] In a fifth aspect, the invention features a human 
anti-PCSK9 antibody or antigen-binding fragment of an anti- 
body comprising a heavy chain variable region (HCVR) 
encoded by nucleotide sequence segments derived from V~, 
D~ and J~ germline sequences, and a light chain variable 
region (LCVR) encoded by nucleotide sequence segments 
derived from V~ and J~ germline sequences, wherein the 
germline sequences are (a) V~ gene segment 3-23, D~ gene 
segment 7-27, J~ gene segment 2, V~ gene segment 4-1 and J~ 
gene segment 2; or (b) V~ gene segment 3-7, D~ gene seg- 
ment 2-8, J~ gene segment 6, V~ gene segment 2-28 and J~ 
gene segment 4. 
[0039] In a sixth aspect, the invention features an antibody 
or antigen-binding fragment thereof that binds to a PCSK9 
protein of SEQ ID NO:755, wherein the binding of the anti- 
body or fragment thereof to a variant PCSK9 protein is less 
than 50% of the binding between the antibody or fragment 
thereof and the PC SK9 protein of SEQ ID NO: 755. In specific 
embodiment, the antibody or fragment thereof binds to the 
variant PCSK9 protein with a binding affinity (K~) which is 
less than about 50%, less than about 60%, less than about 
70%, less than about 80%, less than about 90% or less than 
about 95% compared to the binding to PCSK9 (SEQ ID 
NO:755). 
[0040] In one embodiment, the variant PCSK9 protein 
comprises at least one mutation at position 238 of SEQ ID 
NO:755. In a more specific embodiment, the mutation is 
D238R. In one embodiment, the antibody or antibody frag- 
ment binding affinity for the variant PCSK9 protein is at least 
90% less relative to the wildtype protein of SEQ ID NO:755, 
wherein the variant protein comprises a mutation at residue 
238. In one embodiment, the antibody or antibody fragment 
binding affinity for the variant PCSK9 protein is at least 80% 
less relative to the wildtype protein of SEQ ID NO:755, 
wherein the variant protein comprises a mutation at one or 
more of residue 153, 159, 238 and 343. In a more specific 
embodiment, the mutation is one of S153R, E159R, D238R 
and D343R. 
[0041] In one embodiment, the variant PCSK9 protein 
comprises at least one mutation at position 366 of SEQ ID 
NO:755. In a more specific embodiment, the mutation is 
E366K. In one embodiment, the antibody or antibody frag- 
ment binding affinity for the variant PCSK9 protein is at least 
95% less relative to the wildtype protein of SEQ ID NO:755, 
wherein the variant protein comprises a mutation at residue 
366. In one embodiment, the antibody or antibody fragment 
binding affinity for the variant PCSK9 protein is at least 90% 
less relative to the wildtype protein of SEQ ID NO:755, 
wherein the variant protein comprises a mutation at one or 
more of residue 147, 366 and 380. In a more specific embodi- 
ment, the mutation is one of S147F, E366K and V380M. In 
one embodiment, the antibody or antibody fragment binding 
affinity for the variant PCSK9 protein is at least 80% less 
relative to the wildtype protein of SEQ ID NO:755, wherein 
the variant protein comprises a mutation at one or more of 
US 2010/0166768 A1 JU1. 1, 2010 
residue 147, 366 and 380. In a more specific embodiment, the 
mutation is one of 8147F. E366K and V380M. 
[0042] The invention encompasses anti-PCSK9 antibodies 
having a modified glycosylation pattern. In some applica- 
tions, modification to remove undesirable glycosylation sites 
may be useful, or e. g. , removal of a fucose moiety to increase 
antibody dependent cellular cytotoxicity (ADCC) function 
(see Shield et al. (2002) JBC 277:26733). In other applica- 
tions, modification of galactosylation can be made in order to 
modify complement dependent cytotoxicity (CDC). 
[0043] In a seventh aspect, the invention features a pharma- 
ceutical composition comprising a recombinant human anti- 
body or fragment thereof which specifically binds hPCSK9 
and a pharmaceutically acceptable carrier. In one embodi- 
ment, the invention features a composition which is a com- 
bination of an antibody or antigen-binding fragment of an 
antibody of the invention, and a second therapeutic agent. The 
second therapeutic agent may be any agent that is advanta- 
geously combined with the antibody or fragment thereof of 
the invention, for example, an agent capable of inducing a 
cellular depletion of cholesterol synthesis by inhibiting 3-hy- 
droxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reduc- 
tase, such as, for example, cerovastatin, atorvastatin, simvas- 
tatin, pitavastin, rosuvastatin, fluvastatin, lovastatin, 
pravastatin, etc. ; capable of inhibiting cholesterol uptake and 
or bile acid re-absorption; capable of increasing lipoprotein 
catabolism (such as niacin); and/or activators of the LXR 
transcription factor that plays a role in cholesterol elimination 
such as 22-hydroxycholesterol. 
[0044] In an eighth aspect, the invention features methods 
for inhibiting hPCSK9 activity using the anti-PCSK9 anti- 
body or antigen-binding portion of the antibody of the inven- 
tion, wherein the therapeutic methods comprise administer- 
ing a therapeutically effective amount of a pharmaceutical 
composition comprising an antibody or antigen-binding frag- 
ment of an antibody of the invention. The disorder treated is 
any disease or condition which is improved, ameliorated, 
inhibited or prevented by removal, inhibition or reduction of 
PCSK9 activity. Specific populations treatable by the thera- 
peutic methods of the invention include subjects indicated for 
LDL apheresis, subjects with PCSK9-activating mutations 
(gain of function mutations, "GOF"), subjects with heterozy- 
gous Familial Hypercholesterolemia (heFH); subjects with 
primary hypercholesterolemia who are statin intolerant or 
statin uncontrolled; and subjects at risk for developing hyper- 
cholesterolemia who may be preventably treated. Other indi- 
cations include dyslipidemia associated with secondary 
causes such as Type 2 diabetes mellitus, cholestatic liver 
diseases (primary biliary cirrhosis), nephrotic syndrome, 
hypothyroidism, obesity; and the prevention and treatment of 
atherosclerosis and cardiovascular diseases. 
[0045] In specific embodiments of the method of the inven- 
tion, the anti-hPCSK9 antibody or antibody fragment of the 
invention is useful to reduce elevated total cholesterol, non- 
HDL cholesterol. LDL cholesterol, and/or apolipoprotein B 
(apolipoprotein B100). 
[0046] The antibody or antigen-binding fragment of the 
invention may be used alone or in combination with a second 
agent, for example, an HMG-CoA reductase inhibitor and/or 
other lipid lowering drugs. 
[0047] Other embodiments will become apparent from a 
review of the ensuing detailed description. 
BRIEF DESCRIPTION OF THE FIGURE 
[0048] FIG. 1. Sequence comparison tables of heavy chain 
(A) and light chain (B) variable regions and CDRs of anti- 
bodies HI H316P and H I M300N. 
[0049] FIG. 2. Antibody concentrations in serum over time. 
316P 5 mg/kg ( ); 300N 5 mg/kg (0); 316P 15 mg/kg (8); 
300N 15 mg/kg ( ~ ). 
[0050] FIG. 3. Serum total cholesterol level as a percentage 
of change over buffer control. Buffer control (*); 316P 5 
mg/kg (8); 300N 5 mg/kg (4); 316P 15 mg/kg ( ); 300N 15 
mg/kg (A). 
[0051] FIG. 4. Serum LDL cholesterol level as a percentage 
of change over buffer control: Buffer Control (*); 316P 5 
mg/kg (8); 300N 5 mg/kg (4); 316P 15 mg/kg ( ); 300N 15 
mg/kg (A). 
[0052] FIG. 5. Serum LDL cholesterol level normalized to 
buffer control. Buffer control (*); 316P 5 mg/kg (8); 300N 5 
mg/kg (4); 316P 15 mg/kg ( ); 300N 15 mg/kg (A). 
[0053] FIG. 6. Serum HDL cholesterol level as a percent- 
age of change over buffer control. Buffer control (*); 316P 5 
mg/kg (8); 300N 5 mg/kg (4); 316P 15 mg/kg ( ); 300N 15 
mg/kg (A). 
[0054] FIG. 7. Serum triglyceride level expressed as a per- 
centage of change over buffer control. Buffer control (*); 
316P 5 mg/kg (8); 300N 5 mg/kg (4); 316P 15 mg/kg ( 
300N 15 mg/kg (A). 
[0055] FIG. S. Serum LDL cholesterol level expressed as a 
percentage of change over baseline following a single dose 
subcutaneous administration. 316P 5 mg/kg (8); 300N 5 
mg/kg (0). 
[0056] FIG. 9. Antibody concentrations in serum over time 
following a single dose subcutaneous administration. 316P 5 
mg/kg (0); 300N 5 mg/kg (4). 
[0057] FIG. 10. Western blot for mouse LDL receptor of 
total liver homogenates. Samples were taken 24 hours after 
PBS (lanes 1-3), 5 mg/kg 316P (lanes 4-6), or 5 mg/kg of 
non-hPCSK9 specific mAb (lanes 7-8) administration and 4 
hours after 1. 2 mg/kg hPCSK9-mmh (all lanes). 
[0058] FIG. 11. Effects of 316P on serum LDL cholesterol 
level in PCSK9 "' " mice. Buffer control 316P I mg/kg 
( ); 316P 5 mg/kg ( ); 316P 10 mg/kg ( 
[0059] FIG. 12. Anti-hPCSK9 mAb serum pharmacoki- 
netic profile in C57BL/6 mice. Single dose of Control I mAb 
(0) at 10 mg/kg; 316P (4) at 10 mg/kg and 300N (8) at 10 
mg/kg. 
[0060] FIG. 13. Anti-hPCSK9 mAb serum pharmacoki- 
netic profile in hPCSK9 heterozygous mice. Single dose of 
Control I mAb ( ~ ) at 10 mg/kg; 316P (4) at 10 mg/kg and 
300N (8) at 10 mg/kg. 
[0061] FIG. 14. Effect of 316P on serum LDL cholesterol 
levels in Syrian Hamster fed a normal diet. Buffer control 
(0); 316P I mg/kg (8); 316P 3 mg/kg (4); 316P 5 mg/kg 
(&). 
DETAILED DESCRIPTION 
[0062] Before the present methods are described, it is to be 
understood that this invention is not limited to particular 
methods, and experimental conditions described, as such 
methods and conditions may vary. It is also to be understood 
that the terminology used herein is for the purpose of describ- 
ing particular embodiments only, and is not intended to be 
limiting, since the scope of the present invention will be 
limited only by the appended claims. 
[0063] Unless defined otherwise, all technical and scien- 
tific terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which this 
invention belongs. Although any methods and materials simi- 
lar or equivalent to those described herein can be used in the 
US 2010/0166768 A1 JU1. 1, 2010 
practice or testing of the present invention, preferred methods 
and materials are now described. All publications mentioned 
herein are incorporated herein by reference in their entirety. 
DEFINITIONS 
[0064] The term "human proprotein convertase subtilisin/ 
kexin type 9" or "hPCSK9", as used herein, refers to hPCSK9 
having the nucleic acid sequence shown in SEQ ID NO:754 
and the amino acid sequence of SEQ ID NO:755, or a bio- 
logically active fragment thereof. 
[0065] The term "antibody", as used herein, is intended to 
refer to immunoglobulin molecules comprised of four 
polypeptide chains, two heavy (H) chains and two light (L) 
chains inter-connected by disulfide bonds. Each heavy chain 
is comprised of a heavy chain variable region ("HCVR" or 
"VH") and a heavy chain constant region (comprised of 
domains CHI, CH2 and CH3). Each light chain is comprised 
of a light chain variable region ("LCVR or "VL") and a light 
chain constant region (CL). The VH and VL regions can be 
further subdivided into regions of hypervariability, termed 
complementarity determining regions (CDR), interspersed 
with regions that are more conserved, termed framework 
regions (FR). Each VH and VL is composed of three CDRs 
and four FRs, arranged from amino-terminus to carboxy- 
terminus in the following order: FRI, CDRI, FR2, CDR2, 
FR3, CDR3, FR4. 
[0066] Substitution of one or more CDR residues or omis- 
sion of one or more CDRs is also possible. Antibodies have 
been described in the scientific literature in which one or two 
CDRs can be dispensed with for binding. Padlan et al. (1995 
FASEB J. 9:133-139) analyzed the contact regions between 
antibodies and their antigens, based on published crystal 
structures, and concluded that only about one fifth to one third 
of CDR residues actually contact the antigen. Padlan also 
found many antibodies in which one or two CDRs had no 
amino acids in contact with an antigen (see also, Vajdos et al. 
2002 J Mol Biol 320:415-428). 
[0067] CDR residues not contacting antigen can be identi- 
fied based on previous studies (for example residues H60- 
H65 in CDRH2 are often not required), from regions of Kabat 
CDRs lying outside Chothia CDRs, by molecular modeling 
and/or empirically. If a CDR or residue(s) thereof is omitted, 
it is usually substituted with an amino acid occupying the 
corresponding position in another human antibody sequence 
or a consensus of such sequences. Positions for substitution 
within CDRs and amino acids to substitute can also be 
selected empirically. Empirical substitutions can be conser- 
vative or non-conservative substitutions. 
[0068] The term "human antibody", as used herein, is 
intended to include antibodies having variable and constant 
regions derived from human germline immunoglobulin 
sequences. The human mAbs of the invention may include 
amino acid residues not encoded by human germline immu- 
noglobulin sequences (e. g. , mutations introduced by random 
or site-specific mutagenesis in vitro or by somatic mutation in 
vivo), for example in the CDRs and in particular CDR3. 
However, the term "human antibody", as used herein, is not 
intended to include mAbs in which CDR sequences derived 
from the germline of another mammalian species (e. g. , 
mouse), have been grafted onto human FR sequences. 
[0069] The term "specifically binds, " or the like, means that 
an antibody or antigen-binding fragment thereof forms a 
complex with an antigen that is relatively stable under physi- 
ologic conditions. Specific binding can be characterized by an 
equilibrium dissociation constant of at least about I x10 M 
or less (e. g. , a smaller K~ denotes a tighter binding). Methods 
for determining whether two molecules specifically bind are 
well known in the art and include, for example, equilibrium 
dialysis, surface plasmon resonance, and the like. An isolated 
antibody that specifically binds hPCSK9 may, however, 
exhibit cross-reactivity to other antigens such as PCSK9 mol- 
ecules from other species. Moreover, multi-specific antibod- 
ies (e. g. , bispecifics) that bind to hPCSK9 and one or more 
additional antigens are nonetheless considered antibodies 
that "specifically bind" hPCSK9, as used herein. 
[0070] The term "high affinity" antibody refers to those 
mAbs having a binding affinity to hPCSK9 of at least 10 ' 
M; preferably 10 " M; even more preferably 10 ' M, as 
measured by surface plasmon resonance, e. g. , BIACORE™ 
or solution-affinity ELISA. 
[0071] By the term "slow off rate", "Koff ' or "kd" is meant 
an antibody that dissociates from hPCSK9 with a rate con- 
stant of lx10 s ' or less, preferably Ix10 s ' or less, as 
determined by surface plasmon resonance, e. g. , BIA- 
CORE™ 
[0072] The term "antigen-binding portion" of an antibody 
(or simply "antibody fragment"), as used herein, refers to one 
or more fragments of an antibody that retain the ability to 
specifically bind to hPCSK9. An antibody fragment may 
include a Fab fragment, a F(ab')~ fragment, a Fv fragment, a 
dAb fragment, a fragment containing a CDR, or an isolated 
CDR. 
[0073] The specific embodiments, antibody or antibody 
fragments o f the invention may be conj ugated to a therapeutic 
moiety ("immunoconjugate"), such as a cytotoxin, a chemo- 
therapeutic drug, an immunosuppressant or a radioisotope. 
[0074] An "isolated antibody", as used herein, is intended 
to refer to an antibody that is substantially free of other mAbs 
having different antigenic specificities (e. g. , an isolated anti- 
body that specifically binds hPCSK9 is substantially free of 
mAb s that specifically bind antigens other than hPCSK9). An 
isolated antibody that specifically binds hPCSK9 may, how- 
ever, have cross-reactivity to other antigens, such as PCSK9 
molecules from other species. 
[0075] A "neutralizing antibody", as used herein (or an 
"antibody that neutralizes PCSK9 activity"), is intended to 
refer to an antibody whose binding to hPCSK9 results in 
inhibition of at least one biological activity of PCSK9. This 
inhibition of the biological activity of PCSK9 can be assessed 
by measuring one or more indicators of PCSK9 biological 
activity by one or more of several standard in vitro or in vivo 
assays known in the art (see examples below). 
[0076] The term "surface plasmon resonance", as used 
herein, refers to an optical phenomenon that allows for the 
analysis of real-time biospecific interactions by detection of 
alterations in protein concentrations within a biosensor 
matrix, for example using the BIACORE™ system (Pharma- 
cia Biosensor AB, Uppsala, Sweden and Piscataway, N. J. ). 
[0077] The term "K~", as used herein, is intended to refer to 
the equilibrium dissociation constant of a particular antibody- 
antigen interaction. 
[0078] The term "epitope" is a region of an antigen that is 
bound by an antibody. Epitopes may be defined as structural 
or functional. Functional epitopes are generally a subset of 
the structural epitopes and have those residues that directly 
contribute to the affinity of the interaction. Epitopes may also 
be conformational, that is, composed of non-linear amino 
acids. In certain embodiments, epitopes may include deter- 
US 2010/0166768 A1 JU1. 1, 2010 
minants that are chemically active surface groupings of mol- 
ecules such as amino acids, sugar side chains, phosphoryl 
groups, or sulfonyl groups, and, in certain embodiments, may 
have specific three-dimensional structural characteristics, 
and/or specific charge characteristics. 
[0079] The term "substantial identity" or "substantially 
identical, " when referring to a nucleic acid or fragment 
thereof, indicates that, when optimally aligned with appro- 
priate nucleotide insertions or deletions with another nucleic 
acid (or its complementary strand), there is nucleotide 
sequence identity in at least about 90%, and more preferably 
at least about 95%, 96%, 97%, 98% or 99% of the nucleotide 
bases, as measured by any well-known algorithm of sequence 
identity, such as FASTA. BLAST or GAP, as discussed below. 
[0080] As applied to polypeptides, the term "substantial 
similarity" or "substantially similar" means that two peptide 
sequences, when optimally aligned, such as by the programs 
GAP or BESTFIT using default gap weights, share at least 
90% sequence identity, even more preferably at least 95%, 
98% or 99% sequence identity. Preferably, residue positions 
which are not identical differ by conservative amino acid 
substitutions. A "conservative amino acid substitution" is one 
in which an amino acid residue is substituted by another 
amino acid residue having a side chain (R group) with similar 
chemical properties (e. g. , charge or hydrophobicity). In gen- 
eral, a conservative amino acid substitution will not substan- 
tially change the functional properties of a protein. In cases 
where two or more amino acid sequences differ from each 
other by conservative substitutions, the percent or degree of 
similarity may be adjusted upwards to correct for the conser- 
vative nature of the substitution. Means for making this 
adjustment are well known to those o f skill in the art. See, e. g. , 
Pearson (1994) Methods Mol. Biol. 24: 307-331, which is 
herein incorporated by reference. Examples of groups of 
amino acids that have side chains with similar chemical prop- 
erties include I) aliphatic side chains: glycine, alanine, 
valine, leucine and isoleucine; 2) aliphatic-hydroxyl side 
chains: serine and threonine; 3) amide-containing side 
chains: asparagine and glutamine; 4) aromatic side chains: 
phenylalanine, tyrosine, and tryptophan; 5) basic side chains: 
lysine, arginine, and histidine; 6) acidic side chains: aspartate 
and glutamate, and 7) sulfur-containing side chains: cysteine 
and methionine. Preferred conservative amino acids substi- 
tution groups are: valine-leucine-isoleucine, phenylalanine- 
tyrosine, lysine-arginine, alanine-valine, glutamate-aspar- 
tate, and asparagine-glutamine. Alternatively, a conservative 
replacement is any change having a positive value in the 
PAM250 log-likelihood matrix disclosed in Gonnet et al. 
(1992) Science 256: 1443 45, herein incorporated by refer- 
ence. A "moderately conservative" replacement is any change 
having a nonnegative value in the PAM250 log-likelihood 
matrix. 
[0081] Sequence similarity for polypeptides is typically 
measured using sequence analysis software. Protein analysis 
software matches similar sequences using measures of simi- 
larity assigned to various substitutions, deletions and other 
modifications, including conservative amino acid substitu- 
tions. For instance, GCG software contains programs such as 
GAP and BESTFIT which can be used with default param- 
eters to determine sequence homology or sequence identity 
between closely related polypeptides, such as homologous 
polypeptides from different species of organisms or between 
a wild type protein and a mutein thereof. See, e. g. , GCG 
Version 6. 1. Polypeptide sequences also can be compared 
using FASTA with default or recommended parameters; a 
program in GCG Version 6. 1. FASTA (e. g. , FASTR2 and 
FASTA3) provides alignments and percent sequence identity 
of the regions of the best overlap between the query and 
search sequences (Pearson (2000) supra). Another preferred 
algorithm when comparing a sequence of the invention to a 
database containing a large number of sequences from differ- 
ent organisms is the computer program BLAST, especially 
BLASTP or TBLASTN, using default parameters. See, e. g. , 
Altschul et al. (1990) J. Mol. Biol. 215: 403 410 and (1997) 
Nucleic Acids Res. 25:3389 402, each of which is herein 
incorporated by reference. 
[0082] In specific embodiments, the antibody or antibody 
fragment for use in the method of the invention may be 
monospecific, bispecific, or multispecific. Multispecific anti- 
bodies may be specific for different epitopes of one target 
polypeptide or may contain antigen-binding domains specific 
for epitopes of more than one target polypeptide. An exem- 
plary bi-specific antibody format that can be used in the 
context of the present invention involves the use of a first 
immunoglobulin (Ig) CH3 domain and a second Ig CH3 
domain, wherein the first and second Ig CH3 domains differ 
from one another by at least one amino acid, and wherein at 
least one amino acid difference reduces binding of the bispe- 
cific antibody to Protein A as compared to a bi-specific anti- 
body lacking the amino acid difference. In one embodiment, 
the first Ig CH3 domain binds Protein A and the second Ig 
CH3 domain contains a mutation that reduces or abolishes 
Protein A binding such as an H95R modification (by IMGT 
exon numbering; H435R by EU numbering). The second 
CH3 may further comprise an Y96F modification (by IMGT; 
Y436F by EU). Further modifications that may be found 
within the second CH3 include: D16E, L18M, N44S, K52N, 
V57M, end V82I (by IMGT; D356E, L358M, N384S, 
K392N, V397M, and V422I by EU) in the case of IgGI 
mAbs; N44S. K52N, and V82I (IMGT; N384S, K392N, and 
V422I by EU) in the case of IgG2 mAbs; and Q15R, N44S, 
K52N, V57M, R69K, E79Q, and V82I (by IMGT; Q355R, 
N384S, K392N, V397M, R409K, E419Q, and V422I by EU) 
in the case of IgG4 mAbs. Variations on the bi-specific anti- 
body format described above are contemplated within the 
scope of the present invention. 
[0083] By the phrase "therapeutically effective amount" is 
meant an amount that produces the desired effect for which it 
is administered. The exact amount will depend on the purpose 
o f the treatment, and will be ascertainable by one skilled in the 
art using known techniques (see, for example, Lloyd (1999) 
The Art, Science and Technology of Pharmaceutical Com- 
pounding). 
Preparation of Human Antibodies 
[0084] Methods for generating human antibodies in trans- 
genic mice are known (see for example, U. S. Pat. No. 6, 596, 
541, Regeneron Pharmaceuticals, VELOCIMMUNE™). 
The VELOCIMMUNE™ technology involves generation of 
a transgenic mouse having a genome comprising human 
heavy and light chain variable regions operably linked to 
endogenous mouse constant region loci such that the mouse 
produces an antibody comprising a human variable region 
and a mouse constant region in response to antigenic stimu- 
lation. The DNA encoding the variable regions of the heavy 
and light chains of the antibody are isolated and operably 
linked to DNA encoding the human heavy and light chain 
US 2010/0166768 A1 JU1. 1, 2010 
constant regions. The DNA is then expressed in a cell capable 
of expressing the fully human antibody. In specific embodi- 
ment, the cell is a CHO cell. 
[00S5] Antibodies may be therapeutically useful in block- 
ing a ligand-receptor interaction or inhibiting receptor com- 
ponent interaction, rather than by killing cells through fixa- 
tion of complement and participation in complement- 
dependent cytotoxicity (CDC), or killing cells through 
antibody-dependent cell-mediated cytotoxicity (ADCC). The 
constant region of an antibody is thus important in the ability 
of an antibody to fix complement and mediate cell-dependent 
cytotoxicity. Thus, the isotype of an antibody may be selected 
on the basis of whether it is desirable for the antibody to 
mediate cytotoxicity. 
[00S6] Human antibodies can exist in two forms that are 
associated with hinge heterogeneity. In one form, an antibody 
molecule comprises a stable four-chain construct of approxi- 
mately 150-160 kDa in which the dimers are held together by 
an interchain heavy chain disulfide bond. In a second form, 
the dimers are not linked via inter-chain disulfide bonds and a 
molecule of about 75-80 kDa is formed composed of a 
covalently coupled light and heavy chain (half-antibody). 
These forms have been extremely difficult to separate, even 
after affinity purification. 
[00S7] The frequency of appearance of the second form in 
various intact IgG isotypes is due to, but not limited to, 
structural differences associated with the hinge region iso- 
type of the antibody. A single amino acid substitution in the 
hinge region of the human IgG4 hinge can significantly 
reduce the appearance of the second form (Angal et al. (1993) 
Molecular Immunology 30:105) to levels typically observed 
using a human IgGI hinge. The instant invention encom- 
passes antibodies having one or more mutations in the hinge. 
CH2 or CH3 region which may be desirable, for example, in 
production, to improve the yield of the desired antibody form. 
[00SS] Generally, a VELOCIMMUNE™ mouse is chal- 
lenged with the antigen of interest, and lymphatic cells (such 
as B-cells) are recovered from the mice that express antibod- 
ies. The lymphatic cells may be fused with a myeloma cell 
line to prepare immortal hybridoma cell lines, and such hybri- 
doma cell lines are screened and selected to identify hybri- 
doma cell lines that produce antibodies specific to the antigen 
of interest. DNA encoding the variable regions of the heavy 
chain and light chain may be isolated and linked to desirable 
isotypic constant regions of the heavy chain and light chain. 
Such an antibody protein may be produced in a cell, such as a 
CHO cell. Alternatively, DNA encoding the antigen-specific 
chimeric antibodies or the variable domains of the light and 
heavy chains may be isolated directly from antigen-specific 
lymphocytes. 
[00S9] Initially, high affinity chimeric antibodies are iso- 
lated having a human variable region and a mouse constant 
region. As described below, the antibodies are characterized 
and selected for desirable characteristics, including affinity, 
selectivity, epitope, etc. The mouse constant regions are 
replaced with a desired human constant region to generate the 
fully human antibody of the invention, for example wild-type 
or modified IgGI or IgG4 (for example, SEQ ID NO:751, 
752, 753). While the constant region selected may vary 
according to specific use, high affinity antigen-binding and 
target specificity characteristics reside in the variable region. 
[0090] Epitope Mapping and Related Technologies 
[0091] To screen for antibodies that bind to a particular 
epitope (e. g. , those which block binding of IgE to its high 
affinity receptor), a routine cross-blocking assay such as that 
described Antibodies, Harlow and Lane (Cold Spring Harbor 
Press, Cold Spring Harb. , N. Y) can be performed. Other 
methods include alanine scanning mutants, peptide blots 
(Reineke (2004) Methods Mol Biol 248:443-63) (herein spe- 
cifically incorporated by reference in its entirety), or peptide 
cleavage analysis. In addition, methods such as epitope exci- 
sion, epitope extraction and chemical modification of anti- 
gens can be employed (Tomer (2000) Protein Science 9: 
487-496) (herein specifically incorporated by reference in its 
entirety). 
[0092] The term "epitope" refers to a site on an antigen to 
which B and/or T cells respond. B-cell epitopes can be formed 
both from contiguous amino acids or noncontiguous amino 
acids juxtaposed by tertiary folding of a protein. Epitopes 
formed from contiguous amino acids are typically retained on 
exposure to denaturing solvents, whereas epitopes formed by 
tertiary folding are typically lost on treatment with denaturing 
solvents. An epitope typically includes at least 3, and more 
usually, at least 5 or 8-10 amino acids in a unique spatial 
conformation. 
[0093] Modification-Assisted Profiling (MAP), also 
known as Antigen Structure-based Antibody Profiling 
(ASAP) is a method that categorizes large numbers of mono- 
clonal antibodies (mAbs) directed against the same antigen 
according to the similarities of the binding profile of each 
antibody to chemically or enzymatically modified antigen 
surfaces (US 2004/0101920, herein specifically incorporated 
by reference in its entirety). Each category may reflect a 
unique epitope either distinctly different from or partially 
overlapping with epitope represented by another category. 
This technology allows rapid filtering of genetically identical 
mAbs, such that characterization can be focused on geneti- 
cally distinct mAbs. When applied to hybridoma screening. 
MAP may facilitate identification of rare hybridoma clones 
that produce mAbs having the desired characteristics. MAP 
may be used to sort the anti-PCSK9 mAbs of the invention 
into groups of mAbs binding different epitopes. 
[0094] In various embodiments, the anti-hPCSK9 antibody 
or antigen-binding fragment of an antibody binds an epitope 
within the catalytic domain, which is about 153 to 425 of SEQ 
ID NO:755); more specifically, an epitope from about 153 to 
about 250 or from about 250 to about 425; more specifically, 
the antibody or antibody fragment of the invention binds an 
epitope within the fragment from about 153 to about 208, 
from about 200 to about 260, from about 250 to about 300, 
from about 275 to about 325, from about 300 to about 360, 
from about 350 to about 400, and/or from about 375 to about 
425. 
[0095] In various embodiments, the anti-hPCSK9 antibody 
or antigen-binding fragment of an antibody binds an epitope 
within the propeptide domain (residues 31 to 152 of SEQ ID 
NO:755); more specifically, an epitope from about residue 31 
to about residue 90 or from about residue 90 to about residue 
152; more specifically, the antibody or antibody fragment of 
the invention binds an epitope within the fragment from about 
residue 31 to about residue 60, from about residue 60 to about 
residue 90, from about residue 85 to about residue 110, from 
about residue 100 to about residue 130, from about residue 
125 to about residue 150, from about residue 135 to about 
residue 152, and/or from about residue 140 to about residue 
152. 
[0096] In some embodiments, the anti-hPCSK9 antibody 
or antigen-binding fragment of an antibody binds an epitope 
US 2010/0166768 A1 JU1. 1, 2010 
within the C-terminal domain, (residues 426 to 692 of SEQ 
ID NO:755); more specifically, an epitope from about residue 
426 to about residue 570 or from about residue 570 to about 
residue 692; more specifically, the antibody or antibody frag- 
ment of the invention binds an epitope within the fragment 
from about residue 450 to about residue 500, from about 
residue 500 to about residue 550, from about residue 550 to 
about residue 600, and/or from about residue 600 to about 
residue 692. 
[0097] In some embodiments, the antibody or antibody 
fragment binds an epitope which includes more than one of 
the enumerated epitopes within the catalytic, propeptide or 
C-terminal domain, and/or within two or three different 
domains (for example, epitopes within the catalytic and 
C-terminal domains, or within the propeptide and catalytic 
domains, or within the propeptide, catalytic and C-terminal 
domains. 
[0098] In some embodiments, the antibody or antigen- 
binding fragment binds an epitope on hPCSK9 comprising 
amino acid residue 238 of hPCSK9 (SEQ ID NO:755). 
Experimental results (Table 27) show that when D238 was 
mutated, the K~ of mAb 316P exhibited &400-fold reduction 
in binding affinity (-Ix10 M to -410x10 M) and T„~ 
decreased &30-fold (from -37 to -I min). In a specific 
embodiment, the mutation was D238R. In specific embodi- 
ments, the antibody or antigen-binding fragment of the inven- 
tion binds an epitope of hPCSK9 comprising two or more of 
amino acid residues at positions 153, 159, 238 and 343. 
[0099] As shown below, a mutation in amino acid residue 
153, 159 or 343 resulted in about a 5- to 10-fold decrease in 
affinity or similar shortening in T„~. In specific embodi- 
ments, the mutation was S153R, E159R and/or D343R. 
[0100] In some embodiments, the antibody or antigen- 
binding fragment binds an epitope on hPCSK9 comprising 
amino acid residue 366 of hPCSK9 (SEQ ID NO:755). 
Experimental results (Table 27) show that when E366 was 
mutated, the affinity of mAb 300N exhibited about 50-fold 
decrease (-0. 7x10 M to -36x10 M) and a similar shorten- 
ing in T„~ (from -120 to -2 min). In a specific embodiment, 
the mutation is E366K. 
[0101] The present invention includes anti-PCSK9 anti- 
bodies that bind to the same epitope as any of the specific 
exemplary antibodies described herein. Likewise, the present 
invention also includes anti-PCSK9 antibodies that compete 
for binding to PCSK9 or a PCSK9 fragment with any of the 
specific exemplary antibodies described herein. 
[0102] One can easily determine whether an antibody binds 
to the same epitope as, or competes for binding with, a refer- 
ence anti-PCSK9 antibody by using routine methods known 
in the art. For example, to determine if a test antibody binds to 
the same epitope as a reference anti-PCSK9 antibody of the 
invention, the reference antibody is allowed to bind to a 
PCSK9 protein or peptide under saturating conditions. Next, 
the ability of a test antibody to bind to the PCSK9 molecule is 
assessed. If the test antibody is able to bind to PCSK9 fol- 
lowing saturation binding with the reference anti-PCSK9 
antibody, it can be concluded that the test antibody binds to a 
different epitope than the reference anti-PCSK9 antibody. On 
the other hand, if the test antibody is not able to bind to the 
PCSK9 molecule following saturation binding with the ref- 
erence anti-PCSK9 antibody, then the test antibody may bind 
to the same epitope as the epitope bound by the reference 
anti-PCSK9 antibody of the invention. 
[0103] To determine if an antibody competes for binding 
with a reference anti-PCSK9 antibody, the above-described 
binding methodology is performed in two orientations: In a 
first orientation, the reference antibody is allowed to bind to a 
PCSK9 molecule under saturating conditions followed by 
assessment of binding of the test antibody to the PCSK9 
molecule. In a second orientation, the test antibody is allowed 
to bind to a PCSK9 molecule under saturating conditions 
followed by assessment of binding of the reference antibody 
to the PCSK9 molecule. If, in both orientations, only the first 
(saturating) antibody is capable of binding to the PCSK9 
molecule, then it is concluded that the test antibody and the 
reference antibody compete for binding to PCSK9. As will be 
appreciated by a person of ordinary skill in the art, an anti- 
body that competes for binding with a reference antibody 
may not necessarily bind to the identical epitope as the refer- 
ence antibody, but may sterically block binding of the refer- 
ence antibody by binding an overlapping or adjacent epitope. 
[0104] Two antibodies bind to the same or overlapping 
epitope if each competitively inhibits (blocks) binding of the 
other to the antigen. That is, a I-, 5-, 10-, 20- or 100-fold 
excess of one antibody inhibits binding of the other by at least 
50% but preferably 75%, 90% or even 99% as measured in a 
competitive binding assay (see, e. g. , Junghans et al. , Cancer 
Res. 1990 50: 1495-1502). Alternatively, two antibodies have 
the same epitope if essentially all amino acid mutations in the 
antigen that reduce or eliminate binding of one antibody 
reduce or eliminate binding of the other. Two antibodies have 
overlapping epitopes if some amino acid mutations that 
reduce or eliminate binding of one antibody reduce or elimi- 
nate binding of the other. 
[0105] Additional routine experimentation (e. g. , peptide 
mutation and binding analyses) can then be carried out to 
confirm whether the observed lack of binding of the test 
antibody is in fact due to binding to the same epitope as the 
reference antibody or if steric blocking (or another phenom- 
enon) is responsible for the lack of observed binding. Experi- 
ments of this sort can be performed using ELISA. RIA, sur- 
face plasmon resonance, flow cytometry or any other 
quantitative or qualitative antibody-binding assay available in 
the art. 
[0106] In a specific embodiment, the invention comprises 
an anti-PCSK9 antibody or antigen binding fragment of an 
antibody that binds an PCSK9 protein of SEQ ID NO:755, 
wherein the binding between the antibody or fragment 
thereof to PCSK9 and a variant PCSK9 protein is less than 
50% of the binding between the antibody or fragment and the 
PCSK9 protein of SEQ ID NO:755. In one specific embodi- 
ment, the variant PCSK9 protein comprises at least one muta- 
tion of a residue at a position selected from the group con- 
sisting of 153, 159, 238 and 343. In a more specific 
embodiment, the at least one mutation is S153R, E159R, 
D238R, and/or D343R. In another specific embodiment, the 
variant PCSK9 protein comprises at least one mutation of a 
residue at a position selected from the group consisting of 
366. In one specific embodiment, the variant PCSK9 protein 
comprises at least one mutation of a residue at a position 
selected from the group consisting of 147, 366 and 380. In a 
more specific embodiment, the mutation is S147F, E366K 
and V3 80M. 
Immunoconjugates 
[0107] The invention encompasses a human anti-PCSK9 
monoclonal antibody conjugated to a therapeutic moiety 
US 2010/0166768 A1 
10 
JU1. 1, 2010 
("immunoconjugate"), such as a cytotoxin, a chemotherapeu- 
tic drug, an immunosuppressant or a radioisotope. Cytotoxin 
agents include any agent that is detrimental to cells. Examples 
of suitable cytotoxin agents and chemotherapeutic agents for 
forming immunoconjugates are known in the art, see for 
example, WO 05/103081. 
Bispecifics 
[0108] The antibodies of the present invention may be 
monospecific, bispecific, or multispecific. Multispecific 
mAbs may be specific for different epitopes of one target 
polypeptide or may contain antigen-binding domains specific 
for more than one target polypeptide. See, e. g. , Tutt et al. 
(1991) J. Immunol. 147:60-69. The human anti-PCSK9 
mAbs can be linked to or co-expressed with another func- 
tional molecule, e. g. , another peptide or protein. For example, 
an antibody or fragment thereof can be functionally linked 
(e. g. , by chemical coupling, genetic fusion, noncovalent asso- 
ciation or otherwise) to one or more other molecular entities, 
such as another antibody or antibody fragment, to produce a 
bispecific or a multispecific antibody with a second binding 
specificity. 
[0109] An exemplary bi-specific antibody format that can 
be used in the context of the present invention involves the use 
of a first immunoglobulin (Ig) CH3 domain and a second Ig 
CH3 domain, wherein the first and second Ig CH3 domains 
differ from one another by at least one amino acid, and 
wherein at least one amino acid difference reduces binding of 
the bispecific antibody to Protein A as compared to a bi- 
specific antibody lacking the amino acid difference. In one 
embodiment, the first Ig CH3 domain binds Protein A and the 
second Ig CH3 domain contains a mutation that reduces or 
abolishes Protein A binding such as an H95R modification 
(by IMGT exon numbering; H435R by EU numbering). The 
second CH3 may further comprise a Y96F modification (by 
IMGT; Y436F by EU). Further modifications that may be 
found within the second CH3 include: D16E, L18M, N44S, 
K52N, V57M, and V82I (by IMGT; D356E, L358M, N384S, 
K392N, V397M, and V422I by EU) in the case of IgGI 
antibodies; N44S. K52N, and V82I (IMGT; N384S, K392N, 
and V422I by EU) in the case of IgG2 antibodies; and Q15R, 
N44S, K52N, V57M, R69K, E79Q, and V82I (by IMGT; 
Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I 
by EU) in the case of IgG4 antibodies. Variations on the 
bi-specific antibody format described above are contem- 
plated within the scope of the present invention. 
Bioequivalents 
[0110] The anti-PCSK9 antibodies and antibody fragments 
of the present invention encompass proteins having amino 
acid sequences that vary from those of the described mAbs, 
but that retain the ability to bind human PCSK9. Such variant 
mAbs and antibody fragments comprise one or more addi- 
tions, deletions, or substitutions of amino acids when com- 
pared to parent sequence, but exhibit biological activity that is 
essentially equivalent to that of the described mAbs. Like- 
wise, the anti-PCSK9 antibody-encoding DNA sequences of 
the present invention encompass sequences that comprise one 
or more additions, deletions, or substitutions of nucleotides 
when compared to the disclosed sequence, but that encode an 
anti-PCSK9 antibody or antibody fragment that is essentially 
bioequivalent to an anti-PCSK9 antibody or antibody frag- 
ment of the invention. Examples of such variant amino acid 
and DNA sequences are discussed above. 
[0111] Two antigen-binding proteins, or antibodies, are 
considered bioequivalent if, for example, they are pharma- 
ceutical equivalents or pharmaceutical alternatives whose 
rate and extent of absorption do not show a significant differ- 
ence when administered at the same molar dose under similar 
experimental conditions, either single does or multiple dose. 
Some antibodies will be considered equivalents or pharma- 
ceutical alternatives i f they are equivalent in the extent of their 
absorption but not in their rate of absorption and yet may be 
considered bioequivalent because such differences in the rate 
of absorption are intentional and are reflected in the labeling, 
are not essential to the attainment of effective body drug 
concentrations on, e. g. , chronic use, and are considered medi- 
cally insignificant for the particular drug product studied. In 
one embodiment, two antigen-binding proteins are 
bioequivalent if there are no clinically meaningful differences 
in their safety, purity, and potency. 
[0112] In one embodiment, two antigen-binding proteins 
are bioequivalent if a patient can be switched one or more 
times between the reference product and the biological prod- 
uct without an expected increase in the risk o f adverse effects, 
including a clinically significant change in immunogenicity, 
or diminished effectiveness, as compared to continued 
therapy without such switching. 
[0113] In one embodiment, two antigen-binding proteins 
are bio equivalent if they both act by a common mechanism or 
mechanisms of action for the condition or conditions of use, 
to the extent that such mechanisms are known. 
[0114] Bioequivalence may be demonstrated by in vivo and 
in vitro methods. Bioequivalence measures include, e. g. , (a) 
an in vivo test in humans or other mammals, in which the 
concentration of the antibody or its metabolites is measured 
in blood, plasma, serum, or other biological fluid as a function 
o f time; (b) an in vitro test that has been correlated with and is 
reasonably predictive of human in vivo bioavailability data; 
(c) an in vivo test in humans or other mammals in which the 
appropriate acute pharmacological effect of the antibody (or 
its target) is measured as a function of time; and (d) in a 
well-controlled clinical trial that establishes safety, efficacy, 
or bioavailability or bioequivalence of an antibody. 
[0115] Bioequivalent variants of anti-PCSK9 antibodies of 
the invention may be constructed by, for example, making 
various substitutions of residues or sequences or deleting 
terminal or internal residues or sequences not needed for 
biological activity. For example, cysteine residues not essen- 
tial for biological activity can be deleted or replaced with 
other amino acids to prevent formation of unnecessary or 
incorrect intramolecular disulfide bridges upon renaturation. 
Treatment Population 
[0116] The invention provides therapeutic methods for 
treating a human patient in need of a composition of the 
invention. While modifications in lifestyle and conventional 
drug treatment are often successful in reducing cholesterol 
levels, not all patients are able to achieve the recommended 
target cholesterol levels with such approaches. Various con- 
ditions, such as familial hypercholesterolemia (FH), appear 
to be resistant to lowering of LDL-C levels in spite of aggres- 
sive use of conventional therapy. Homozygous and heterozy- 
gous familial hypercholesterolemia (hoFH, heFH) is a con- 
dition associated with premature atherosclerotic vascular 
disease. However, patients diagnosed with hoFH are largely 
US 2010/0166768 A1 JU1. 1, 2010 
unresponsive to conventional drug therapy and have limited 
treatment options. Specifically, treatment with statins, which 
reduce LDL-C by inhibiting cholesterol synthesis and 
upregulating the hepatic LDL receptor, may have little effect 
in patients whose LDL receptors are non-existent or defec- 
tive. A mean LDL-C reduction of only less than about 20% 
has been recently reported in patients with genotype-con- 
firmed hoFH treated with the maximal dose of statins. The 
addition of ezetimibe 10 mg/day to this regimen resulted in a 
total reduction of LDL-C levels of 27%, which is still far from 
optimal. Likewise, many patients are statin non-responsive, 
poorly controlled with statin therapy, or cannot tolerate statin 
therapy; in general, these patients are unable to achieve cho- 
lesterol control with alternative treatments. There is a large 
unmet medical need for new treatments that can address the 
short-comings of current treatment options. 
[0117] Specific populations treatable by the therapeutic 
methods of the invention include patients indicated for LDL 
apheresis, subjects with PCSK9-activating (GOF) mutations, 
heterozygous Familial Hypercholesterolemia (heFH); sub- 
jects with primary hypercholesterolemia who are statin intol- 
erant or statin uncontrolled; and subjects at risk for develop- 
ing hypercholesterolemia who may be preventably treated. 
Therapeutic Administration and Formulations 
[0118] The invention provides therapeutic compositions 
comprising the anti-PCSK9 antibodies or antigen-binding 
fragments thereof of the present invention. The administra- 
tion of therapeutic compositions in accordance with the 
invention will be administered with suitable carriers, excipi- 
ents, and other agents that are incorporated into formulations 
to provide improved transfer, delivery, tolerance, and the like. 
A multitude of appropriate formulations can be found in the 
formulary known to all pharmaceutical chemists: Reming- 
ton's Pharmaceutical Sciences, Mack Publishing Company, 
Easton, Pa. These formulations include, for example, pow- 
ders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cat- 
ionic or anionic) containing vesicles (such as LIPOFEC- 
TIN ). DNA conjugates, anhydrous absorption pastes, oil- 
in-water and water-in-oil emulsions, emulsions carbowax 
(polyethylene glycols of various molecular weights), semi- 
solid gels, and semi-solid mixtures containing carbowax. See 
also Powell et al. "Compendium of excipients for parenteral 
formulations" PDA (1998) J Pharm Sci Technol 52:238-311. 
[0119] The dose may vary depending upon the age and the 
size of a subject to be administered, target disease, conditions, 
route of administration, and the like. When the antibody of the 
present invention is used for treating various conditions and 
diseases associated with PCSK9, including hypercholester- 
olemia, disorders associated with LDL and apolipoprotein B, 
and lipid metabolism disorders, and the like, in an adult 
patient, it is advantageous to intravenously administer the 
antibody of the present invention normally at a single dose of 
about 0. 01 to about 20 mg/kg body weight, more preferably 
about 0. 02 to about 7, about 0. 03 to about 5, or about 0. 05 to 
about 3 mg/kg body weight. Depending on the severity of the 
condition, the frequency and the duration of the treatment can 
be adjusted. 
[0120] Various delivery systems are known and can be used 
to administer the pharmaceutical composition of the inven- 
tion, e. g. , encapsulation in liposomes, microparticles, micro- 
capsules, recombinant cells capable of expressing the mutant 
viruses, receptor mediated endocytosis (see, e. g. , Wu et al. 
(1987) J. Biol. Chem. 262:4429-4432). Methods of introduc- 
tion include, but are not limited to, intradermal, intramuscu- 
lar, intraperitoneal, intravenous, subcutaneous, intranasal, 
epidural, and oral routes. The composition may be adminis- 
tered by any convenient route, for example by infusion or 
bolus injection, by absorption through epithelial or mucocu- 
taneous linings (e. g. , oral mucosa, rectal and intestinal 
mucosa, etc. ) and may be administered together with other 
biologically active agents. Administration can be systemic or 
local. 
[0121] The pharmaceutical composition can be also deliv- 
ered in a vesicle, in particular a liposome (see Langer (1990) 
Science 249:1527-1533; Treat et al. (1989) in Liposomes in 
the Therapy of Infectious Disease and Cancer, Lopez Berest- 
ein and Fidler (eds. ), Liss, New York, pp. 353-365; Lopez- 
Berestein, ibid. , pp. 317-327; see generally ibid. ). 
[0122] In certain situations, the pharmaceutical composi- 
tion can be delivered in a controlled release system. In one 
embodiment, a pump may be used (see Langer, supra; Sefton 
(1987) CRC Crit. Ref. Biomed. Eng. 14:201). In another 
embodiment, polymeric materials can be used; see, Medical 
Applications of Controlled Release, Langer and Wise (eds. ), 
CRC Pres. , Boca Raton, Fla. (1974). In yet another embodi- 
ment, a controlled release system can be placed in proximity 
of the composition's target, thus requiring only a fraction of 
the systemic dose (see, e. g. , Goodson, in Medical Applica- 
tions of Controlled Release, supra, vol. 2, pp. 115-138, 1984). 
[0123] The injectable preparations may include dosage 
forms for intravenous, subcutaneous, intracutaneous and 
intramuscular injections, drip infusions, etc. These injectable 
preparations may be prepared by methods publicly known. 
For example, the injectable preparations may be prepared, 
e. g. , by dissolving, suspending or emulsifying the antibody or 
its salt described above in a sterile aqueous medium or an oily 
medium conventionally used for injections. As the aqueous 
medium for injections, there are, for example, physiological 
saline, an isotonic solution containing glucose and other aux- 
iliary agents, etc. , which may be used in combination with an 
appropriate solubilizing agent such as an alcohol (e. g. , etha- 
nol), a polyalcohol (e. g. , propylene glycol, polyethylene gly- 
col), a nonionic surfactant [e. g. , polysorbate 80, HCO-50 
(polyoxyethylene (50 mol) adduct of hydrogenated castor 
oil)], etc. As the oily medium, there are employed, e. g. , 
sesame oil, soybean oil, etc. , which may be used in combina- 
tion with a solubilizing agent such as benzyl benzoate, benzyl 
alcohol, etc. The injection thus prepared is preferably filled in 
an appropriate ampoule. A pharmaceutical composition of 
the present invention can be delivered subcutaneously or 
intravenously with a standard needle and syringe. In addition, 
with respect to subcutaneous delivery, a pen delivery device 
readily has applications in delivering a pharmaceutical com- 
position of the present invention. Such a pen delivery device 
can be reusable or disposable. A reusable pen delivery device 
generally utilizes a replaceable cartridge that contains a phar- 
maceutical composition. Once all of the pharmaceutical com- 
position within the cartridge has been administered and the 
cartridge is empty, the empty cartridge can readily be dis- 
carded and replaced with a new cartridge that contains the 
pharmaceutical composition. The pen delivery device can 
then be reused. In a disposable pen delivery device, there is no 
replaceable cartridge. Rather, the disposable pen delivery 
device comes prefilled with the pharmaceutical composition 
held in a reservoir within the device. Once the reservoir is 
emptied of the pharmaceutical composition, the entire device 
is discarded. 
US 2010/0166768 A1 
12 
JU1. 1, 2010 
[0124] Numerous reusable pen and autoinjector delivery 
devices have applications in the subcutaneous delivery of a 
pharmaceutical composition of the present invention. 
Examples include, but certainly are not limited to 
AUTOPEN (Owen Mumford, Inc. , Woodstock, UK), DIS- 
ETRONIC™ pen (Disetronic Medical Systems, Burghdorf, 
Switzerland), HUMALOG MIX 75/25™ pen, HUMA- 
LOG™ pen, HUMALIN 70/30™ pen (Eli Lilly and Co. , 
Indianapolis, Ind. ), NOVOPEN I, II and III (Novo Nordisk, 
Copenhagen, Denmark), NOVOPEN JUNIOR™ (Novo Nor- 
disk, Copenhagen, Denmark), BD™ pen (Becton Dickinson, 
Franklin Lakes, N. J. ), OPTIPEN OPTIPEN PRO™ 
OPTIPEN STARLET™, and OPTICLIK™ (sanofi-aventis, 
Frankfurt, Germany), to name only a few. Examples of dis- 
posable pen delivery devices having applications in subcuta- 
neous delivery of a pharmaceutical composition of the 
present invention include, but certainly are not limited to the 
SOLOSTAR™ pen (sanofi-aventis), the FLEXPEN (Novo 
Nordisk), and the KWIKPEN (Eli Lilly). 
[0125] Advantageously, the pharmaceutical compositions 
for oral or parenteral use described above are prepared into 
dosage forms in a unit dose suited to fit a dose of the active 
ingredients. Such dosage forms in a unit dose include, for 
example, tablets, pills, capsules, injections (ampoules), sup- 
positories, etc. The amount of the aforesaid antibody con- 
tained is generally about 5 to about 500 mg per dosage form 
in a unit dose; especially in the form of injection, it is pre- 
ferred that the aforesaid antibody is contained in about 5 to 
about 100 mg and in about 10 to about 250 mg for the other 
dosage forms. 
[0126] The invention provides therapeutic methods in 
which the antibody or antibody fragment of the invention is 
useful to treat hypercholestero1emia associated with a variety 
of conditions involving hPCSK9. The anti-PCSK9 antibodies 
or antibody fragments of the invention are particularly useful 
for the treatment of hypercholesterolemia and the like. Com- 
bination therapies may include the anti-PCSK9 antibody of 
the invention with, for example, one or more of any agent that 
(I) induces a cellular depletion of cholesterol synthesis by 
inhibiting 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A 
(CoA) reductase, such as cerivastatin, atorvastatin, simvasta- 
tin, pitavastatin, rosuvastatin, fluvastatin, lovastatin, pravas- 
tatin; (2) inhibits cholesterol uptake and or bile acid re-ab- 
sorption; (3) increase lipoprotein catabolism (such as niacin); 
and activators of the LXR transcription factor that plays a role 
in cholesterol elimination such as 22-hydroxycholesterol or 
fixed combinations such as ezetimibe plus simvastatin; a sta- 
tin with a bile resin (e. g. , cholestyramine, colestipol, 
colesevelam), a fixed combination of niacin plus a statin (e. g. , 
niacin with Iovastatin); or with other lipid lowering agents 
such as omega-3-fatty acid ethyl esters (for example, oma- 
cor). 
EXAMPLES 
[0127] The following examples are put forth so as to pro- 
vide those of ordinary skill in the art with a complete disclo- 
sure and description of how to make and use the methods and 
compositions of the invention, and are not intended to limit 
the scope of what the inventors regard as their invention. 
Efforts have been made to ensure accuracy with respect to 
numbers used but some experimental errors and deviations 
should be accounted for. Unless indicated otherwise, molecu- 
lar weight is average molecular weight, temperature is in 
degrees Centigrade, and pressure is at or near atmospheric. 
Example I 
Generation of Human Antibodies to Human PCSK9 
[0128] VELOCIMMUNE™ mice were immunized with 
human PCSK9, and the antibody immune response moni- 
tored by antigen-specific immunoas say using serum obtained 
from these mice. Anti-hPCSK9 expressing B cells were har- 
vested from the spleens of immunized mice shown to have 
elevated anti-hPCSK9 antibody titers were fused with mouse 
myeloma cells to form hybridomas. The hybridomas were 
screened and selected to identify cell lines expressing 
hPCSK9-specific antibodies using as says as described below. 
The assays identified several cell lines that produced chimeric 
anti-hPCSK9 antibodies designated as HIM300, HIM504, 
HI M505, HIM500, HI M497, HI M498, HI M494, HIM309, 
HI M312, HIM499, HI M493, HI M496, HI M503, HIM502, 
HIM508, HIM495 and HIM492. 
[0129] Human PCSK9-specific antibodies were also iso- 
lated directly from antigen-immunized B cells without fusion 
to myeloma cells, as described in U. S. 2007/0280945AI, 
hereby incorporated by reference in its entirety. Heavy and 
light chain variable regions were cloned to generate fully 
human anti-hPCSK9 antibodies designated as HIH313, 
HIH314, HIH315, HIH316, HIH317, HIH318, HIH320, 
HI H321 and HI H334. Stable recombinant antibody-express- 
ing CHO cell lines expressing these antibodies were estab- 
lished. 
TABLE I 
Heavy Chain 
Variable Re ion 
Light Chain 
Variable Re ion 
Antibody VH D JH VK JK 
H313 
H1H314 
H1H316 
H1H316 
H1H317 
H1H318 
H1H320 
H1H321 
H1H334 
H1M300 
H1M604 
H1M606 
H1M600 
H1M497 
H1M498 
H1M494 
H1M309 
H1M312 
H1M499 
H1M493 
3-13 1-26 4 3-16 
3-33 3-3 4 1-6 
3-33 3-3 4 4-1 
3-23 7-27 2 4-1 
3-13 1-26 4 1-6 
4-69 3-10 6 1-9 
1-18 2-2 6 2-30 
2-6 1-7 6 2-28 
2-6 6-6 6 2-28 
3-7 2-8 6 2-28 
3-30 2-8 6 2-28 
3-30 2-8 6 2-28 
2-6 6-6 6 2-28 
1-18 2-2 6 2-30 
3-21 2-2 4 1-6 
3-11 6-12 6 3-20 
3-21 6-13 4 1-6 
3-21 6-13 4 1-6 
3-21 6-13 4 1-6 
3-21 6-13 4 1-6 
Example 2 
Gene Utilization Analysis 
[0130] To analyze the structure of the mAbs produced, the 
nucleic acids encoding antibody variable regions were cloned 
and sequenced. The predicted amino acid sequences of the 
variable regions were confirmed by ¹erminal amino acid 
sequencing. From the nucleic acid sequence and predicted 
amino acid sequence of the mAbs, gene usage was identified 
for each antibody chain. 
US 2010/0166768 A1 
13 
JU1. 1, 2010 
TABLE I-continued TABLE 3 
Heavy Chain 
Variable Re ion 
Light Chain 
Variable Re ion 
Antibody VH D JH VK 
H1M496 
H1M503 
H1M502 
HJM508 
HJM495 
H1M492 
3-13 6-19 4 3-15 
1-18 2-2 6 2-28 
3-13 6-13 4 3-15 
3-13 6-13 4 3-15 
3-9 4-17 6 1-9 
3-23 3-3 2 3-20 
JK 
Antibody 
H1H313P 
H1H314P 
HJH315P 
H1H316P 
H1H317P 
H1H318P 
H1H320P 
H1H321P 
H1H334P 
25' C. 
244 
3990 
129 
377 
30400 
972 
771 
865 
3750 
230 
65 
151 
42 
137 
59 
28 
106 
46 
KD T I/2 
37' C. 
780 
3560 
413 
1080 
18600 
1690 
1930 
3360 
15900 
60 
43 
35 
ll 
70 
28 
8 
23 
8 
KD T I/2 
Example 3 
Antigen Binding Affinity Determination 
[0131] Equilibrium dissociation constants (K~) for 
hPCSK9 binding to mAbs generated by hybridoma cell lines 
described above were determined by surface kinetics in a 
real-time biosensor surface plasmon resonance assay (BIA- 
CORE™ T100). Each antibody was captured at a flow rate of 
4 [JI/min for 90 sec on a goat anti-mouse IgG polyclonal 
antibody surface created through direct chemical coupling to 
a BIACORE™ chip to form a captured antibody surface. 
Human PCSK9-myc-myc-his (hPCSK9-mmh) at a concen- 
tration of 50 nM or 12. 5 nM was injected over the captured 
antibody surfaces at a flowrate of 50 [Jl/min for 300 sec, and 
antigen-antibody dissociation was monitored for 15 min at 
either 25' C. or 37' C. (K~=pM; Tt/2=min). 
Antibody 
H1H313P 
H1H318P 
H1H334P 
HJH315P 
H1H316P 
H1H320P 
H1M300 
H1M504 
H1M497 
H1M503 
H1M496 
kd (1/si 
2 92 x 10 
3. 69 x 10 
8. 06 x 10 
2 29 x 10 
2 29 x 10 
3. 17 x 10 
1. 52 x 10 
5. 04 x 10 
6. 60 x 10 
8. 73 x 10 
4. 45 x 10 
Tt/r (min) 
396 
3 
1 
51 
51 
36 
76 
23 
175 
132 
260 
[0133] Dissociation rate (kd) of selected mAbs for tagged 
rhesus monkey (Macaca mulata) PCSK9 (mmPCSK9; SEQ 
ID NO:756) (mmPCSK9-mmh) at 25' C. was determined as 
described above. 
TABLE 4 
TABLE 2 
Antibody KD 
25' C. 37' C. 
T I/2 KD T I/2 
Example 4 
Effect of pH on Antigen Binding Affinity 
H1M300 
H1M309 
H1M312 
H1M493 
H1M494 
HJM495 
H1M496 
H1M497 
H1M498 
H1M499 
H1M500 
H1M502 
H1M503 
H1M504 
H1M505 
HJM508 
H1M510 
399 
29. 9 
0. 225 
46. 5 
870 
440 
254 
20. 1 
6400 
106 
1400 
78. 3 
510 
3470 
2740 
138 
1070 
170 
7461 
15568 
4921 
114 
222 
257 
5801 
30 
2253 
91 
958 
118 
35 
42 
572 
68 
1510 
537 
432 
522 
2350 
7500 
421 
480 
7500 
582 
6010 
411 
1880 
11200 
9200 
442 
3960 
32 
326 
392 
341 
30 
19 
118 
290 
14 
316 
15 
151 
30 
6 
6 
139 
10 
[0132] Equilibrium dissociation constants (K~) for 
hPCSK9 binding to mAbs generated via direct isolation of 
splenocytes were determined by surface kinetics in a real- 
time biosensor surface plasmon resonance assay (BIA- 
CORE™ T100). Each selected antibody was captured at a 
flowrate of 2 [JI/min for 6 min on a goat anti-human IgG 
polyclonal antibody surface created through direct chemical 
coupling to a BIACORE™ chip to form a captured antibody 
surface. Human PCSK9-mmh at a concentration of 50 nM or 
12. 5 nM was injected over the captured antibody surface at a 
flowrate of 70 [JI/min for 5 min, and antigen-antibody disso- 
ciation was monitored for 15 min at either 25' C. or 37' C. 
(Kra~M; Tt/2=min). 
High hPCSK9 
Densi Surface 
Low hPCSK9 
Densi Surface 
~H7. 4 ~H5. 5 ~H7. 4 ~H5. 5 
Antibody KD Tt/r KD Tt/r KD Tt/r KD Tt/r 
316P 191 74 144 83 339 45 188 58 
300N 65 507 1180 26 310 119 1380 13 
Control I 20000 29 ND ND ND ND ND ND 
[0134] The effects of pH on antigen binding affinity for 
CHO cell-produced fully human anti-hPCSK9 mAbs was 
assessed as described above. The mAbs tested are fully 
human versions of HIH316P ("316P") (HCVR/LCVR SEQ 
ID NO: 90/92; CDR sequences SEQ ID NO: 76/78/80 and 
84/86/88) and HI M300N ("300N") (HCVR/LCVR SEQ ID 
NO: 218/226; CDR sequences SEQ ID NO:220/222/224 and 
228/230/232). Human PCSK9-myc-myc-his (hPCSK9- 
mmh) was captured on an anti-myc mAb surface either at a 
high density (about 35 to 45 resonance units) (RU) or at a low 
density (about 5 to 14 RU). Each antibody, at 50 nM in HBST 
(pH 7. 4 or pH 5. 5) was injected over the captured hPCSK9 
surface at a flow rate of 100 [JI/ml for 1. 5 min at 25' C. and 
antigen-antibody dissociation was monitored for 10 min. 
Control I: anti-hPCSK9 mAb SEQ ID NO:79/101 (WO 2008/ 
063382) (K =pM; Tt/, =min). 
TABLE 5 
US 2010/0166768 A1 
14 
JU1. ], 2010 
[0135] The antigen binding properties of 316P and 300N at 
pH 7. 4 or pH 5. 5 were determined by a modified BIA- 
CORE™ assay as described above. Briefly, mAbs were 
immobilized onto BIACORE™CM5 sensor chips via amine 
coupling. Varying concentrations of myc-myc-his tagged 
hPCSK9, mouse PCSK9 (mPCSK9, SEQ ID NO:757), 
hPCSK9 with a gain of function (GOF) point mutation of 
D374Y (hPCSK9(D374Y), cynomolgus monkey (Macaca 
fascicuiaris) PCSK9 (mfPCSK9, SEQ ID NO:761) (mf- 
PCSK9), rat (Rattus norvegicus) PCSK9 (rPCSK9, SEQ ID 
NO:763), and his-tagged Syrian golden hamster (Mesocrice- 
tus auratus) PCSK9 (maPCSK9, SEQ ID NO:762) 
(maPCSK9), ranging from 11 to 100 nM, were injected over 
the antibody surface at the flow rate of 100 pl/ml for 1. 5 min 
and antigen-antibody dissociation was monitored in real time 
for 5 min at either 25' C. (Table 6) or 37' C. (Table 7). Control 
II: anti-hPCSK9 mAbs SEQ ID NO:67/12 (WO 2009/ 
026558) (NB: no binding was observed under the experimen- 
tal condition) (Ko7 PM; Tt/2=min). 
TABLE 6 
H Effect at 26' C. 
~H7. 4 ~H4. 4 
hPCSK9(D347YFmmh 
mfPCSK9-mmh 
maPCSK9-h 
rPCSK9-mmh 
hPCSK9-mmh 
mPCSK9-mmh 
hPCSK9(D347YFmmh 
mfPCSK9-mmh 
maPCSK9-h 
rPCSK9-mmh 
hPCSK9-mmh 
mPCSK9-mmh 
hPCSK9(D347YFmmh 
mfPCSK9-mmh 
maPCSK9-h 
rPCSK9 
TABLE 7-continued 
H Effect at 37' C. 
KD T t/r KD T t/r 
6660 
3770 
21700 
66100 
4 1660 
ll 44 
2 ND 
2 399 
300N 
6 
6 
ND 
I 
2470 
NB 
2610 
4810 
NB 
NB 
20 11900 
NB NB 
14 28000 
8 66200 
NB NB 
NB NB 
Control I 
I 
NB 
I 
0. 1 
NB 
NB 
46900 
NB 
169000 
600000 
NB 
NB 
0. 1 11300 
NB NB 
0. 4 27000 
0 6 6360 
NB NB 
NB NB 
Control H 
3 
NB 
3 
0. 3 
NB 
NB 
~H7. 4 ~H4. 7 
Antigen KD T t/r KD T t/r 
hPCSK9-mmh 
mPCSK9-mmh 
hPCSK9(D347YFmmh 
mfPCSK9-mmh 
maPCSK9-h 
rPCSK9-mmh 
1260 
4460 
2490 
1420 
8360 
24100 
316P 
36 22 
10 63 
16 166 
42 8 
8 87 
2 349 
300N 
39 
ll 
13 
23 
8 
6 
hPCSK9-mmh 
mPCSK9-mmh 
hPCSK9(D347YFmmh 
mfPCSK9-mmh 
maPCSK9-h 
rPCSK9p-mmh 
284 87 20 44 
8680 3 89 3 
261 67 483 26 
180 127 214 66 
8830 0. 6 ND ND 
30200 I 233 I 
Example 5 
hPCSK9-mmh 
mPCSK9-mmh 
hPCSK9(D347YFmmh 
mfPCSK9-mmh 
maPCSK9-h 
rPCSK9-mmh 
hPCSK9-mmh 
mPCSK9-mmh 
hPCSK9(D347YFmmh 
mfPCSK9-mmh 
maPCSK9-h 
rPCSK9-mmh 
hPCSK9-mmh 
mPCSK9-mmh 
hPCSK9(D347YFmmh 
mfPCSK9-mmh 
maPCSK9-h 
rPCSK9-mmh 
1100 
NB 
1310 
2170 
NB 
NB 
76 3100 
NB NB 
46 9030 
31 38600 
NB NB 
NB NB 
Control I 
6 
NB 
3 
0. 4 
NB 
NB 
33100 
NB 
71000 
362000 
NB 
NB 
14 1740 
NB NB 
11 7320 
0. 2 67200 
NB NB 
NB NB 
Control H 
31 
NB 
30 
3 
NB 
NB 
143 266 2 212 
3600 ll 33 12 
191 166 49 66 
102 262 12 63 
6600 3 ND ND 
22400 2 106 6 
Anti-hPCSK9 mAbs Binding to hPCSK9 with Point 
Mutation D374Y 
[0136] The binding affinity of selected anti-hPCSK9 mAbs 
to hPCSK9 with a gain of function (GOF) point mutation of 
D374Y (hPCSK9(D374Y)-mmh) was determined as 
described above. Each antibody was captured at a flowrate of 
40 pl/min for 8-30 sec on a goat anti-human IgG polyclonal 
antibody surface created through direct chemical coupling to 
a BIACORE™ chip to form a captured antibody surface. 
hPCSK9(D374Y)-mmh at varying concentrations of 1. 78 nM 
to 100 nM was injected over the captured antibody surface at 
a flowrate of 50 pl/min for 5 min, and the dissociation of 
hPCSK9(D374Y)-mmh and antibody was monitored for 15 
min at 25' C. Control III: anti-hPCSK9 mAbs SEQ ID 
NO;49/23 (WO 2009/026558) (Kra:pM' Tt/2:min). 
TABLE 8 
TABLE 7 
H Effect at 37' C. 
~H7. 4 ~H4. 4 
Antibody 
316P 
300N 
Control I 
Control H 
Control HI 
KD 
1780 
1060 
23600 
66 
1020 
T I/2 
14 
49 
26 
216 
126 
KD T t/r KD T t/r 
hPCSK9-mmh 
mPCSK9-mmh 
4000 
12200 
316P 
9 142 11 
3 13600 3 
Example 6 
Binding Specificity of Anti-hPCSK9 mAbs 
[0137] 316P, 300N, and Control I anti-hPCSK9 mAbs were 
captured on an amine-coupled anti-hFc CM5 chip on BIA- 
US 2010/0166768 A1 
15 
JU1. 1, 2010 
Example 7 
Cross-Reactivity of Anti-hPCSK9 mAbs 
[0139] Cross-reactivity of anti-hPCSK9 mAbs with 
mmPCSK9, mfPCSK9, mPCSK9, maPCSK9, or rPCSK9 
was determined using BIACORE™3000. Briefly, anti- 
hPCSK9 mAbs were captured on an anti-hFc surface created 
through direct chemical coupling to a BIACORE™ chip. 
Purified tagged hPCSK9, hPCSK9(D374Y), mmPCSK9, 
mfPCSK9, mPCSK9, maPCSK9, or rPCSK9, each at 1. 56 
nM to 50 nM, was injected over the antibody surface at either 
25' C. or 37' C. Binding between 316P, 300N, Control I, 
Control II, or Control III and the PCSK9 proteins was deter- 
mined (K~=pM; Tt/2=min) (ND=not determined). 
TABLE 9 
316P mAb 
37' C. 25' C. 
CORE™2000. Tagged (myc-myc-his) human PCS K9, 
human PCSKI (hPCSKI) (SEQ ID NO:759), human PCSK7 
(hPCSK7) (SEQ ID NO:760), ormouse PCSK9 were injected 
(100 nM) over the captured mAb surface and allowed to bind 
at 25' C. for 5 min. Changes in RU were recorded. Results: 
300N and Control I bound only to hPCSK9, and 316P bound 
both hPCSK9 and mPCSK9. 
[0138] The binding specificities of anti-hPCSK9 mAbs 
were determined by ELISA. Briefly, anti-hPCSK9 antibody 
was coated on a 96-well plate. Human PCSK9-mmh, 
mPCSK9-mmh, maPCSK9-h, hPCSKl-mmh, or hPCSK7- 
mmh, at 1. 2 nM, were added to antibody-coated plates and 
incubated at RT for I hr. Plate-bound PCSK protein was then 
detected by HRP-conjugated anti-His antibody. Results show 
that 316P binds human, mouse, and hamster PCSK9, whereas 
300N and Control I only bound hPCSK9. None of the anti- 
hPCSK9 mAbs exhibited significant binding to hPCSKI or 
hPCSK7. 
Antigen 
mPCSK9-mmh 
maPCSK9-h 
rPCSK9-mmh 
Antigen 
hPCSK9-mmh 
hPCSK9(D374Yl-mmh 
mmPCSK9-mmh 
mfPCSK9-mmh 
mPCSK9-mmh 
maPCSK9-h 
rPCSK9-mmh 
Antigen 
hPCSK9-mmh 
hPCSK9(D374Yl-mmh 
mfPCSK9-mmh 
mPCSK9-mmh 
maPCSK9-h 
rPCSK9-mmh 
TABLE 10-continued 
300N mAb 
37' C. 25' C. 
KD T t/r KD T t/r 
NB NB NB NB 
NB NB NB NB 
NB NB NB NB 
TABLE 11 
Control I mAb 
37' C. 25' C. 
KD T t/r KD T t/r 
226000 
ND 
420000 
14300 
NB 
NB 
NB 
2 27500 16 
ND 23600 25 
3 291000 2 
10 24900 14 
NB NB NB 
NB NB NB 
NB NB NB 
TABLE 12 
Control II mAb 
37' C. 25' C. 
KD T t/r KD T t/r 
91 162 61 372 
93 90 66 216 
33 252 26 546 
4700 3 2300 11 
60800 0. 4 25000 2 
14100 I 6900 3 
Antigen 
hPCSK9-mmh 
hPCSK9(D374Yl-mmh 
mmPCSK9-mmh 
mfPCSK9-mmh 
mPCSK9-mmh 
maPCSK9-h 
rPCSK9-mmh 
1800 
4200 
1800 
1800 
4700 
19000 
37500 
9 580 36 
4 1690 15 
21 550 92 
11 520 60 
3 2300 11 
I 6810 5 
I 14500 2 
TABLE 10 
300N mAb 
KD T t/r KD T t/r 
Antigen 
hPCSK9-mmh 
hPCSK9(D374Yl-mmh 
mfPCSK9-mmh 
mPCSK9-mmh 
maPCSK9-h 
rPCSK9-mmh 
TABLE 13 
Control III mAb 
37' C. 25' C. 
KD T t/r KD T t/r 
380 378 490 450 
130 660 1000 126 
110 750 340 396 
33500 I 10900 4 
780 107 2100 67 
NB NB 33200 2 
Antigen 
hPCSK9-mmh 
hPCSK9(D374Yl-mmh 
mmPCSK9-mmh 
mfPCSK9-mmh 
37' C. 
Kr) Tt/r 
2400 22 
2200 14 
1600 26 
3800 11 
25' C. 
Kr) Tt/r 
740 110 
900 65 
610 79 
1500 45 
Example 8 
Inhibition of Binding Between hPCSK9 and hLDLR 
Domains 
[0140] The ability of selected anti-hPCSK9 mAbs to block 
hPCSK9 binding to human LDLR full length extracellular 
US 2010/0166768 A1 
16 
JU1. 1, 2010 
domain (hLDLR-ecto SEQ ID NO:758), hLDLR EGF-A 
domain (amino acids 313-355 of SEQ ID NO:758), or 
hLDLR EGF-AB domains (amino acids of 314-393 of SEQ 
ID NO:758) (LDLR Genbank number NM 000527) was 
evaluated using BIACORE™ 3000. Briefly, hLDLR-ecto, 
EGF-A-hFc, or EGF-AB-hFc protein was amine-coupled on 
a CM5 chip to create a receptor or receptor fragment surface. 
Selected anti-hPCSK9 mAbs, at 62. 5 nM (2. 5 fold excess 
over antigen), were premixed with 25 nM of hPCSK9-mmh, 
followed by 40 min incubation at 25' C. to allow antibody- 
antigen binding to reach equilibrium to form equilibrated 
solutions. The equilibrated solutions were injected over the 
receptor or receptor fragment surfaces at 2 pl/min for 40 min 
at 25' C. Changes in RU due to the binding of the anti- 
hPCSK9 mAbs to hLDLR-ecto. EGF-A-hFc, or EGF-AB- 
hFc were determined. Results show that HIH316P and 
HI M300N blocked the binding of hPCSK9-mmh to hLDLR- 
ecto, hLDLR EGF-A domain, and hLDLR EGF-AB 
domains; HI H320P blocked the binding of hPCSK9-mmh to 
hLDLR-ecto and hLDLR EGF-A domain; and HIH321P 
blocked the binding of hPCSK9-mmh to hLDLR EGF-A 
domain. 
[0141] The ability of the mAbs to block hPCSK9 binding to 
hLDLR-ecto, hLDLR EGF-A domain, or hLDLR EGF-AB 
domains was also evaluated with an ELISA-based immu- 
noassay. Briefly, hLDLR-ecto, hLDLR EGF-A-hFc or 
hLDLR EGF-AB-hFc, each at 2 pg/ml, was coated on a 
96-well plate in PBS buffer overnight at 4' C. , and nonspe- 
cific binding sites blocked with BSA. This plate was used to 
measure free hPCSK9-mmh in a PCSK9-mmh solution pre- 
equilibrated with varying concentrations of anti-hPCSK9 
mAbs. A constant amount of hPCSK9-mmh (500 pM) was 
pre-mixed with varied amounts of antibody, ranging from 0 to 
-50 nM in serial dilutions, followed by I hr incubation at 
room temperature (RT) to allow antibody-antigen binding to 
reach equilibrium. The equilibrated sample solutions were 
transferred to receptor or receptor fragment coated plates. 
After I hour of binding, the plates were washed and bound 
hPCSK9-mmh detected using HRP conjugated anti-myc anti- 
body. IC5o values (in pM) were determined as the amount of 
antibody required to achieve 50'ro reduction of hPCSK9- 
mmh bound to the plate-coated receptor or receptor fragment. 
The results show that specific mAbs functionally block 
PCSK9 from binding the three receptors at both neutral pH 
(7. 2) and acidic pH (5. 5). 
[0142] The ability of the mAbs to block hPCSK9 GOF 
mutant hPCSK9(D374Y)-mmh binding to hLDLR EGF-A 
domain or hLDLR EGF-AB domain (IC5o values in pM) was 
also evaluated with the ELISA-based immunoassay 
described above using a constant amount of 0. 05 nM hPCSK9 
(D374Y)-mmh. 
TABLE 15 
pH 7. 2 pH 5. 5 
Plate Contin Surface 
EGF-A EGF-AB EGF-A EGF-AB 
316P 
300N 
Control I 
Control H 
Control HI 
203 
135 
&100, 000 
72 
537 
139 
142 
&100, 000 
57 
427 
1123 
3463 
&100, 000 
129 
803 
1139 
3935 
&100, 000 
118 
692 
TABLE 16 
I nM mmPCSK9-mmh I nM mPCSK9-mmh 
hLDLR-ecto EGF-A EGF-AB EGF-A EGF-AB 
316P &250 &250 &250 &250 &250 
300N 255 256 290 &33000 &33000 
[0144] The ability of the mAbs to block hPCSK9, 
mmPCSK9, rPCSK9, maPCSK9, mfPCSK9, or mPCSK9 
binding to hLDLR EGF-A domain (IC5o values in pM) was 
evaluated at neutral pH (7. 2) (Table 17) acidic pH (5. 5, Table 
18) with the ELISA-based immunoassay described above 
using a constant amount of 0. 5 nM of hPCSK9-mmh, I nM of 
mmPCSK9-mmh, I nM of rPCSK9-mmh, I nM of 
maPCSK9-h, 0. 3 nM of mfPCSK9-mmh, or I nM of 
mPCSK9-mmh. 
[0143] The ability of the mAbs to block either mmPCSK9 
or mPCSK9 binding to hLDLR-ecto domain, hLDLR EGF-A 
domain, orhLDLR EGF-AB domain (IC5o values in pM) was 
evaluated at neutral pH (7. 2) with the ELISA-based immu- 
noassay describe above using a constant amount of I nM of 
mmh-tagged mmPCSK9 or I nM of mPCSK9. 
TABLE 14 
pH 7. 2 
Plate Coating Surface 
pH 5. 5 
Ab hLDLR-ecto EGF-A EGF-AB hLDLR-ecto EGF-A EGF-AB 
316P &125 &125 &125 &125 &125 &125 
300N 144 146 &125 1492 538 447 
Control I 
Control H 288 
&100, 000 &100, 000 
510 274 411 
&100, 000 &100, 000 
528 508 
Control HI 303 635 391 742 787 1073 
US 2010/0166768 A1 
17 
JU1. ], 2010 
TABLE 17 
hPCSK9 mmPCSK9 rPCSK9 maPCSK9 mfPCSK9 mPCSK9 
316P 
300N 
Control I 
Control H 
Control HI 
&126 
182 
146 
249 
&260 
460 
&100000 
83 
293 
2662 
&100000 
&100000 
2672 
&100000 
349 
&100000 
&100000 
2038 
246 
76 
473 
&100000 
361 
672 
306 
&100000 
&100000 
866 
&100000 
TABLE 18 TABLE 19 
hPCSK9 mmPCSK9 rPCSK9 maPCSK9 mPCSK9 
316P 
300N 
Control I 
Control H 
Control HI 
&126 
223 
&10000 
164 
390 
&260 
3704 
&100000 
&260 
376 
42880 
&100000 
&100000 
11640 
&100000 
1299 
&100000 
&100000 
8339 
414 
991 
&100000 
&100000 
2826 
&100000 
[0145] The ability of 316P and Control I to block hPCSK9 
binding to hLDLR was also determined. Briefly, either 
recombinant hLDLR or hLDLR-EGFA-mFc was immobi- 
lized onto BIACORE™ CM5 chips via amine coupling. An 
antigen-antibody mixture of 100 nM hPCSK9-mmh and 
316P, Control I mAb, or a non-hPCSK9 specific mAb (each at 
250 nM) was incubated at RT for I hr, and then injected over 
the hLDLR or hLDLR-EGFA surface at the flow rate of 10 
pl/ml for 15 min at 25' C. Changes in RU due to the binding 
between the free hPCSK9-mmh in the mixture to either 
hLDLR or hLDLR-EGFA were recorded. The binding of 
hPCSK9 to either hLDLR or hLDLR-EGFA was completely 
blocked by 316P and 300N but not by Control I mAb. 
Example 9 
Epitope Mapping 
[0146] In order to determine epitope-binding specificity, 
three chimeric PCSK9-mmh proteins were generated in 
which specific human PCSK9 domains were substituted with 
mouse PCSK9 domains. Chimeric protein ¹I consists of a 
mouse PCSK9 pro-domain (amino acid residues 1-155 of 
SEC) ID NO:757) followed by a human PCSK9 catalytic 
domain (residues 153-425 of SEQ ID NO:755) and a mouse 
PCSK9 C-terminal domain (residues 429-694 SEQ ID 
NO:757) (mPro-hCat-mC-term-mmh). Chimeric protein ¹2 
consists of a human PCSK9 pro-domain (residues 1-152 of 
SEQ ID NO:755) followed by a mouse PCSK9 catalytic 
domain (residues 156-428 of SEQ ID NO:757) and a mouse 
PCSK9 C-terminal (hpro-mCat-mC-term-mmh). Chimeric 
protein ¹3 consists of mouse PCSK9 pro-domain and a mouse 
PCSK9 catalytic domain followed by a human PCSK9 C-ter- 
minal domain (residues 426-692 of SEQ ID NO:755) (mPro- 
mCat-hC-term-mmh). In addition, hPCSK9 with a point 
mutation of D374Y (hPCSK9 (D374Y)-mmh) was gener- 
ated. 
[0147] Binding specificity of mAbs to test proteins 
hPCSK9-mmh, mouse PCSK9-mmh, chimeric proteins ¹I, 
¹2, and ¹3, and hPCSK9 (D374Y)-mmh were tested as fol- 
lows: the mAbs were coated on a 96-well plate overnight at 4' 
C. , then each test protein (1. 2 nM) was added to the plate. 
After I hr binding at RT, the plate was washed and bound test 
protein detected using HRP-conjugated anti-myc polyclonal 
antibody (++=OD&1. 0; +=OD 0. 4 — 1. 0; — =OD&0. 4). 
Chimeric Protein 
Antibody hPCSK9 mPCSK9 ¹I ¹2 ¹3 hPCSK9(D374Yi 
HI M300 
HI M309 
HI M312 
HI M492 
HI M493 
HI M494 
HI M496 
HI M496 
HI M497 
HI M498 
HI M499 
HI M600 
HI M602 
HI M603 
HI M604 
HI M606 
HI M608 
HIH318P 
HI H334P 
HIH316P 
HIH320P 
Control I 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ + 
++ 
++ 
++ 
+ ++ 
++ 
++ 
++ + 
++ 
++ 
++ 
++ 
++ + 
++ 
++ 
++ 
++ ++ ++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
[0148] Binding specificity of 316P, 300N and control anti- 
hPCSK9 mAbs to hPCSK9-mmh, mPCSK9-mmh, 
mmPCSK9-mmh, mfPCSK9-mmh, rPCSK9-mmh, chimeric 
proteins ¹I, ¹2, and ¹3, and hPCSK9 (D374Y)-mmh were 
tested as described above except that the protein concentra- 
tion is 1. 7 nM ( — =OD&0. 7; +=OD 0. 7-1. 5; ++=OD&1. 5). 
TABLE 20 
316P 300N Control I Control H Control HI 
hPCSK9-mmh 
mPCSK9-mmh 
mmPCSK9-mmh 
mfPCSK9-mmh 
rPCSK9-mmh 
Chimeric Protein ¹I 
Chimeric Protein ¹2 
Chimeric Protein ¹3 
hPCSK9(D374Y1 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
[0149] Similar results for selected mAbs were obtained by 
BIACORE™ binding assay. Briefly, 316P, 300N, or Control 
I mAb was captured on an amine-coupled anti-hFc CM5 chip 
and 100 nM of each protein injected over the mAb-captured 
surface. Changes in RU due to the binding of each protein to 
the mAb surface was determined. 
US 2010/0166768 A1 
18 
JU1. 1, 2010 
TABLE 21 
Chimeric Protein 
Antibody hPCSK9 mPCSK9 ¹I ¹2 ¹3 
ment (ICso=antibody concentration at which increases LDL 
uptake by 50%). In addition, the experiment also showed that 
both 316P and 300N were able to completely reverse the 
inhibitory effect of hPCSK9 on LDL uptake, while Control I 
mAb or HI M508 anti-hPCSK9 mAb reversed the inhibitory 
effect by about 50%. 
316P 
300N 
Control I 
500 
320 
65 
505 529 451 467 
13 243 76 10 
7 4 3 69 
Antibody 
TABLE 23 
ICso (nM1 
[0150] To further assess the binding specificity of 316P, 
which cross-reacts with mPCSK9-mmh, a cross-competition 
ELISA assay was developed to determine binding domain 
specificity. Briefly, mAbs specific for chimeric protein ¹I, ¹2, 
or ¹3, were first coated on a 96-well plate overnight at I 
pg/ml. Human PCSK9-mmh (2 pg/I) was then added to each 
well followed by I hr incubation at RT. 316P (I pg/ml) was 
added and incubated for another hour at RT. Plate-bound 
316P was detected using HRP-conjugated anti-hEc poly- 
clonal antibody. Although 316P binding to hPCSK9-mmh 
was not affected by the presence of mAbs specific for either 
chimeric protein ¹2 or chimeric protein ¹3, 316P binding to 
hPCSK9-mmh was greatly reduced by the presence of anti- 
body specific for chimeric protein ¹1. 
Example 10 
BIACORE™-Based Antigen Binding Profile Assess- 
ment 
[0151] Antibody binding profiles were also established for 
316P, 300N, Control I, II, and III mAbs using BIA- 
CORE™1000. Briefly, hPCSK9-mmh was captured on an 
anti-myc surface. A first anti-hPCSK9 mAb (50 pg/ml) was 
injected over the PCSK9-bound surface for 10 min, at a flow 
rate of 10 pl/min at 25' C. A second anti-hPCSK9 mAb (50 
pg/ml) was then injected over the first mAb-bound surface for 
10 min, at a flow rate of 10 pl/min at 25' C. Ability of the first 
mAb to block binding of the second mAb was measured and 
is expressed as percent inhibition. 
TABLE 22 
316P 
300N 
Control I 
HIM508 
21. 30 
22. 12 
&250 
&250 
TABLE 24 
Control 
316P 300N Control I Control H HI 
hPCSK9-mmh 
hPCSK9(D374Y1-mmh 
mfPCSK9-mmh 
mPCSK9-mmh 
rPCSK9-mmh 
maPCSK9-h 
14. 1 12. 6 
2. 1 1. 1 
14. 7 13. 4 
21. 2 &500 
27. 7 &500 
14. 4 &500 
&500 
&50 
&500 
&500 
&500 
&500 
13. 4 
0. 7 
14. 2 
19 
21. 9 
29. 5 
12. 4 
0. 6 
13. 6 
&500 
&500 
12. 7 
[0153] The ability of anti-hPCSK9 mAbs to reverse the 
inhibitory effect on LDL uptake by PCSK9 protein from 
different mammalian species was also tested in a HepG2 cell 
line as described above. Briefly. HepG2 cells were incubated 
overnight with serial dilutions of antibody in LPDS medium 
(beginning with 500 nM) and 50 nM of hPCSK9-mmh, 
mfPCSK9-mmh, mPCSK9-mmh, rPCSK9-mmh, or 
maPCSK9-h. HepG2 cells were also incubated overnight 
with serial dilutions of antibody in LPDS (beginning with 50 
nM) and I nM hPCSK9(D374Y). As shown in Table 24, while 
316P was able to completely reverse the inhibitory effect on 
LDL by all PCSK9 proteins tested, 300N was only able to 
reverse the inhibitory effect on LDL uptake by hPCSK9, 
hPCSK9 (D374Y), and mfPCSK9. Values are expressed as 
nM ICso. 
Second mAb 
First mAb 316P 300N Control I Control H Control HI 
316P 
300N 
Control I 
Control H 
Control HI 
100 101 27 99 101 
77 100 12 82 — 2 
6 12 100 6 9 
91 102 — 6 100 3 
73 10 — 12 I 100 
Example 11 
Increase of LDL Uptake by Anti-hPCSK9 Antibod- 
ies 
[0152] The ability of anti-hPCSK9 mAbs to increase LDL 
uptake in vitro was determined using a human hepatocellular 
liver carcinoma cell line (HepG2). HepG2 cells were seeded 
onto 96-well plates at 9x10 cells/well in DMEM complete 
media and incubated at 37' C. , 5% COn, for 6 hr to form 
HepG2 monolayers. Human PCSK9-mmh, at 50 nM in lipo- 
protein deficient medium (LPDS), and a test mAb was added 
in various concentrations from 500 nM to 0. 98 nM in LPDS 
medium. Data are expressed as ICso values for each experi- 
Example 12 
Neutralization of Biological Effect of hPCSK9 In 
Vivo 
[0154] To assess the biological effect of neutralizing 
PCSK9, hPCSK9 was over-expressed in C57BL/6 mice by 
hydrodynamic delivery (HDD) of DNA constructs encoding 
full-length hPCSK9-mmh. 4 mice (C57BL/6) were injected 
with empty vector/saline (control), and 16 mice were injected 
with a 50 pg hPCSK9-mmh-DNA/saline mixture in the tail 
vein equal to 10% of their body weight. At day 7 after HDD, 
delivery of hPCSK9 resulted in a 1. 6-fold elevation of total 
cholesterol, 3. 4-fold elevation in LDL-cholesterol (LDL-C) 
and a 1. 9-fold elevation in non-HDL cholesterol (relative to 
control). Serum hPCSK9 levels on day 7 were all greater than 
I pg/ml, as assessed by quantitative ELISA. 
[0155] Administration of HI M300N on day 6 after HDD to 
3 experimental groups (I, 5 or 10 mg/kg) (n=4 per group) via 
intraperitoneal (Lp. ) injection resulted in a significant attenu- 
ation of serum cholesterol levels. At 18 hours after adminis- 
tration, total cholesterol was reduced by 9. 8%, 26. 3% and 
26. 8%, LDL-C was reduced by 5. 1%, 52. 3% and 56. 7%, and 
US 2010/0166768 A1 
19 
JU1. 1, 2010 
non-HDL cholesterol was reduced by 7. 4%, 33. 8% and 
28. 6% in the I, 5 or 10 mg/kg HIM300N treated groups, 
respectively. 
Example 13 
Pharmacokinetic and Serum Chemistry Study in 
Monkeys 
[0156] A pharmacokinetic (PK) study was conducted in 
na'ive male cynomolgus monkeys (Macaca fascictdari s) with 
a body weight range between 5-7 kg and aged between 3-5 
years. 
[0157] Group assignments. The monkeys were assigned 
into 5 treatment groups: Treatment Group I (n=3) received 
control buffer (10 mM sodium phosphate, pH 6, I ml/kg); 
Treatment Group 2 (n=3) received I ml/kg of 316P (5 mg/ml); 
Treatment Group 3 (n=3) received I ml/kg 300N (5 mg/ml); 
Treatment Group 4 (n=3) received I ml/kg 316P (15 mg/ml); 
and Treatment Group 5 (n=3) received I ml/kg 300N (15 
mg/ml). All treatments were administered by IV bolus fol- 
lowed by a I ml saline flush. Total dose volume (ml) was 
calculated on the most recent body weight (each animal was 
weighed twice during acclimation and once weekly through- 
out the study). A single dose of test mAb or buffer control was 
administered on Day 1. 
[0158] Animal care. Animals were housed in a tempera- 
ture- and humidity-monitored environment. The targeted 
range of temperature and relative humidity was between 
18-29' C. and 30-70%, respectively. An automatic lighting 
system provided a 12-hour diurnal cycle. The dark cycle 
could be interrupted for study- or facility-related activities. 
The animals were individually housed in cages that comply 
with the Animal Welfare Act and recommendations set forth 
in The Guide for the Care and Use of Laboratory Animals 
(National Research Council 1996). 
[0159] Diet and Feeding. Animals were fed twice per day 
according to SNBL USA SOPs. Animals were fasted when 
required by specific procedures (e. g. , prior to blood draws for 
serum chemistry, urine collection, or when procedures 
involving sedation are performed). The diet was routinely 
analyzed for contaminants and found to be within manufac- 
turer's specifications. No contaminants were expected to be 
present at levels that would interfere with the outcome of the 
study. 
[0160] Experimental Design. An appropriate number of 
animals were selected from SNBL USA stock. Animals were 
examined for health by veterinary staff, and had undergone 
serum chemistry, hematology, and coagulation screening. 
Sixteen males, confirmed healthy, were assigned to the study. 
Fifteen males were assigned to specific study groups and the 
remaining animal was available as a spare. A stratified ran- 
domization scheme incorporating serum cholesterol level 
(based on the average of two draws in acclimation) was used 
to assign animals to study groups. 
[0161] Acclimation Period. Previously quarantined ani- 
mals were acclimated to the study room for a minimum of 14 
days prior to initiation of dosing. Acclimation phase data was 
collected from all animals, including the spare. All animals 
were assessed for behavioral abnormalities that could affect 
performance on study. The spare animal was returned to stock 
after day 1. 
[0162] Blood collection. Blood was collected by venipunc- 
ture from a peripheral vein from restrained, conscious ani- 
TABLE 25 
316P 300N 
PK Parameter 6 mg/kg 16 mg/kg 6 mg/kg 16 mg/kg 
T 
„„ 
(hi 
C (ttg/mli 
Tea (hi 
0. 428 
184 
83 
0. 106 
627 
184 
4. 02 0. 428 
226 1223 
216 366 
[0165] Serum Chemistry. Blood samples were collected at 
pre-dose, 12 hr, 48 hr, and subsequently once every 48 hr, for 
clinical chemistry analysis, in particular lipid profiles (i. e. 
cholesterol, LDL-C. HDL-C, trlglycerldes). With the excep- 
tion of the 12hrpost-dose sample, all animals were subject to 
an overnight fast prior to sample collection. The sample vol- 
ume was approximately I ml. Chemistry parameters were 
determined using an Olympus automated analyzer. Param- 
eters measured (Xybion code): Albumin (ALB); Alkaline 
Phosphatase (ALP); Alanine Aminotransferase (ALT); 
Aspartate Transaminase (AST); Total Bilirubin (TBIL); Cal- 
cium (Ca); Total Cholesterol (TCho); Creatine Kinase (CK); 
Creatinine (CRN); Gamma Glutamyltransaminase (GGT); 
Glucose (GLU); Inorganic Phosphorus (IP); Total Protein 
(TP); Triglyceride (TRIG); Blood Urea Nitrogen (BUN); 
Globulin (GLOB); Albumin/Globulin Ratio (A/G); Chloride 
(CI); Potassium (K); Sodium (Na); LDL and HDL choles- 
terol. Residual serum was stored at — 20' C. or below and 
disposed of no sooner than one week after analysis. 
[0166] Results from samples through Day 105 post-dose 
time point are shown in FIGS. 3-7. There was a reduction in 
total cholesterol and LDL-C in animals receiving 316P and 
300N, regardless of dose, within 24 hours of the first dose. 
Serum total cholesterol reduced rapidly and robustly (-35%, 
FIG. 3). A robust decrease of -80% was seen in LDL-C 
(FIGS. 4-5) by day 6. In animals that received a 15 mg/kg 
dose of 300N, the reduction in both total cholesterol (-10- 
15% reduction) and LDL-C (-40% reduction) continued to at 
least day 80 of the study. In addition, HDL-C was elevated in 
animals that received 316P at 15 mg/kg (FIG. 6). Animals that 
received a higher dose (15 mg/kg) o f either 316P or 300N also 
showed a reduction in triglycerides during the course of study 
(FIG. 7). 316P exhibited maximal suppression of LDL-C 
mals. Whenever possible, blood was collected via a single 
draw and then divided appropriately. 
[0163] PK Study. Blood samples (1. 5 ml) were collected at 
pre-dose, 2 min, 15, min, 30 min, I hr, 2 hr, 4 hr, 8 hr, 12 hr, 
24 hr, and subsequently once every 24 hr in serum separator 
tubes (SST). Specimen storage serum is transferred to 2 vials 
and stored at — 60' C. or below. 
[0164] Serum samples were analyzed using an optimized 
ELISA (enzyme-linked immunosorbant assay) procedure. 
Briefly, a microtiter plate was first coated with hPCSK9- 
mmh. Test mAb 316P or 300N was then captured on the 
hPCSK9-mmh plate. The captured 316P or 300N was 
detected using a biotinylated mouse anti-hlgG4 followed by 
binding to NeutrAvidin-HRP. Varying concentrations of 316P 
or 300N, ranging from 100 to 1. 56 ng/ml, were used as 
standards. One percent monkey serum (assay matrix) in the 
absence of 316P or 300N was used as the zero (0 ng/ml) 
standard. The results, shown in FIG. 2, indicate a dose-de- 
pendent increase in serum 316P and 300N levels. PK param- 
eters were analyzed using WinNonlin software (Noncompart- 
mental analysis, Model 201-IV bolus administration). 
US 20 1 0/0 1 66768 A 1 
20 
JU1. 1, 2010 
levels of up to 80% relative to baseline. The length of this 
suppression was dose-dependent with at least 60% suppres- 
sion (relative to baseline LDL-C levels) lasting approxi- 
mately I 8 days (5 mg/kg dose) and approximately 45 days ( I 5 
mg/kg dose). 300N exhibits a distinct pharmacodynamic pro- 
file from 3 I 6P. LDL-C suppression by 300N was sustained 
for a much longer period of time at comparable doses (50% 
LDL-C suppression for 28 days following a 5 mg/kg dose and 
50% LDL-C suppression for approximately 90 days follow- 
ing a I 5 mg/kg dose). There was little or no measurable 
change in liver function as determined by ALT and AST 
measurements. All animals receiving an anti-PCSK9 anti- 
body in the study exhibited a rapid suppression If LDL-C and 
total cholesterol. 
[01 67] A similar LDL-C lowering effect of 3 I 6P and 300N 
was also observed in cynomolgous monkeys that received a 
single subcutaneous (SC) administration of either 5 mg/kg 
3 I 6P or 5 mg/kg 300N (FIG. S). Both 3 I 6P and 300N dra- 
matically suppressed LDL-C levels and maintained an 
LDL-C lowering effect for approximately I 5 and 30 days, 
respectively (FIG. S). The pharmacodynamic effect (approxi- 
mately 40% LDL-C suppression) approximately correlates 
with functional antibody levels in monkey serum (FIG. 9) . As 
antibody levels decrease below I 0 pg/ml, LDL-C suppression 
appeared to diminish as well. In addition, 300N demonstrated 
a substantially longer circulating half-life than 3 I 6P and 
hence a longer observed LDL-C suppression. 
administration of 3 I 6P significantly blocked the PCSK9- 
mediated increases in total cholesterol and LDL cholesterol 
(LDL-C=2. 49 mg/dl at baseline and 3. 1 mg/dl 6 hours after 
PCSK9; a 25% increase compared to 135% with vehicle). 
Prior administration of the non-hPCSK9 specific mAb 
blocked LDL-C increases by approximately 27% from PBS 
alone (LDL-C=4. I mg/dl compared to PBS 5. 6 mg/dl). 
Analysis of LDL receptor levels in a separate cohort of mice 
(n=3 per treatment group) revealed a significant reduction in 
LDL receptor levels with PCSK9 administration, which was 
blocked by 3 I 6P but not by the non-hPCSK9 specific mAb 
(FIG. 1 0). 
[0170] Effect of different doses of 3 I 6P was also evaluated 
in PCSK9 "' " mice with both elevated LDL-C and elevated 
hPCSK9 levels. PCSK9 "' " mice were first placed on a high 
carbohydrate diet for 8 weeks, resulting in a -2-fold elevation 
in both LDL-C and hPCSK9 levels. Either 3 I 6P or a non- 
hPCSK9 specific mAb, each at I mg/kg, 5 mg/kg, or 10 
mg/kg, were administered to the mice. Sera were collected 24 
hours later and LDL-C levels were analyzed. 3 I 6P was effec- 
tive in decreasing LDL-C levels in a dose-dependent manner 
(FIG. 1 1). In addition, 3 I 6P administered at a dose of 10 
mg/kg, rapidly reduced LDL-C levels back to original (pre- 
dict) values within 24 hours. 
Example I 5 
Mouse PK Studies 
TABLE 26 
PK Parameter 3 1 6P 300N 
T (hi 
C „„(gg™1 
Tta 00 
60 
46 
64 
84 
63 
286 
Example I 4 
Attenuation of LDL Receptor Degradation by Anti- 
hPCSK9 Antibodies 
[01 6S] To assess the biological effect of PCSK9 on hepatic 
LDL receptor levels and subsequent effects on serum LDL-C 
levels, hPCSK9 was administered to mice expressing 
hPCSK9 but not mPCSK9 (PCSK9 "' " mice) by intravenous 
injection. Specifically, PCSK9 "' " mice were injected with 
PBS (control), or I . 2 mg/kg hPCSK9-mmh via the tail vein. 
Six hours after delivery of hPCSK9, a I . 4-fold elevation 
(relative to baseline level) in total cholesterol and a 23-fold 
elevation in LDL-C) in serum were observed. Analysis of 
hepatic LDL receptor levels in a separate cohort (n=3) of 
animals 4 hours after hPCSK9 administration revealed a sig- 
nificant reduction in detectable LDL receptor in liver homo- 
g enate s . 
[0169] To assess the biological effect of anti-hPCSK9 on 
hepatic LDL receptor levels and subsequent effects on serum 
LDL-C levels, 3 I 6P and a non-hPCSK9 specific mAb were 
administeredto PCSK9 "' "mice at equivalent dose (5 mg/kg 
i. p. ) 20 hours prior to the hPCSK9-mmh protein injection 
described above. Four hours after the hPCSK9 administra- 
tion, mice were sacrificed and a total of eight tissues (liver, 
brain, lung, kidney, heart, ileum, adrenal, and pancreas) were 
collected and levels of LDL receptor were determined by 
Western blot. Changes in LDL receptor levels were only 
observed in liver. In comparison to PBS control dosing, 
[0171] A PK study was conducted in 6-week-old C57BL/6 
mice and I I - I 5 week old hPCSK9 heterozygous mice. A 
single injection o f Control I, 3 I 6P, or 3 OON, each at I 0 mg/kg, 
was administered SC. Serum bleeds were measured for hIgG 
levels at 0 hr (pre-bleed), 6 hr, day I, 3, 6, 10, 14, 21, 28, 35, 
42 and 56, for a total of 12 time points, using an anti-hFc 
capture and anti-hFc detection sandwich ELISA (FIGS. 12 
and 13). All mAbs achieved their T at approximately 3 
days with corresponding C levels of approximately 
47-1 I 5 pg/ml for C57BL/6 mice and 55-1 96 pg/ml for 
hPCSK9 heterozygous mice. At Day 5 6, Control I mAb levels 
were about 12 pg/ml and 300N levels were about I I pg/ml 
whereas 3 I 6P levels were about less than 0. 02 pg/ml in 
C57BL/6 mice. At Day 56 in hPCSK9 heterozygous mice, 
Control I mAb levels were about 29 pg/ml, while both 300N 
and 3 I 6P levels were below the quantifiable limit (BQL) of 
0. 02 pg/ml. 
Example I 6 
Anti-hPCSK9 Antibody Binding to Mutant/Variant 
hPCSK9 
[0172] To further assess binding between hPCSK9 and 
anti-hPCSK9 mAbs, 2 I variant hPCSK9 proteins in which 
each variant contained a single point mutation and two variant 
hPCSK9 proteins each contained a double mutation were 
generated. Each selected antibody was captured on a F(ab')a 
anti-hIgG surface created through direct chemical coupling to 
a BIACORE™ chip to form a captured antibody surface. 
Each mmh-tagged variant hPCSK9 at varying concentrations 
from 100 nM to 25 nM was then injected over the captured 
antibody surface at a flowrate of 60 pl/min for 240 sec, and the 
dissociation of variant hPCSK9 and antibody was monitored 
in real time for 20 min at 25' C. nb: no binding was observed 
under these experimental conditions (K~=Mx10 
Ttra:min; WT~ildtype). 
US 2010/0166768 A1 
21 
JU1. ], 2010 
TABLE 27 
316P 300N Control I Control H Control HI 
KD Tt/r KD Tt/r KD Tt/r KD Tt/r Kr) Tt/r 
WT 
P70A 
S127R 
D129G 
S147F 
SI63R 
EI69R 
T162R 
D192R 
R194E 
E197R 
R216H 
R216E 
F216L 
R237E 
D238R 
A341 R 
D343R 
R367H 
E366K 
D374Y 
V380M 
P70A, S147F 
E366K, V380M 
1. 00 
1. 42 
2. 40 
1. 27 
1. 29 
6. 64 
6. 96 
0. 98 
1. 36 
0. 38 
1. 42 
0. 86 
0. 90 
1. 83 
2. 48 
410 
1. 64 
7. 88 
6. 26 
2. 92 
2. 04 
0. 48 
1. 18 
3. 33 
37 
32 
36 
36 
32 
4 
6 
43 
28 
71 
27 
41 
43 
32 
16 
I 
21 
6 
30 
13 
16 
63 
34 
12 
0. 69 120 
1. 68 80 
1. 87 110 
1. 40 88 
9. 07 24 
0. 66 141 
0. 82 94 
0. 68 140 
0. 76 119 
0. 66 129 
0. 67 116 
1. 03 98 
1. 81 77 
0. 99 121 
1. 03 109 
0. 78 123 
0. 34 190 
1. 18 89 
6. 63 66 
36. 0 2 
0. 66 83 
2. 82 28 
7. 87 24 
783 I 
30. 6 
19. 0 
26. 0 
22. 9 
21. 1 
36. 6 
31. 7 
29. 0 
30. 2 
31. 4 
30. 2 
37. 8 
44. 0 
21. 2 
29. 6 
26. 9 
28. 7 
27. 0 
26. 4 
28. 8 
26. 0 
26. 9 
23. 6 
26. 6 
16 0. 10 
16 0. 24 
18 0. 26 
18 0. 19 
16 0. 22 
17 0. 09 
16 0. 08 
17 0. 09 
16 0. 09 
16 0. 07 
17 0. 09 
17 0. 66 
16 4. 48 
16 1. 36 
16 0. 07 
19 0. 24 
18 0. 08 
16 0. 08 
13 0. 63 
18 0. 46 
17 0. 08 
17 0. 16 
18 0. 23 
18 0. 69 
333 
168 
288 
267 
178 
322 
360 
322 
326 
389 
339 
49 
12 
39 
481 
144 
340 
402 
166 
69 
286 
177 
164 
60 
0. 60 481 
0. 90 326 
0. 66 660 
0. 76 446 
0. 23 1468 
3. 33 60 
297 68 
0. 48 362 
nb nb 
nb nb 
nb nb 
0. 74 272 
0. 78 276 
0. 33 880 
6. 89 43 
0. 14 1273 
0. 88 200 
4. 13 66 
1. 91 896 
0. 38 808 
1. 02 161 
0. 36 711 
0. 79 348 
0. 62 661 
[0173] The results show that when residue D238 was 
mutated, the binding affinity of 316P for hPCSK9 was 
reduced &400-fold, from a K~ of I x10 M to 410x10 M; 
and T„2 shortened about 30-fold, from 37 to I min, indicating 
that 316P binds an epitope on hPCSK9 comprising D238 of 
hPCSK9 (SEQ ID NO:755). Additionally, BIACORE™ 
assays show that 316P binding affinity and T„2 were reduced 
about 5- to 10-fold when a residue at 153, 159 or 343 was 
mutated. Specifically. K~ was reduced from about I x10 M 
to between about 5-8x10 M when any one of S153, E159 or 
D343 were mutated; while T„2 was decreased from about 37 
min to between about 4-6 min. 
[0174] 300N binding to hPCSK9 was reduced about 
50-fold when the residue at position 366 was mutated, result- 
ing in a decreased K~ of from about 0. 7x10 M to about 
36x10 M and a shorter T„2 from about 120 to 2 min. These 
results indicate that 300N binds an epitope on hPCSK9 com- 
prising E366 ofhPCSK9 (SEQ ID NO:755). Additionally, the 
BIACORE™ assays show that 300N binding affinity and T„2 
were reduced between 2- to &10-fold when a residue at 147 or 
380 was mutated. Specifically, K~ was reduced from about 
0. 69x10 M to between about 2-9x10 M when any of S147 
or V380 were mutated; while T„2 was shortened from about 
120 min to between about 24-66 min. Compared to 316P, 
300N binding to hPCSK9 was not reduced by a mutation at 
residue 238. 
[0175] In contrast, Control I antibody did not exhibit an 
altered binding affinity or T„2 in response to any of the posi- 
tional mutations tested; Control II antibody exhibited a 
40-fold decreased affinity when residue 215 was mutated 
(R215E) (from -O. I x10 to -4. 5x10 ), and T„2 was about 
27-fold shorter (from -333 to 12 min); while Control III 
antibody exhibited a decreased affinity when residue 237 was 
mutated (K~ decreased from-0. 6x10 to -5. 9x10, and T„2 
decreased from -481 to -43 min). 
[0176] Binding specificity of 316P, 300N, and control anti- 
hPCSK9 mAbs to hPCSK9 variants was tested using an 
TABLE 28 
hPCSK9 or Variant 
Control Control 
316P 300N I Control H HI 
IIPCSK9(WTi 
hPCSK9(SI27Ri 
hPCSK9(DI29Gi 
hPCSK9(SI63Ri 
hPCSK9(R216H1 
hPCSK9(F216Li 
hPCSK9(R237E1 
hPCSK9(D238Ri 
hPCSK9(A34IRi 
hPCSK9(D343Ri 
hPCSK9(R367H1 
hPCSK9(EI 69Ri 
hPCSK9(TI 62Ri 
HPCSK9(DI92Ri 
hPCSK9(RI94Ei 
hPCSK9(EI 97Ri 
hPCSK9(R216E1 
hPCSK9(P70Ai 
hPCSK9(SI47Fi 
hPCSK9(E366Ki 
hPCSK9(V380Mi 
hPCSK9(P70A, SI47Fi 
hPCSK9(E366K, V380Mi 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
ELISA-based immunoassay. Anti-PCSK9 mAbs were coated 
on a 96-well plate overnight at 4' C. Each mmh-tagged vari- 
ant hPCSK9 in CHO-kl transient transfection lysate super- 
natants was added to the antibody-coated plate at various 
concentrations ranging from 0 to 5 nM. After I hr binding at 
RT, the plate was washed and bound variant hPCSK9 was 
detected using HRP-conjugated anti-myc polyclonal anti- 
body ( — =OD&0. 7; +=OD 0. 7-1. 5; ++=OD&1. 5). 
US 2010/0166768 A1 
22 
JU1. 1, 2010 
Example 17 
Effect of 316P on Normolipemic and Hyperlipemic 
Hamster 
[0177] The ability of anti-PCSK9 mAb 316P to reduce 
serum LDL-C was tested in normolipemic or hyperlipemic 
Gold Syrian hamsters (Mesocricetus auratus). Male Syrian 
Hamsters, age 6-8 weeks, weighing between 80-100 grams, 
were allowed to acclimate for a period of 7 days before entry 
into the study. All animals were placed on either a standard 
chow diet or a hyperlipemic diet of chow supplemented with 
0. 1% cholesterol and 10% coconut oil. The 316P mAb was 
delivered to hamsters by a single subcutaneous injection at 
doses of I, 3, or 10 mg/kg for normolipemic hamsters and at 
doses of 3, 10, or 30 mg/kg for hyperlipemic hamsters. Serum 
samples were taken from all groups at 24 hr and 7, 14, and 22 
days post injection, at which time serum lipid levels were 
assessed and compared to baseline levels taken 7 days prior to 
the administration of the mAbs. Circulating total cholesterol 
and LDL-C in normolipemic hamsters was significantly 
reduced in a dose-dependent manner compared to vehicle 
injection. As shown in FIG. 14, administration of 316P effec- 
tively reduced LDL-C levels by up to 60% seven days post 
injection at the highest dose (10 mg/kg) tested. Similar cho- 
lesterol reducing effect of 316P was not observed in hyper- 
lipemic hamsters. 
SEQUENCE LISTING 
&160& NUMBER OF SEQ ID NOS: 763 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 1 
LENGTH: 351 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 1 
caggtccagc tggtgcagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt tactctaagt agttacgaca tgcactgggt ccgccaatct 120 
acaggaaaag gtctggagtg ggtctcagct attggttcta ccggtgacac atactatcca 180 
ggctccgtga agggccgatt caccatcacc agagaaaaag ccaagaactc cgtgtatctt 240 
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgtaag agaggggtgg 300 
gaggtaccct ttgactactg gggccaggga accctggtca ctgtctcctc a 351 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 2 
LENGTH: 117 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 2 
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Ser Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys 
50 55 60 
Gly Arg Phe Thr Ile Thr Arg Glu Lys Ala Lys Asn Ser Val Tyr Leu 
65 70 75 80 
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Val 
85 90 95 
Arg Glu Gly Trp Glu Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
100 105 110 
Val Thr Val Ser Ser 
115 
US 2010/0166768 A1 
23 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 3 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 3 
ggatttactc taagtagtta cgac 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 4 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 4 
Gly Phe Thr Leu Ser Ser Tyr Asp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 5 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 5 
attggttcta ccggtgacac a 21 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 6 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 6 
Ile Gly Ser Thr Gly Asp Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 7 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 7 
gtaagagagg ggtgggaggt accctttgac tac 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 8 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 8 
Val Arg Glu Gly Trp Glu Val Pro Phe Asp Tyr 
1 5 10 
US 2010/0166768 A1 
24 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 9 
LENGTH: 327 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 9 
gacatccaga tgacccagtc tccagccacc ctgtctgtgt ctccagggga aagagccgcc 60 
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca ccagaaacct 
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 
120 
180 
aggttcagtg gcattgggtc tgggacagag ttcactctca ttatcagcag cctgcagtct 
gaagattttg cattttattt ctgtcagcag tataataact ggcctccatt cactttcggc 
240 
300 
cctgggacca aggtggagat caaacga 327 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 10 
LENGTH: 109 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 10 
Asp Ile Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Ala Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
20 25 30 
Leu Ala Trp Tyr His Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
35 40 45 
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
50 55 60 
Ile Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Ser 
65 70 75 80 
Glu Asp Phe Ala Phe Tyr Phe Cys Gln Gln Tyr Asn Asn Trp Pro Pro 
85 90 95 
Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys Arg 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 11 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 11 
cagagtgtta gcagcaac 18 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 12 
LENGTH: 6 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 12 
Gln Ser Val Ser Ser Asn 
US 2010/0166768 A1 
25 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 13 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 13 
ggtgcatcc 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 14 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 14 
Gly Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 15 
LENGTH: 30 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 15 
cagcagtata ataactggcc tccattcact 30 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 16 
LENGTH: 10 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 16 
Gln Gln Tyr Asn Asn Trp Pro Pro Phe Thr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 17 
LENGTH: 351 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 17 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 
tcctgtgcag cctctggatt tactctaagt agttacgaca tgcactgggt ccgccaatct 
60 
120 
acaggaaaag gtctggagtg ggtctcagct attggttcta ccggtgacac atactatcca 180 
ggctccgtga agggccgatt caccatcacc agagaaaaag ccaagaactc cgtgtatctt 240 
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgtaag agaggggtgg 
gaggtaccct ttgactactg gggccaggga accctggtca ccgtctcctc a 
300 
351 
&210& SEQ ID NO 18 
US 2010/0166768 A1 
26 
JU1. 1, 2010 
-continued 
&211& 
&212& 
&213& 
&220& 
&223& 
LENGTH: 117 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 18 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Ser Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys 
50 55 60 
Gly Arg Phe Thr Ile Thr Arg Glu Lys Ala Lys Asn Ser Val Tyr Leu 
65 70 75 80 
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Val 
85 90 95 
Arg Glu Gly Trp Glu Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
100 105 110 
Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 19 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 19 
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccgcc 
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca ccagaaacct 
60 
120 
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 
aggttcagtg gcattgggtc tgggacagag ttcactctca ttatcagcag cctgcagtct 
180 
240 
gaagattttg cattttattt ctgtcagcag tataataact ggcctccatt cactttcggc 
cctgggacca aagtggatat caaa 
300 
324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 20 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 20 
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Ala Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
20 25 30 
Leu Ala Trp Tyr His Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
35 40 45 
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
50 55 60 
US 2010/0166768 A1 
27 
JU1. 1, 2010 
-continued 
Ile Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Ser 
65 70 75 80 
Glu Asp Phe Ala Phe Tyr Phe Cys Gln Gln Tyr Asn Asn Trp Pro Pro 
85 90 95 
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 21 
LENGTH: 351 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 21 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 
tcctgtgcag cctctggatt tactctaagt agttacgaca tgcactgggt ccgccaagct 
60 
120 
acaggaaaag gtctggagtg ggtctcagct attggttcta ccggtgacac atactatcca 
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 
180 
240 
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgtaag agaggggtgg 
gaggtaccct ttgactactg gggccaggga accctggtca ccgtctcctc a 
300 
351 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 22 
LENGTH: 117 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 22 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu 
65 70 75 80 
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Val 
85 90 95 
Arg Glu Gly Trp Glu Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu 
100 105 110 
Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 23 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 23 
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60 
US 2010/0166768 A1 
28 
JU1. 1, 2010 
-continued 
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 
120 
180 
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 
gaagattttg cagtttatta ctgtcagcag tataataact ggcctccatt cactttcggc 
240 
300 
cctgggacca aagtggatat caaa 324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 24 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 24 
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
35 40 45 
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65 70 75 80 
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro 
85 90 95 
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 25 
LENGTH: 342 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 25 
caggtgcagc tggtgcagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 
ccaggcaagg ggctggagtg ggtggcgttt ataggatttg atggaagtaa tatacattat 
120 
180 
ggagactccg tgaggggccg aatcatcata tccagagaca attccgagaa cacgttgtat 
ctggaaatga acagcctgag agccgaggac acggcaatgt actattgtgc gagagagaag 
240 
300 
ggtttagact ggggccaggg aaccacggtc accgtctcct ca 342 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 26 
LENGTH: 114 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 26 
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
US 2010/0166768 A1 
29 
JU1. 1, 2010 
-continued 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Phe Ile Gly Phe Asp Gly Ser Asn Ile His Tyr Gly Asp Ser Val 
50 55 60 
Arg Gly Arg Ile Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr 
65 70 75 80 
Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys 
85 90 95 
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Thr Val Thr Val 
100 105 110 
Ser Ser 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 27 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 27 
ggattcacct tcagtagcta tggc 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 28 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 28 
Gly Phe Thr Phe Ser Ser Tyr Gly 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 29 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 29 
ataggatttg atggaagtaa tata 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 30 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 30 
Ile Gly Phe Asp Gly Ser Asn Ile 
1 5 
&210& SEQ ID NO 31 
&211& LENGTH: 21 
&212& TYPE: DNA 
&213& ORGANISM: Artificial Sequence 
US 2010/0166768 A1 
30 
JU1. 1, 2010 
-continued 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 31 
gcgagagaga agggtttaga c 21 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 32 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 32 
Ala Arg Glu Lys Gly Leu Asp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 33 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 33 
gccatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 
120 
180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 240 
gatgattttg caacttatta ctgccaacag tataatagtt attacacttt tggccagggg 300 
accaaggtgg aaatcaaacg a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 34 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 34 
Ala Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr 
85 90 95 
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
100 105 
&210& SEQ ID NO 35 
&211& LENGTH: 18 
US 2010/0166768 A1 
31 
JU1. 1, 2010 
-continued 
&212& TYPE: DNA 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 35 
cagagtatta gtagctgg 18 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 36 
LENGTH: 6 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 36 
Gln Ser Ile Ser Ser Trp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 37 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 37 
aaggcgtct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 38 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 38 
Lys Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 39 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 39 
caacagtata atagttatta cact 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 40 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 40 
Gln Gln Tyr Asn Ser Tyr Tyr Thr 
1 5 
&210& SEQ ID NO 41 
&211& LENGTH: 342 
&212& TYPE: DNA 
US 2010/0166768 A1 
32 
JU1. 1, 2010 
-continued 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 41 
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 
ccaggcaagg ggctggagtg ggtggcgttt ataggatttg atggaagtaa tatacattat 
120 
180 
ggagactccg tgaggggccg aatcatcata tccagagaca attccgagaa cacgttgtat 
ctggaaatga acagcctgag agccgaggac acggcaatgt actattgtgc gagagagaag 
240 
300 
ggtttagact ggggccaggg aaccctggtc accgtctcct ca 342 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 42 
LENGTH: 114 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 42 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Phe Ile Gly Phe Asp Gly Ser Asn Ile His Tyr Gly Asp Ser Val 
50 55 60 
Arg Gly Arg Ile Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr 
65 70 75 80 
Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys 
85 90 95 
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val 
100 105 110 
Ser Ser 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 43 
LENGTH: 318 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 43 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120 
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 
180 
240 
gatgattttg caacttatta ctgccaacag tataatagtt attacacttt tggccagggg 300 
accaagctgg agatcaaa 318 
&210& SEQ ID NO 44 
&211& LENGTH: 106 
US 2010/0166768 A1 
33 
JU1. 1, 2010 
-continued 
&212& TYPE: PRT 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 44 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr 
85 90 95 
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 45 
LENGTH: 342 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 45 
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 
tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 
60 
120 
ccaggcaagg ggctggagtg ggtggcagtt ataggatttg atggaagtaa tatatactat 180 
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 
ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gagagagaag 
ggtttagact ggggccaggg aaccctggtc accgtctcct ca 
300 
342 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 46 
LENGTH: 114 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 46 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Val Ile Gly Phe Asp Gly Ser Asn Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
US 2010/0166768 A1 
34 
JU1. 1, 2010 
-continued 
85 90 95 
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val 
100 105 110 
Ser Ser 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 47 
LENGTH: 319 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 47 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 
120 
180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 
gatgattttg caacttatta ctgccaacag tataatagtt attacacttt tggccagggg 
240 
300 
accaagctgg agatcaaac 319 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 48 
LENGTH: 106 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 48 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Tyr Thr 
85 90 95 
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 49 
LENGTH: 342 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 49 
caggtgcagc tgcaggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 
60 
120 
ccaggcaagg ggctggagtg ggtggcgttt ataggatttg atggaagtaa tatatattat 180 
US 2010/0166768 A1 
35 
JU1. 1, 2010 
-continued 
ggagactccg tgaggggccg aatcatcata tccagagaca attccgagaa cacgttgtat 240 
ctggaaatga acagcctgag agccgaggac acggcagtgt attattgtgc gagagagaag 300 
ggtttagact ggggccaggg aaccctggtc actgtctcct ca 342 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 50 
LENGTH: 114 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 50 
Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Phe Ile Gly Phe Asp Gly Ser Asn Ile Tyr Tyr Gly Asp Ser Val 
50 55 60 
Arg Gly Arg Ile Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr 
65 70 75 80 
Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val 
100 105 110 
Ser Ser 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 51 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 51 
ggattcacct tcagtagcta tggc 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 52 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 52 
Gly Phe Thr Phe Ser Ser Tyr Gly 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 53 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 53 
ataggatttg atggaagtaa tata 24 
US 2010/0166768 A1 
36 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 54 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 54 
Ile Gly Phe Asp Gly Ser Asn Ile 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 55 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 55 
gcgagagaga agggtttaga c 21 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 56 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 56 
Ala Arg Glu Lys Gly Leu Asp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 57 
LENGTH: 342 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 57 
gccatccaga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60 
atcaactgca agtccagcca gagtgttttt cacacctcca acaataagaa ctacttagtt 120 
tggtatcagc agaaaccagg acagcctcct aagttgctcc tttactgggc ctctacccgg 180 
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 
atcagcagcc tgcaggctga agatgtggca aattattact gtcaccaata ttacagtatt 
240 
300 
ccgtggacgt tcggccaagg gaccaaggtg gagatcaaac ga 342 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 58 
LENGTH: 114 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 58 
Ala Ile Gln Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1 5 10 15 
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Phe His Thr 
20 25 30 
US 2010/0166768 A1 
37 
JU1. 1, 2010 
-continued 
Ser Asn Asn Lys Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln 
35 40 45 
Pro Pro Lys Leu Leu Leu Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
50 55 60 
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65 70 75 80 
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Asn Tyr Tyr Cys His Gln 
85 90 95 
Tyr Tyr Ser Ile Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 
100 105 110 
Lys Arg 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 59 
LENGTH: 36 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 59 
cagagtgttt ttcacacctc caacaataag aactac 36 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 60 
LENGTH: 12 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 60 
Gln Ser Val Phe His Thr Ser Asn Asn Lys Asn Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 61 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 61 
tgggcctct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 62 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 62 
Trp Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 63 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 63 
US 2010/0166768 A1 
38 
JU1. 1, 2010 
-continued 
caccaatatt acagtattcc gtggacg 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 64 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 64 
His Gln Tyr Tyr Ser Ile Pro Trp Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 65 
LENGTH: 342 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 65 
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 
tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 
ccaggcaagg ggctggagtg ggtggcgttt ataggatttg atggaagtaa tatatattat 
120 
180 
ggagactccg tgaggggccg aatcatcata tccagagaca attccgagaa cacgttgtat 
ctggaaatga acagcctgag agccgaggac acggcagtgt attattgtgc gagagagaag 
240 
300 
ggtttagact ggggccaggg aaccctggtc accgtctcct ca 342 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 66 
LENGTH: 114 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 66 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Phe Ile Gly Phe Asp Gly Ser Asn Ile Tyr Tyr Gly Asp Ser Val 
50 55 60 
Arg Gly Arg Ile Ile Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr 
65 70 75 80 
Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val 
100 105 110 
Ser Ser 
&210& SEQ ID NO 67 
&211& LENGTH: 339 
&212& TYPE: DNA 
&213& ORGANISM: Artificial Sequence 
US 2010/0166768 A1 
39 
JU1. 1, 2010 
-continued 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 67 
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60 
atcaactgca agtccagcca gagtgttttt cacacctcca acaataagaa ctacttagtt 120 
tggtatcagc agaaaccagg acagcctcct aagttgctcc tttactgggc ctctacccgg 180 
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 
atcagcagcc tgcaggctga agatgtggca aattattact gtcaccaata ttacagtatt 
240 
300 
ccgtggacgt tcggccaagg gaccaaggtg gaaatcaaa 339 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 68 
LENGTH: 113 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 68 
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1 5 10 15 
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Phe His Thr 
20 25 30 
Ser Asn Asn Lys Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln 
35 40 45 
Pro Pro Lys Leu Leu Leu Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
50 55 60 
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65 70 75 80 
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Asn Tyr Tyr Cys His Gln 
85 90 95 
Tyr Tyr Ser Ile Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 
100 105 110 
Lys 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 69 
LENGTH: 342 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 69 
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 
tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 
ccaggcaagg ggctggagtg ggtggcagtt ataggatttg atggaagtaa tatatactat 
120 
180 
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 
ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gagagagaag 300 
ggtttagact ggggccaggg aaccctggtc accgtctcct ca 342 
&210& SEQ ID NO 70 
&211& LENGTH: 114 
&212& TYPE: PRT 
US 2010/0166768 A1 
40 
JU1. 1, 2010 
-continued 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 70 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Val Ile Gly Phe Asp Gly Ser Asn Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Glu Lys Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val 
100 105 110 
Ser Ser 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 71 
LENGTH: 339 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 71 
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60 
atcaactgca agtccagcca gagtgttttt cacacctcca acaataagaa ctacttagct 120 
tggtaccagc agaaaccagg acagcctcct aagctgctca tttactgggc ctctacccgg 
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 
180 
240 
atcagcagcc tgcaggctga agatgtggca gtttattact gtcaccaata ttacagtatt 
ccgtggacgt tcggccaagg gaccaaggtg gaaatcaaa 
300 
339 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 72 
LENGTH: 113 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 72 
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1 5 10 15 
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Phe His Thr 
20 25 30 
Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
35 40 45 
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
50 55 60 
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65 70 75 80 
US 2010/0166768 A1 
41 
JU1. 1, 2010 
-continued 
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln 
85 90 95 
Tyr Tyr Ser Ile Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 
100 105 110 
Lys 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 73 
LENGTH: 354 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 73 
gaagtgcagc tggtgcagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt cacctttaac aactatgcca tgaactgggt ccgccaggct 
ccaggaaagg gactggactg ggtctcaact attagtggta gcggtggtac tacaaactac 
120 
180 
gcagactccg tgaagggccg tttcattatt tcccgagaca gttccaaaca cacgctgtat 
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagattct 
240 
300 
aactggggaa atttcgatct ctggggccgt ggcaccacgg tcactgtctc ctca 354 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 74 
LENGTH: 118 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 74 
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asn Tyr 
20 25 30 
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val 
35 40 45 
Ser Thr Ile Ser Gly Ser Gly Gly Thr Thr Asn Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Ile Ile Ser Arg Asp Ser Ser Lys His Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Lys Asp Ser Asn Trp Gly Asn Phe Asp Leu Trp Gly Arg Gly Thr 
100 105 110 
Thr Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 75 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 75 
ggattcacct ttaacaacta tgcc 24 
US 2010/0166768 A1 
42 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 76 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 76 
Gly Phe Thr Phe Asn Asn Tyr Ala 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 77 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 77 
attagtggta gcggtggtac taca 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 78 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 78 
Ile Ser Gly Ser Gly Gly Thr Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 79 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 79 
gcgaaagatt ctaactgggg aaatttcgat ctc 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 80 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 80 
Ala Lys Asp Ser Asn Trp Gly Asn Phe Asp Leu 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 81 
LENGTH: 342 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 81 
gacatccaga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 
atcaactgca agtccagcca gagtgtttta tacaggtcca acaataggaa cttcttaggt 
60 
120 
US 2010/0166768 A1 
43 
JU1. 1, 2010 
-continued 
tggtaccagc agaaaccagg gcagcctcct aatctactca tttactgggc atctacccgg 180 
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 240 
atcagcagcc tgcaggctga agatgtggca gtttattact gtcaacaata ttatactact 
ccgtacactt ttggccaggg gaccaaggtg gaaatcaaac ga 
300 
342 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 82 
LENGTH: 114 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 82 
Asp Ile Gln Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1 5 10 15 
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Arg 
20 25 30 
Ser Asn Asn Arg Asn Phe Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln 
35 40 45 
Pro Pro Asn Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
50 55 60 
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65 70 75 80 
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 
85 90 95 
Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile 
100 105 110 
Lys Arg 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 83 
LENGTH: 36 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 83 
cagagtgttt tatacaggtc caacaatagg aacttc 36 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 84 
LENGTH: 12 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 84 
Gln Ser Val Leu Tyr Arg Ser Asn Asn Arg Asn Phe 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 85 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 85 
US 2010/0166768 A1 
44 
JU1. 1, 2010 
-continued 
tgggcatct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 86 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 86 
Trp Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 87 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 87 
caacaatatt atactactcc gtacact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 88 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 88 
Gln Gln Tyr Tyr Thr Thr Pro Tyr Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 89 
LENGTH: 354 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 89 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 
tcctgtgcag cctctggatt cacctttaac aactatgcca tgaactgggt ccgccaggct 
60 
120 
ccaggaaagg gactggactg ggtctcaact attagtggta gcggtggtac tacaaactac 
gcagactccg tgaagggccg tttcattatt tcccgagaca gttccaaaca cacgctgtat 
180 
240 
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagattct 
aactggggaa atttcgatct ctggggccgt ggcaccctgg tcactgtctc ctca 
300 
354 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 90 
LENGTH: 118 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 90 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
US 2010/0166768 A1 
45 
JU1. 1, 2010 
-continued 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asn Tyr 
20 25 30 
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val 
35 40 45 
Ser Thr Ile Ser Gly Ser Gly Gly Thr Thr Asn Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Ile Ile Ser Arg Asp Ser Ser Lys His Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Lys Asp Ser Asn Trp Gly Asn Phe Asp Leu Trp Gly Arg Gly Thr 
100 105 110 
Leu Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 91 
LENGTH: 339 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 91 
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 
atcaactgca agtccagcca gagtgtttta tacaggtcca acaataggaa cttcttaggt 
60 
120 
tggtaccagc agaaaccagg gcagcctcct aatctactca tttactgggc atctacccgg 180 
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 240 
atcagcagcc tgcaggctga agatgtggca gtttattact gtcaacaata ttatactact 
ccgtacactt ttggccaggg gaccaagctg gagatcaaa 
300 
339 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 92 
LENGTH: 113 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 92 
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1 5 10 15 
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Arg 
20 25 30 
Ser Asn Asn Arg Asn Phe Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln 
35 40 45 
Pro Pro Asn Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
50 55 60 
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65 70 75 80 
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 
85 90 95 
Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 
100 105 110 
Lys 
US 2010/0166768 A1 
46 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 93 
LENGTH: 354 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 93 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt cacctttaac aactatgcca tgagctgggt ccgccaggct 
ccagggaagg ggctggagtg ggtctcagct attagtggta gcggtggtac tacatactac 
120 
180 
gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240 
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagattct 300 
aactggggaa atttcgatct ctggggccgt ggcaccctgg tcactgtctc ctca 354 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 94 
LENGTH: 118 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 94 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asn Tyr 
20 25 30 
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Lys Asp Ser Asn Trp Gly Asn Phe Asp Leu Trp Gly Arg Gly Thr 
100 105 110 
Leu Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 95 
LENGTH: 339 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 95 
gacatcgtga tgacccagtc tccagactcc ctggctgtgt ctctgggcga gagggccacc 60 
atcaactgca agtccagcca gagtgtttta tacaggtcca acaataggaa cttcttagct 120 
tggtaccagc agaaaccagg acagcctcct aagctgctca tttactgggc atctacccgg 
gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt cactctcacc 
180 
240 
atcagcagcc tgcaggctga agatgtggca gtttattact gtcaacaata ttatactact 300 
US 2010/0166768 A1 
47 
JU1. 1, 2010 
-continued 
ccgtacactt ttggccaggg gaccaagctg gagatcaaa 339 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 96 
LENGTH: 113 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 96 
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 
1 5 10 15 
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Arg 
20 25 30 
Ser Asn Asn Arg Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 
35 40 45 
Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 
50 55 60 
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
65 70 75 80 
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 
85 90 95 
Tyr Tyr Thr Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 
100 105 110 
Lys 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 97 
LENGTH: 351 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 97 
caggtgcagc tggtgcagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 
tcctgtgcag tctctggatt caccctcagt agctacgata tgcactgggt ccgccaacct 
acaggaaaag gtctggagtg ggtctcagct attggttcta ctggtgacac atactatcca 
120 
180 
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agagggatgg 
240 
300 
gacgtaccct ttgacttctg gggccaggga accctggtca ccgtctcctc a 351 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 98 
LENGTH: 117 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 98 
Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Leu Ser Ser Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Pro Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
US 2010/0166768 A1 
48 
JU1. 1, 2010 
-continued 
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu 
65 70 75 80 
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Gly Trp Asp Val Pro Phe Asp Phe Trp Gly Gln Gly Thr Leu 
100 105 110 
Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 99 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 99 
ggattcaccc tcagtagcta cgat 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 100 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 100 
Gly Phe Thr Leu Ser Ser Tyr Asp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 101 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 101 
attggttcta ctggtgacac a 21 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 102 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 102 
Ile Gly Ser Thr Gly Asp Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 103 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 103 
gcaagagagg gatgggacgt accctttgac ttc 33 
US 2010/0166768 A1 
49 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 104 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 104 
Ala Arg Glu Gly Trp Asp Val Pro Phe Asp Phe 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 105 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 105 
gccatccagt tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggcaagtca ggacattaga aatgatttag gctggtatca gcagaaacca 120 
gggaaagccc ctaagctcct gatctatgct gcatccagtt tacaaagtgg ggtcccatca 
cggttcagcg gcagtggatc tggcacagat ttcactctca ccatcagcag cctgcagcct 
180 
240 
gaagattttg caacttatta ctgtctacaa gattacaatt acccgtggac gttcggccaa 
gggaccaagg tggagatcaa acga 
300 
324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 106 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 106 
Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Asp 
20 25 30 
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Trp 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 107 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 107 
US 2010/0166768 A1 
50 
JU1. 1, 2010 
-continued 
caggacatta gaaatgat 18 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 108 
LENGTH: 6 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 108 
Gln Asp Ile Arg Asn Asp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 109 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 109 
gctgcatcc 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 110 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 110 
Ala Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 111 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 111 
ctacaagatt acaattaccc gtggacg 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 112 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 112 
Leu Gln Asp Tyr Asn Tyr Pro Trp Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 113 
LENGTH: 351 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 113 
US 2010/0166768 A1 
51 
JU1. 1, 2010 
-continued 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 
tcctgtgcag tctctggatt caccctcagt agctacgata tgcactgggt ccgccaacct 
60 
120 
acaggaaaag gtctggagtg ggtctcagct attggttcta ctggtgacac atactatcca 
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 
180 
240 
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agagggatgg 
gacgtaccct ttgacttctg gggccaggga accctggtca ccgtctcctc a 
300 
351 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 114 
LENGTH: 117 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 114 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Leu Ser Ser Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Pro Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu 
65 70 75 80 
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Gly Trp Asp Val Pro Phe Asp Phe Trp Gly Gln Gly Thr Leu 
100 105 110 
Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 115 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 115 
gccatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggcaagtca ggacattaga aatgatttag gctggtatca gcagaaacca 
gggaaagccc ctaagctcct gatctatgct gcatccagtt tacaaagtgg ggtcccatca 
120 
180 
cggttcagcg gcagtggatc tggcacagat ttcactctca ccatcagcag cctgcagcct 
gaagattttg caacttatta ctgtctacaa gattacaatt acccgtggac gttcggccaa 
240 
300 
gggaccaagg tggaaatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 116 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
52 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 116 
Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Asp 
20 25 30 
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Trp 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 117 
LENGTH: 351 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 117 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt caccctcagt agctacgata tgcactgggt ccgccaagct 
acaggaaaag gtctggagtg ggtctcagct attggttcta ctggtgacac atactatcca 
120 
180 
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agagggatgg 
240 
300 
gacgtaccct ttgacttctg gggccaggga accctggtca ccgtctcctc a 351 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 118 
LENGTH: 117 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 118 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu 
65 70 75 80 
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Gly Trp Asp Val Pro Phe Asp Phe Trp Gly Gln Gly Thr Leu 
100 105 110 
US 2010/0166768 A1 
53 
JU1. 1, 2010 
-continued 
Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 119 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 119 
gccatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggcaagtca ggacattaga aatgatttag gctggtatca gcagaaacca 
gggaaagccc ctaagctcct gatctatgct gcatccagtt tacaaagtgg ggtcccatca 
120 
180 
aggttcagcg gcagtggatc tggcacagat ttcactctca ccatcagcag cctgcagcct 
gaagattttg caacttatta ctgtctacaa gattacaatt acccgtggac gttcggccaa 
240 
300 
gggaccaagg tggaaatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 120 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 120 
Ala Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Asp 
20 25 30 
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Asp Tyr Asn Tyr Pro Trp 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 121 
LENGTH: 384 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 121 
caggtgcagc tgcaggagtc ggggccagga ctggtgaagc cttcggagac cctgtccctc 
acctgcactg tctctgggga ctccatcaat acttactact ggagctggtt ccggcagccc 
60 
120 
ccagggaagg gactggagtg gattgggtat atctattata gtggaaccac caactacaac 180 
ccctccctca agagtcgagt caccatatca atagacacgc ccaggaacca gttctccctg 240 
aagctgatct ctgtgaccgc agcggacacg gccgtgtatt actgtgcgag agagaggatt 300 
US 2010/0166768 A1 
54 
JU1. 1, 2010 
-continued 
actatgattc ggggagttac cctctactat tactcctacg gtatggacgt ctggggccaa 360 
gggaccacgg tcaccgtctc ctca 384 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 122 
LENGTH: 128 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 122 
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1 5 10 15 
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Asn Thr Tyr 
20 25 30 
Tyr Trp Ser Trp Phe Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
35 40 45 
Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 
50 55 60 
Ser Arg Val Thr Ile Ser Ile Asp Thr Pro Arg Asn Gln Phe Ser Leu 
65 70 75 80 
Lys Leu Ile Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Arg Ile Thr Met Ile Arg Gly Val Thr Leu Tyr Tyr Tyr Ser 
100 105 110 
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 123 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 123 
ggggactcca tcaatactta ctac 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 124 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 124 
Gly Asp Ser Ile Asn Thr Tyr Tyr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 125 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 125 
atctattata gtggaaccac c 21 
US 2010/0166768 A1 
55 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 126 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 126 
Ile Tyr Tyr Ser Gly Thr Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 127 
LENGTH: 66 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 127 
gcgagagaga ggattactat gattcgggga gttaccctct actattactc ctacggtatg 60 
gacgtc 66 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 128 
LENGTH: 22 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 128 
Ala Arg Glu Arg Ile Thr Met Ile Arg Gly Val Thr Leu Tyr Tyr Tyr 
1 5 10 15 
Ser Tyr Gly Met Asp Val 
20 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 129 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 129 
gacatccaga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgct gggccagtca ggacattagc agttatttag cctggtatca gcaaaaacca 
gggatagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca 
120 
180 
aggttcggcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 
gaagattttg caacttatta ctgtcaacag cttaatagtt accctcggac gttcggccaa 
240 
300 
gggaccaagg tggaaatcaa acga 324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 130 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 130 
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 
1 5 10 15 
US 2010/0166768 A1 
56 
JU1. 1, 2010 
-continued 
Asp Arg Val Thr Ile Thr Cys Trp Ala Ser Gln Asp Ile Ser Ser Tyr 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Ile Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Gly Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 131 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 131 
caggacatta gcagttat 18 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 132 
LENGTH: 6 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 132 
Gln Asp Ile Ser Ser Tyr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 133 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 133 
gctgcatcc 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 134 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 134 
Ala Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 135 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
57 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 135 
caacagctta atagttaccc tcggacg 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 136 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 136 
Gln Gln Leu Asn Ser Tyr Pro Arg Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 137 
LENGTH: 384 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 137 
caggtgcagc tgcaggagtc ggggccagga ctggtgaagc cttcggagac cctgtccctc 
acctgcactg tctctgggga ctccatcaat acttactact ggagctggtt ccggcagccc 
60 
120 
ccagggaagg gactggagtg gattgggtat atctattata gtggaaccac caactacaac 180 
ccctccctca agagtcgagt caccatatca atagacacgc ccaggaacca gttctccctg 240 
aagctgatct ctgtgaccgc agcggacacg gccgtgtatt actgtgcgag agagaggatt 300 
actatgattc ggggagttac cctctactat tactcctacg gtatggacgt ctggggccaa 
gggaccacgg tcaccgtctc ctca 
360 
384 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 138 
LENGTH: 128 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 138 
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1 5 10 15 
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Asn Thr Tyr 
20 25 30 
Tyr Trp Ser Trp Phe Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
35 40 45 
Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 
50 55 60 
Ser Arg Val Thr Ile Ser Ile Asp Thr Pro Arg Asn Gln Phe Ser Leu 
65 70 75 80 
Lys Leu Ile Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Arg Ile Thr Met Ile Arg Gly Val Thr Leu Tyr Tyr Tyr Ser 
100 105 110 
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
US 2010/0166768 A1 
58 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 139 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 139 
gacatccaga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgct gggccagtca ggacattagc agttatttag cctggtatca gcaaaaacca 
gggatagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca 
120 
180 
aggttcggcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 
gaagattttg caacttatta ctgtcaacag cttaatagtt accctcggac gttcggccaa 
240 
300 
gggaccaagg tggaaatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 140 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 140 
Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Trp Ala Ser Gln Asp Ile Ser Ser Tyr 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Ile Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Gly Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 141 
LENGTH: 384 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 141 
caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60 
acctgcactg tctctgggga ctccatcaat acttactact ggagctggat ccggcagccc 
ccagggaagg gactggagtg gattgggtat atctattata gtggaaccac caactacaac 
120 
180 
ccctccctca agagtcgagt caccatatca gtagacacgt ccaagaacca gttctccctg 240 
aagctgagct ctgtgaccgc tgcggacacg gccgtgtatt actgtgcgag agagaggatt 300 
actatgattc ggggagttac cctctactat tactcctacg gtatggacgt ctggggccaa 
gggaccacgg tcaccgtctc ctca 
360 
384 
US 2010/0166768 A1 
59 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 142 
LENGTH: 128 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 142 
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1 5 10 15 
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Asn Thr Tyr 
20 25 30 
Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
35 40 45 
Gly Tyr Ile Tyr Tyr Ser Gly Thr Thr Asn Tyr Asn Pro Ser Leu Lys 
50 55 60 
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65 70 75 80 
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Arg Ile Thr Met Ile Arg Gly Val Thr Leu Tyr Tyr Tyr Ser 
100 105 110 
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 143 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 143 
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggcaagtca ggacattagc agttatttag gctggtatca gcagaaacca 
gggaaagccc ctaagcgcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 
120 
180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 
gaagattttg caacttatta ctgtcaacag cttaatagtt accctcggac gttcggccaa 
240 
300 
gggaccaagg tggaaatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 144 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 144 
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Tyr 
20 25 30 
Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile 
35 40 45 
US 2010/0166768 A1 
60 
JU1. 1, 2010 
-continued 
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 145 
LENGTH: 378 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 145 
caggtgcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 
tcctgcaagg cttctggtta cacctttacc aactatggta tcagctgggt gcgacaggcc 
cctggacaag gacttgagtt aatgggatgg attagtggtt acaatggtaa cacaaactat 
120 
180 
gcacaagaac tccaggccag agtcaccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggaacctgag atctgacgac acggccgtat attactgtgc gagagataga 300 
gtcgttgtag cagctgctaa ttactacttt tattctatgg acgtctgggg ccaagggacc 360 
acggtcaccg tctcctca 378 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 146 
LENGTH: 126 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 146 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Leu Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Glu Leu 
50 55 60 
Gln Ala Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Asn Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Arg Val Val Val Ala Ala Ala Asn Tyr Tyr Phe Tyr Ser 
100 105 110 
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
SEQ ID NO 147 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
US 2010/0166768 A1 
61 
JU1. 1, 2010 
-continued 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 147 
ggttacacct ttaccaacta tggt 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 148 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 148 
Gly Tyr Thr Phe Thr Asn Tyr Gly 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 149 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 149 
attagtggtt acaatggtaa caca 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 150 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 150 
Ile Ser Gly Tyr Asn Gly Asn Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 151 
LENGTH: 57 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 151 
gcgagagata gagtcgttgt agcagctgct aattactact tttattctat ggacgtc 57 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 152 
LENGTH: 19 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 152 
Ala Arg Asp Arg Val Val Val Ala Ala Ala Asn Tyr Tyr Phe Tyr Ser 
1 5 10 15 
Met Asp Val 
&210& SEQ ID NO 153 
&211& LENGTH: 339 
&212& TYPE: DNA 
&213& ORGANISM: Artificial Sequence 
US 2010/0166768 A1 
62 
JU1. 1, 2010 
-continued 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 153 
gccatccaga tgacccagtc tccactctcc ctgtccgtca cccttggaca gccggcctcc 60 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gagacaccta cttgaattgg 120 
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 180 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgctttcac actgaaaatc 
agcggggtgg aggccgagga tgttggggtt tactactgca tgcaagctac acactggcct 
240 
300 
cggacgttcg gccaagggac caaggtggaa atcaaacga 339 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 154 
LENGTH: 113 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 154 
Ala Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asp Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Gly Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Thr His Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 155 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 155 
caaagcctcg tatacagtga tggagacacc tac 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 156 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 156 
Gln Ser Leu Val Tyr Ser Asp Gly Asp Thr Tyr 
1 5 10 
US 2010/0166768 A1 
63 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 157 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 157 
aaggtttct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 158 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 158 
Lys Val Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 159 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 159 
atgcaagcta cacactggcc tcggacg 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 160 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 160 
Met Gln Ala Thr His Trp Pro Arg Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 161 
LENGTH: 378 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 161 
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 
tcctgcaagg cttctggtta cacctttacc aactatggta tcagctgggt gcgacaggcc 
60 
120 
cctggacaag gacttgagtt aatgggatgg attagtggtt acaatggtaa cacaaactat 180 
gcacaagaac tccaggccag agtcaccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggaacctgag atctgacgac acggccgtat attactgtgc gagagataga 300 
gtcgttgtag cagctgctaa ttactacttt tattctatgg acgtctgggg ccaagggacc 360 
acggtcaccg tctcctca 378 
&210& SEQ ID NO 162 
&211& LENGTH: 126 
US 2010/0166768 A1 
64 
JU1. 1, 2010 
-continued 
&212& TYPE: PRT 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 162 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Leu Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Glu Leu 
50 55 60 
Gln Ala Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Asn Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Arg Val Val Val Ala Ala Ala Asn Tyr Tyr Phe Tyr Ser 
100 105 110 
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 163 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 163 
gatgttgtga tgactcagtc tccactctcc ctgtccgtca cccttggaca gccggcctcc 60 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gagacaccta cttgaattgg 
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 
120 
180 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgctttcac actgaaaatc 
agcggggtgg aggccgagga tgttggggtt tactactgca tgcaagctac acactggcct 
240 
300 
cggacgttcg gccaagggac caaggtggaa atcaaa 336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 164 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 164 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asp Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Lys Ile 
US 2010/0166768 A1 
65 
JU1. 1, 2010 
-continued 
65 70 75 80 
Ser Gly Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Thr His Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 165 
LENGTH: 378 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 165 
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 
tcctgcaagg cttctggtta cacctttacc aactatggta tcagctgggt gcgacaggcc 
cctggacaag ggcttgagtg gatgggatgg attagtggtt acaatggtaa cacaaactat 
120 
180 
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagataga 300 
gtcgttgtag cagctgctaa ttactacttt tattctatgg acgtctgggg ccaagggacc 360 
acggtcaccg tctcctca 378 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 166 
LENGTH: 126 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 166 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu 
50 55 60 
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Arg Val Val Val Ala Ala Ala Asn Tyr Tyr Phe Tyr Ser 
100 105 110 
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 167 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 167 
US 2010/0166768 A1 
66 
JU1. 1, 2010 
-continued 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gagacaccta cttgaattgg 
60 
120 
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 
180 
240 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaagctac acactggcct 
cggacgttcg gccaagggac caaggtggaa atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 168 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 168 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asp Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Thr His Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 169 
LENGTH: 375 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 169 
caggtccact tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60 
acctgcacct tctctggatt ctcactcatc actagtggag tgggtgtggg ctggattcgt 
cagccccccg gaaaggccct ggagtggctt gcactcattt attggaatgg tgataagcgc 
120 
180 
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240 
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacagg 300 
ataactgaaa ctagttacta cttctactac ggtatggacg tctggggcca agggaccacg 360 
gtcaccgtct cctca 375 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 170 
LENGTH: 125 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 170 
US 2010/0166768 A1 
67 
JU1. 1, 2010 
-continued 
Gln Val His Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 
1 5 10 15 
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ile Thr Ser 
20 25 30 
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 
35 40 45 
Trp Leu Ala Leu Ile Tyr Trp Asn Gly Asp Lys Arg Tyr Ser Pro Ser 
50 55 60 
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 
65 70 75 80 
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
85 90 95 
Cys Ala His Arg Ile Thr Glu Thr Ser Tyr Tyr Phe Tyr Tyr Gly Met 
100 105 110 
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 171 
LENGTH: 30 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 171 
ggattctcac tcatcactag tggagtgggt 30 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 172 
LENGTH: 10 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 172 
Gly Phe Ser Leu Ile Thr Ser Gly Val Gly 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 173 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 173 
atttattgga atggtgataa g 21 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 174 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 174 
Ile Tyr Trp Asn Gly Asp Lys 
1 5 
US 2010/0166768 A1 
68 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 175 
LENGTH: 51 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 175 
gcacacagga taactgaaac tagttactac ttctactacg gtatggacgt c 51 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 176 
LENGTH: 17 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 176 
Ala His Arg Ile Thr Glu Thr Ser Tyr Tyr Phe Tyr Tyr Gly Met Asp 
1 5 10 15 
Val 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 177 
LENGTH: 339 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 177 
gacatccaga tgacccagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60 
atctcctgca ggtctagtca gagcctcctg catagtcatg gatacgacta tttggattgg 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 
120 
180 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactccg 
240 
300 
ctcactttcg gcggagggac caaggtggaa atcaaacga 339 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 178 
LENGTH: 113 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 178 
Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
His Gly Tyr Asp Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
US 2010/0166768 A1 
69 
JU1. 1, 2010 
-continued 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 179 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 179 
cagagcctcc tgcatagtca tggatacgac tat 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 180 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 180 
Gln Ser Leu Leu His Ser His Gly Tyr Asp Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 181 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 181 
ttgggttct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 182 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 182 
Leu Gly Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 183 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 183 
atgcaagctc tacaaactcc gctcact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 184 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 184 
US 2010/0166768 A1 
70 
JU1. 1, 2010 
-continued 
Met Gln Ala Leu Gln Thr Pro Leu Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 185 
LENGTH: 375 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 185 
cagatcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60 
acctgcacct tctctggatt ctcactcatc actagtggag tgggtgtggg ctggattcgt 
cagccccccg gaaaggccct ggagtggctt gcactcattt attggaatgg tgataagcgc 
120 
180 
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240 
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacagg 300 
ataactgaaa ctagttacta cttctactac ggtatggacg tctggggcca agggaccacg 360 
gtcaccgtct cctca 375 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 186 
LENGTH: 125 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 186 
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 
1 5 10 15 
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ile Thr Ser 
20 25 30 
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 
35 40 45 
Trp Leu Ala Leu Ile Tyr Trp Asn Gly Asp Lys Arg Tyr Ser Pro Ser 
50 55 60 
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 
65 70 75 80 
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
85 90 95 
Cys Ala His Arg Ile Thr Glu Thr Ser Tyr Tyr Phe Tyr Tyr Gly Met 
100 105 110 
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 187 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 187 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60 
atctcctgca ggtctagtca gagcctcctg catagtcatg gatacgacta tttggattgg 120 
US 2010/0166768 A1 
71 
JU1. 1, 2010 
-continued 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactccg 
ctcactttcg gcggagggac caaggtggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 188 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 188 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
His Gly Tyr Asp Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 189 
LENGTH: 375 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 189 
cagatcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60 
acctgcacct tctctggatt ctcactcatc actagtggag tgggtgtggg ctggatccgt 
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaatgg tgataagcgc 
120 
180 
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240 
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacagg 300 
ataactgaaa ctagttacta cttctactac ggtatggacg tctggggcca agggaccacg 360 
gtcaccgtct cctca 375 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 190 
LENGTH: 125 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 190 
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 
1 5 10 15 
US 2010/0166768 A1 
72 
JU1. 1, 2010 
-continued 
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ile Thr Ser 
20 25 30 
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 
35 40 45 
Trp Leu Ala Leu Ile Tyr Trp Asn Gly Asp Lys Arg Tyr Ser Pro Ser 
50 55 60 
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 
65 70 75 80 
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
85 90 95 
Cys Ala His Arg Ile Thr Glu Thr Ser Tyr Tyr Phe Tyr Tyr Gly Met 
100 105 110 
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 191 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 191 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctg catagtcatg gatacgacta tttggattgg 
60 
120 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactccg 
ctcactttcg gcggagggac caaggtggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 192 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 192 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
His Gly Tyr Asp Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& SEQ ID NO 193 
US 2010/0166768 A1 
73 
JU1. 1, 2010 
-continued 
&211& 
&212& 
&213& 
&220& 
&223& 
LENGTH: 375 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 193 
cagatcacct tgaaggagtc tggtcctact ctggtgaaac cctcacagac cctcacgctg 60 
acctgcacct tctctgggtt ctcactcagc actagtggag tgggtgtggg ctggatccgt 120 
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaattc tgataagcgc 180 
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggta 240 
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300 
catgacagct cgtcctacta cttctactac ggtatggacg tctggggcca agggatcacg 360 
gtcaccgtct cctca 375 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 194 
LENGTH: 125 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 194 
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 
1 5 10 15 
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 
20 25 30 
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 
35 40 45 
Trp Leu Ala Leu Ile Tyr Trp Asn Ser Asp Lys Arg Tyr Ser Pro Ser 
50 55 60 
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 
65 70 75 80 
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
85 90 95 
Cys Ala His Arg His Asp Ser Ser Ser Tyr Tyr Phe Tyr Tyr Gly Met 
100 105 110 
Asp Val Trp Gly Gln Gly Ile Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 195 
LENGTH: 30 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 195 
gggttctcac tcagcactag tggagtgggt 30 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 196 
LENGTH: 10 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
74 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 196 
Gly Phe Ser Leu Ser Thr Ser Gly Val Gly 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 197 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 197 
atttattgga attctgataa g 21 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 198 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 198 
Ile Tyr Trp Asn Ser Asp Lys 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 199 
LENGTH: 51 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 199 
gcacacagac atgacagctc gtcctactac ttctactacg gtatggacgt c 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 200 
LENGTH: 17 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 200 
Ala His Arg His Asp Ser Ser Ser Tyr Tyr Phe Tyr Tyr Gly Met Asp 
1 5 10 15 
Val 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 201 
LENGTH: 339 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 201 
gacatccaga tgacccagtc tccgctctcc ctgcccgtca cccctggaga gccggcctcc 60 
atctcctgca ggtctagtca gagcctcctc catagtcatg gatacaacta tttggattgg 
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttc taatcgggcc 
120 
180 
tccggggtcc ctgacaggtt cagtggcggt ggatcaggca cagattttac actgaaaatc 
agcagagtgg aggctgagga tgttgggatt tattactgca tgcaagctct acagactcct 
240 
300 
US 2010/0166768 A1 
75 
JU1. 1, 2010 
-continued 
ctcactttcg gcggagggac caaggtggag atcaaacga 339 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 202 
LENGTH: 113 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 202 
Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
His Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 203 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 203 
cagagcctcc tccatagtca tggatacaac tat 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 204 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 204 
Gln Ser Leu Leu His Ser His Gly Tyr Asn Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 205 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 205 
ttgggttct 
&210& SEQ ID NO 206 
&211& LENGTH: 3 
US 2010/0166768 A1 
76 
JU1. 1, 2010 
-continued 
&212& TYPE: PRT 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 206 
Leu Gly Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 207 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 207 
atgcaagctc tacagactcc tctcact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 208 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 208 
Met Gln Ala Leu Gln Thr Pro Leu Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 209 
LENGTH: 375 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 209 
cagatcacct tgaaggagtc tggtcctact ctggtgaaac cctcacagac cctcacgctg 60 
acctgcacct tctctgggtt ctcactcagc actagtggag tgggtgtggg ctggatccgt 
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaattc tgataagcgc 
120 
180 
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggta 240 
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300 
catgacagct cgtcctacta cttctactac ggtatggacg tctggggcca agggaccacg 360 
gtcaccgtct cctca 375 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 210 
LENGTH: 125 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 210 
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 
1 5 10 15 
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 
20 25 30 
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 
US 2010/0166768 A1 
77 
JU1. 1, 2010 
-continued 
35 40 45 
Trp Leu Ala Leu Ile Tyr Trp Asn Ser Asp Lys Arg Tyr Ser Pro Ser 
50 55 60 
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 
65 70 75 80 
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
85 90 95 
Cys Ala His Arg His Asp Ser Ser Ser Tyr Tyr Phe Tyr Tyr Gly Met 
100 105 110 
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 211 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 211 
gatattgtga tgactcagtc tccgctctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctc catagtcatg gatacaacta tttggattgg 
60 
120 
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttc taatcgggcc 
tccggggtcc ctgacaggtt cagtggcggt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttgggatt tattactgca tgcaagctct acagactcct 
ctcactttcg gcggagggac caaggtggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 212 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 212 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
His Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
SEQ ID NO 213 
LENGTH: 375 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
US 2010/0166768 A1 
78 
JU1. 1, 2010 
-continued 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 213 
cagatcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60 
acctgcacct tctctgggtt ctcactcagc actagtggag tgggtgtggg ctggatccgt 120 
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaattc tgataagcgc 180 
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240 
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300 
catgacagct cgtcctacta cttctactac ggtatggacg tctggggcca agggaccacg 360 
gtcaccgtct cctca 375 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 214 
LENGTH: 125 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 214 
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 
1 5 10 15 
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 
20 25 30 
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 
35 40 45 
Trp Leu Ala Leu Ile Tyr Trp Asn Ser Asp Lys Arg Tyr Ser Pro Ser 
50 55 60 
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 
65 70 75 80 
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
85 90 95 
Cys Ala His Arg His Asp Ser Ser Ser Tyr Tyr Phe Tyr Tyr Gly Met 
100 105 110 
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 215 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 215 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctc catagtcatg gatacaacta tttggattgg 
60 
120 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acagactcct 
ctcactttcg gcggagggac caaggtggag atcaaa 
300 
336 
&210& SEQ ID NO 216 
US 2010/0166768 A1 
79 
JU1. 1, 2010 
-continued 
&211& 
&212& 
&213& 
&220& 
&223& 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 216 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
His Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 217 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 217 
gagatgcaac tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 
tcctgtgcag cctctggatt cacctttagt agtcactgga tgaagtgggt ccgccaggct 
60 
120 
ccagggaagg ggctggagtg ggtggccaac ataaaccaag atggaagtga gaaatactat 
gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgttt 
180 
240 
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatatt 
gtactaatgg tctatgatat ggactactac tactacggta tggacgtctg gggccaaggg 
300 
360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 218 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 218 
Glu Met Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser His 
20 25 30 
Trp Met Lys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Asn Ile Asn Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe 
US 2010/0166768 A1 
80 
JU1. 1, 2010 
-continued 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Ile Val Leu Met Val Tyr Asp Met Asp Tyr Tyr Tyr Tyr 
100 105 110 
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 219 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 219 
ggattcacct ttagtagtca ctgg 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 220 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 220 
Gly Phe Thr Phe Ser Ser His Trp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 221 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 221 
ataaaccaag atggaagtga gaaa 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 222 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 222 
Ile Asn Gln Asp Gly Ser Glu Lys 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 223 
LENGTH: 60 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 223 
gcgagagata ttgtactaat ggtctatgat atggactact actactacgg tatggacgtc 60 
&210& SEQ ID NO 224 
&211& LENGTH: 20 
US 2010/0166768 A1 
81 
JU1. 1, 2010 
-continued 
&212& TYPE: PRT 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 224 
Ala Arg Asp Ile Val Leu Met Val Tyr Asp Met Asp Tyr Tyr Tyr Tyr 
1 5 10 15 
Gly Met Asp Val 
20 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 225 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 225 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctg catagtaatg gaaacaacta tttggattgg 
60 
120 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaaactct acaaactccg 
ctcactttcg gcggagggac caaggtggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 226 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 226 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
Asn Gly Asn Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 227 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 227 
US 2010/0166768 A1 
82 
JU1. 1, 2010 
-continued 
cagagcctcc tgcatagtaa tggaaacaac tat 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 228 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 228 
Gln Ser Leu Leu His Ser Asn Gly Asn Asn Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 229 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 229 
ttgggttct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 230 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 230 
Leu Gly Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 231 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 231 
atgcaaactc tacaaactcc gctcact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 232 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 232 
Met Gln Thr Leu Gln Thr Pro Leu Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 233 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 233 
gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60 
US 2010/0166768 A1 
83 
JU1. 1, 2010 
-continued 
tcctgtgcag cctctggatt cacctttagt agtcactgga tgaagtgggt ccgccaggct 
ccagggaagg ggctggagtg ggtggccaac ataaaccaag atggaagtga gaaatactat 
120 
180 
gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgttt 
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatatt 
240 
300 
gtactaatgg tctatgatat ggactactac tactacggta tggacgtctg gggccaaggg 360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 234 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 234 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser His 
20 25 30 
Trp Met Lys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Asn Ile Asn Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Ile Val Leu Met Val Tyr Asp Met Asp Tyr Tyr Tyr Tyr 
100 105 110 
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 235 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 235 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60 
atctcctgca ggtctagtca gagcctcctg catagtaatg gaaacaacta tttggattgg 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 
120 
180 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaaactct acaaactccg 
ctcactttcg gcggagggac caaggtggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 236 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
84 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 236 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
Asn Gly Asn Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 237 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 237 
gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt cacctttagt agtcactgga tgagctgggt ccgccaggct 120 
ccagggaagg ggctggagtg ggtggccaac ataaaccaag atggaagtga gaaatactat 
gtggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 
180 
240 
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatatt 
gtactaatgg tctatgatat ggactactac tactacggta tggacgtctg ggggcaaggg 
300 
360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 238 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 238 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser His 
20 25 30 
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Asn Ile Asn Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
US 2010/0166768 A1 
85 
JU1. 1, 2010 
-continued 
Ala Arg Asp Ile Val Leu Met Val Tyr Asp Met Asp Tyr Tyr Tyr Tyr 
100 105 110 
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 239 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 239 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctg catagtaatg gaaacaacta tttggattgg 
60 
120 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaaactct acaaactccg 
ctcactttcg gcggagggac caaggtggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 240 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 240 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
Asn Gly Asn Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 241 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 241 
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 
tcctgtgcag tctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 
60 
120 
ccaggcaagg ggctggagtg ggtggcagct atatcatatg atggaagtaa taaatactat 180 
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa aacgctgtat 240 
US 2010/0166768 A1 
86 
JU1. 1, 2010 
-continued 
ctgcaaatga acagcctgag agctgaggac acggctgtgt ataattgtgc gaaaaatatt 300 
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg gggccaaggg 360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 242 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 242 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Asn Cys 
85 90 95 
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr 
100 105 110 
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 243 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 243 
ggattcacct tcagtagcta tggc 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 244 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 244 
Gly Phe Thr Phe Ser Ser Tyr Gly 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 245 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 245 
US 2010/0166768 A1 
87 
JU1. 1, 2010 
-continued 
atatcatatg atggaagtaa taaa 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 246 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 246 
Ile Ser Tyr Asp Gly Ser Asn Lys 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 247 
LENGTH: 60 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 247 
gcgaaaaata ttgtactagt gatgtatgat atagactatc actactatgg gatggacgtc 60 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 248 
LENGTH: 20 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 248 
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr 
1 5 10 15 
Gly Met Asp Val 
20 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 249 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 249 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60 
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttt taatcgggcc 
120 
180 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 
240 
300 
ctcactttcg gcggagggac caaggtggag atcaga 336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 250 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 250 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
US 2010/0166768 A1 
88 
JU1. 1, 2010 
-continued 
10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Arg 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 251 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 251 
cagagcctcc tgcatagtaa tggatacaac tat 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 252 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 252 
Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 253 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 253 
ttgggtttt 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 254 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 254 
Leu Gly Phe 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
SEQ ID NO 255 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
US 2010/0166768 A1 
89 
JU1. 1, 2010 
-continued 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 255 
atgcaagctc tacaaactcc tctcact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 256 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 256 
Met Gln Ala Leu Gln Thr Pro Leu Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 257 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 257 
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 
tcctgtgcag tctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 
ccaggcaagg ggctggagtg ggtggcagct atatcatatg atggaagtaa taaatactat 
120 
180 
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa aacgctgtat 240 
ctgcaaatga acagcctgag agctgaggac acggctgtgt ataattgtgc gaaaaatatt 300 
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg gggccaaggg 360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 258 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 258 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Asn Cys 
85 90 95 
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr 
100 105 110 
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
US 2010/0166768 A1 
90 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 259 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 259 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 
60 
120 
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttt taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 
ctcactttcg gcggagggac caaggtggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 260 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 260 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 261 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 261 
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 
tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 
ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactat 
120 
180 
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 
ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gaaaaatatt 300 
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg ggggcaaggg 360 
US 2010/0166768 A1 
91 
JU1. 1, 2010 
-continued 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 262 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 262 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr 
100 105 110 
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 263 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 263 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 
60 
120 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 
ctcactttcg gcggagggac caaggtggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 264 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 264 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
US 2010/0166768 A1 
92 
JU1. 1, 2010 
-continued 
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 265 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 265 
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 
tcctgtgcag tctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 
60 
120 
ccaggcaagg ggctggagtg ggtggcagct atatcatatg atggaagtaa taaatactat 180 
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa aacgctgtat 240 
ctgcaaatga acagcctgag agctgaggac acggctgtgt ataattgtgc gaaaaatatt 
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg gggccaaggg 
300 
360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 266 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 266 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Asn Cys 
85 90 95 
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr 
100 105 110 
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& SEQ ID NO 267 
&211& LENGTH: 24 
&212& TYPE: DNA 
&213& ORGANISM: Artificial Sequence 
US 2010/0166768 A1 
93 
JU1. 1, 2010 
-continued 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 267 
ggattcacct tcagtagcta tggc 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 268 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 268 
Gly Phe Thr Phe Ser Ser Tyr Gly 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 269 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 269 
atatcatatg atggaagtaa taaa 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 270 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 270 
Ile Ser Tyr Asp Gly Ser Asn Lys 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 271 
LENGTH: 60 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 271 
gcgaaaaata ttgtactagt gatgtatgat atagactatc actactatgg gatggacgtc 60 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 272 
LENGTH: 20 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 272 
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr 
1 5 10 15 
Gly Met Asp Val 
20 
&210& SEQ ID NO 273 
&211& LENGTH: 336 
US 2010/0166768 A1 
94 
JU1. 1, 2010 
-continued 
&212& TYPE: DNA 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 273 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60 
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 120 
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttt taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 
ctcactttcg gcggagggac caaggtggag atcaga 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 274 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 274 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Arg 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 275 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 275 
cagagcctcc tgcatagtaa tggatacaac tat 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 276 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 276 
Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr 
1 5 10 
US 2010/0166768 A1 
95 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 277 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 277 
ttgggtttt 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 278 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 278 
Leu Gly Phe 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 279 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 279 
atgcaagctc tacaaactcc tctcact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 280 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 280 
Met Gln Ala Leu Gln Thr Pro Leu Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 281 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 281 
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 
tcctgtgcag tctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 
60 
120 
ccaggcaagg ggctggagtg ggtggcagct atatcatatg atggaagtaa taaatactat 180 
gtagactccg tgaagggccg attcaccatc tccagagaca attccaagaa aacgctgtat 240 
ctgcaaatga acagcctgag agctgaggac acggctgtgt ataattgtgc gaaaaatatt 300 
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg gggccaaggg 360 
accacggtca ccgtctcctc a 381 
&210& SEQ ID NO 282 
&211& LENGTH: 127 
US 2010/0166768 A1 
96 
JU1. 1, 2010 
-continued 
&212& TYPE: PRT 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 282 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Asn Cys 
85 90 95 
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr 
100 105 110 
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 283 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 283 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60 
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 
tacctgcaga agccagggca gtctccacaa ctcctgatct atttgggttt taatcgggcc 
120 
180 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 
240 
300 
ctcactttcg gcggagggac caaggtggag atcaaa 336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 284 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 284 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
US 2010/0166768 A1 
97 
JU1. 1, 2010 
-continued 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 285 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 285 
caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 
tcctgtgcag cctctggatt caccttcagt agctatggca tgcactgggt ccgccaggct 
ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagtaa taaatactat 
120 
180 
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240 
ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gaaaaatatt 300 
gtactagtga tgtatgatat agactatcac tactatggga tggacgtctg ggggcaaggg 360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 286 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 286 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Lys Asn Ile Val Leu Val Met Tyr Asp Ile Asp Tyr His Tyr Tyr 
100 105 110 
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 287 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 287 
US 2010/0166768 A1 
98 
JU1. 1, 2010 
-continued 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctg catagtaatg gatacaacta tttggattgg 
60 
120 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 
ctcactttcg gcggagggac caaggtggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 288 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 288 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
20 25 30 
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 289 
LENGTH: 372 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 289 
cagatcacct tgaaggagtc tggtcctacg ctggtaaaac ccacacagac cctcacgctg 60 
acctgcacct tctctgggtt ctcactcagc gctagtggag tgggtgtggg ctggttccgt 
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaatga tgataagcgt 
120 
180 
tacagcccat ctctaaagaa cagcctcacc atcaccaagg acacctccaa aaaccaggtg 240 
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300 
atacatctat ggtcctactt ctactacggt atggacgtct ggggccaagg gaccacggtc 360 
accgtctcct ca 372 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 290 
LENGTH: 124 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 290 
US 2010/0166768 A1 
99 
JU1. 1, 2010 
-continued 
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 
1 5 10 15 
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ala Ser 
20 25 30 
Gly Val Gly Val Gly Trp Phe Arg Gln Pro Pro Gly Lys Ala Leu Glu 
35 40 45 
Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Ser Pro Ser 
50 55 60 
Leu Lys Asn Ser Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 
65 70 75 80 
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
85 90 95 
Cys Ala His Arg Ile His Leu Trp Ser Tyr Phe Tyr Tyr Gly Met Asp 
100 105 110 
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 291 
LENGTH: 30 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 291 
gggttctcac tcagcgctag tggagtgggt 30 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 292 
LENGTH: 10 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 292 
Gly Phe Ser Leu Ser Ala Ser Gly Val Gly 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 293 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 293 
atttattgga atgatgataa g 21 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 294 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 294 
Ile Tyr Trp Asn Asp Asp Lys 
1 5 
US 2010/0166768 A1 
100 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 295 
LENGTH: 48 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 295 
gcacacagaa tacatctatg gtcctacttc tactacggta tggacgtc 48 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 296 
LENGTH: 16 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 296 
Ala His Arg Ile His Leu Trp Ser Tyr Phe Tyr Tyr Gly Met Asp Val 
1 5 10 15 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 297 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 297 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60 
atctcctgca ggtctagtca gactctcctg catagtaatg gatacaacta tttcgattgg 120 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 
tccggggtcc ctgacagatt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggaatt tattactgca tgcaagctct acaaactcct 
ctcactttcg gcggagggac caaggtggag atcaga 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 298 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 298 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Leu Leu His Ser 
20 25 30 
Asn Gly Tyr Asn Tyr Phe Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Arg 
100 105 110 
US 2010/0166768 A1 
101 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 299 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 299 
cagactctcc tgcatagtaa tggatacaac tat 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 300 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 300 
Gln Thr Leu Leu His Ser Asn Gly Tyr Asn Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 301 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 301 
ttgggttct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 302 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 302 
Leu Gly Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 303 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 303 
atgcaagctc tacaaactcc tctcact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 304 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 304 
Met Gln Ala Leu Gln Thr Pro Leu Thr 
1 5 
US 2010/0166768 A1 
102 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 305 
LENGTH: 372 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 305 
cagatcacct tgaaggagtc tggtcctacg ctggtaaaac ccacacagac cctcacgctg 60 
acctgcacct tctctgggtt ctcactcagc gctagtggag tgggtgtggg ctggttccgt 
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaatga tgataagcgt 
120 
180 
tacagcccat ctctaaagaa cagcctcacc atcaccaagg acacctccaa aaaccaggtg 240 
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300 
atacatctat ggtcctactt ctactacggt atggacgtct ggggccaagg gaccacggtc 360 
accgtctcct ca 372 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 306 
LENGTH: 124 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 306 
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 
1 5 10 15 
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ala Ser 
20 25 30 
Gly Val Gly Val Gly Trp Phe Arg Gln Pro Pro Gly Lys Ala Leu Glu 
35 40 45 
Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Ser Pro Ser 
50 55 60 
Leu Lys Asn Ser Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 
65 70 75 80 
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
85 90 95 
Cys Ala His Arg Ile His Leu Trp Ser Tyr Phe Tyr Tyr Gly Met Asp 
100 105 110 
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 307 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 307 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60 
atctcctgca ggtctagtca gactctcctg catagtaatg gatacaacta tttcgattgg 120 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 180 
tccggggtcc ctgacagatt cagtggcagt ggatcaggca cagattttac actgaaaatc 240 
US 2010/0166768 A1 
103 
JU1. 1, 2010 
-continued 
agcagagtgg aggctgagga tgttggaatt tattactgca tgcaagctct acaaactcct 
ctcactttcg gcggagggac caaggtggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 308 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 308 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Leu Leu His Ser 
20 25 30 
Asn Gly Tyr Asn Tyr Phe Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 309 
LENGTH: 372 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 309 
cagatcacct tgaaggagtc tggtcctacg ctggtgaaac ccacacagac cctcacgctg 60 
acctgcacct tctctgggtt ctcactcagc gctagtggag tgggtgtggg ctggatccgt 
cagcccccag gaaaggccct ggagtggctt gcactcattt attggaatga tgataagcgc 
120 
180 
tacagcccat ctctgaagag caggctcacc atcaccaagg acacctccaa aaaccaggtg 240 
gtccttacaa tgaccaacat ggaccctgtg gacacagcca catattactg tgcacacaga 300 
atacatctat ggtcctactt ctactacggt atggacgtct gggggcaagg gaccacggtc 360 
accgtctcct ca 372 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 310 
LENGTH: 124 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 310 
Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 
1 5 10 15 
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Ala Ser 
20 25 30 
Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 
US 2010/0166768 A1 
104 
JU1. 1, 2010 
-continued 
35 40 45 
Trp Leu Ala Leu Ile Tyr Trp Asn Asp Asp Lys Arg Tyr Ser Pro Ser 
50 55 60 
Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 
65 70 75 80 
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 
85 90 95 
Cys Ala His Arg Ile His Leu Trp Ser Tyr Phe Tyr Tyr Gly Met Asp 
100 105 110 
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 311 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 311 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gactctcctg catagtaatg gatacaacta tttggattgg 
60 
120 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct acaaactcct 
ctcactttcg gcggagggac caaggtggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 312 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 312 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Leu Leu His Ser 
20 25 30 
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
SEQ ID NO 313 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
US 2010/0166768 A1 
105 
JU1. 1, 2010 
-continued 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 313 
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 
60 
120 
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 180 
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 
ttagtagtac cacctgccct taattattcc tactacgtta tggacgtctg gggccaaggg 
300 
360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 314 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 314 
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe 
50 55 60 
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys 
85 90 95 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Ser Tyr Tyr 
100 105 110 
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 315 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 315 
ggttacacct ttaccaccta tggt 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 316 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 316 
Gly Tyr Thr Phe Thr Thr Tyr Gly 
1 5 
US 2010/0166768 A1 
106 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 317 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 317 
atcagcggtt acaatggtaa aaca 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 318 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 318 
Ile Ser Gly Tyr Asn Gly Lys Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 319 
LENGTH: 60 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 319 
tcgagagatc gtttagtagt accacctgcc cttaattatt cctactacgt tatggacgtc 60 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 320 
LENGTH: 20 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 320 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Ser Tyr Tyr 
1 5 10 15 
Val Met Asp Val 
20 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 321 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 321 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 
tctcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 
120 
180 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 
240 
300 
tacacttttg gccaggggac caagctggag atcaaa 336 
US 2010/0166768 A1 
107 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 322 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 322 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asn Thr Tyr Leu Asn Trp Ser Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
85 90 95 
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 323 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 323 
caaagcctcg tatacagtga tggaaacacc tac 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 324 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 324 
Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 325 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 325 
aaggtttct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 326 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
108 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 326 
Lys Val Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 327 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 327 
atgcaaggta cacactggcc gtacact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 328 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 328 
Met Gln Gly Thr His Trp Pro Tyr Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 329 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 329 
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60 
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 
120 
180 
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300 
ttagtagtac cacctgccct taattattcc tactacgtta tggacgtctg gggccaaggg 360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 330 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 330 
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe 
50 55 60 
US 2010/0166768 A1 
109 
JU1. 1, 2010 
-continued 
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys 
85 90 95 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Ser Tyr Tyr 
100 105 110 
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 331 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 331 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 
tctcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 
120 
180 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 
240 
300 
tacacttttg gccaggggac caagctggag atcaaa 336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 332 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 332 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asn Thr Tyr Leu Asn Trp Ser Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
85 90 95 
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 333 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 333 
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 
US 2010/0166768 A1 
110 
JU1. 1, 2010 
-continued 
tcctgcaagg cttctggtta cacctttacc acctatggta tcagctgggt gcgacaggcc 
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaactat 
120 
180 
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccgtgt attactgttc gagagatcgt 300 
ttagtagtac cacctgccct taattattcc tactacgtta tggacgtctg ggggcaaggg 360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 334 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 334 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Tyr Ala Gln Lys Leu 
50 55 60 
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Ser Tyr Tyr 
100 105 110 
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 335 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 335 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 
120 
180 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 240 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 
tacacttttg gccaggggac caagctggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 336 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 JU1. 1, 2010 
-continued 
&400& SEQUENCE: 336 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
85 90 95 
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 337 
LENGTH: 354 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 337 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt caccttcagt agctatagca tggactgggt ccgccaggct 120 
ccagggaagg ggctggagtg ggtctcatcc attagtagta gtagtagtta catatactac 180 
gcagactctg tgaagggccg attcaccatc tccagagaca ccgccaagaa ctcactgtat 240 
ctgcaaatga acagcctgag agacgaggac acggctgttt attactgtgc gagagagggc 
agtagcagac tttttgacta ctggggccag ggaaccctgg tcaccgtctc ctca 
300 
354 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 338 
LENGTH: 118 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 338 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Ser Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Glu Gly Ser Ser Arg Leu Phe Asp Tyr Trp Gly Gln Gly Thr 
100 105 110 
US 2010/0166768 A1 
112 
JU1. 1, 2010 
-continued 
Leu Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 339 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 339 
ggattcacct tcagtagcta tagc 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 340 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 340 
Gly Phe Thr Phe Ser Ser Tyr Ser 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 341 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 341 
attagtagta gtagtagtta cata 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 342 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 342 
Ile Ser Ser Ser Ser Ser Tyr Ile 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 343 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 343 
gcgagagagg gcagtagcag actttttgac tac 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 344 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 344 
US 2010/0166768 A1 
113 
JU1. 1, 2010 
-continued 
Ala Arg Glu Gly Ser Ser Arg Leu Phe Asp Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 345 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 345 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagagacca 
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaggtgg agtcccatca 
120 
180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 
gaggattttg caacttatta ctgccaacag tataatagtt attggtacac ttttggccag 
240 
300 
gggaccaagc tggagatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 346 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 346 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Gly Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Trp Tyr 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 347 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 347 
cagagtatta gtagctgg 18 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 348 
LENGTH: 6 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
114 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 348 
Gln Ser Ile Ser Ser Trp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 349 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 349 
aaggcgtct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 350 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 350 
Lys Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 351 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 351 
caacagtata atagttattg gtacact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 352 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 352 
Gln Gln Tyr Asn Ser Tyr Trp Tyr Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 353 
LENGTH: 354 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 353 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 
tcctgtgcag cctctggatt caccttcagt agctatagca tggactgggt ccgccaggct 
60 
120 
ccagggaagg ggctggagtg ggtctcatcc attagtagta gtagtagtta catatactac 180 
gcagactctg tgaagggccg attcaccatc tccagagaca ccgccaagaa ctcactgtat 240 
ctgcaaatga acagcctgag agacgaggac acggctgttt attactgtgc gagagagggc 
agtagcagac tttttgacta ctggggccag ggaaccctgg tcaccgtctc ctca 
300 
354 
US 2010/0166768 A1 
115 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 354 
LENGTH: 118 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 354 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Ser Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Glu Gly Ser Ser Arg Leu Phe Asp Tyr Trp Gly Gln Gly Thr 
100 105 110 
Leu Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 355 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 355 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagagacca 
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaggtgg agtcccatca 
120 
180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 
gaggattttg caacttatta ctgccaacag tataatagtt attggtacac ttttggccag 
240 
300 
gggaccaagc tggagatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 356 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 356 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
US 2010/0166768 A1 
116 
JU1. 1, 2010 
-continued 
Tyr Lys Ala Ser Ser Leu Glu Gly Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Trp Tyr 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 357 
LENGTH: 354 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 357 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt caccttcagt agctatagca tgaactgggt ccgccaggct 
ccagggaagg ggctggagtg ggtctcatcc attagtagta gtagtagtta catatactac 
120 
180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240 
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagagggc 300 
agtagcagac tttttgacta ctggggccaa ggaaccctgg tcaccgtctc ctca 354 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 358 
LENGTH: 118 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 358 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Ser Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Glu Gly Ser Ser Arg Leu Phe Asp Tyr Trp Gly Gln Gly Thr 
100 105 110 
Leu Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 359 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
117 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 359 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 
120 
180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 
gatgattttg caacttatta ctgccaacag tataatagtt attggtacac ttttggccag 
240 
300 
gggaccaagc tggagatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 360 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 360 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Trp Tyr 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 361 
LENGTH: 384 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 361 
caggtgcacc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct 
60 
120 
ccagggaagg ggctggagtg gatttcatac attagtaatg atggtggtac caaatactat 
gtggactctg tggagggccg attcatcatt tccagggaca acgccaagaa ctcattgtat 
180 
240 
ctacatatga acagcctcag agccgacgac acggccgtgt attactgtgc gagagatcag 300 
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctggggccaa 
gggaccacgg tcaccgtcgc ctca 
360 
384 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 362 
LENGTH: 128 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
118 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 362 
Gln Val His Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His 
20 25 30 
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
35 40 45 
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Val Asp Ser Val 
50 55 60 
Glu Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu His Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser 
100 105 110 
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ala Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 363 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 363 
ggattcacct tcagtgacca ctac 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 364 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 364 
Gly Phe Thr Phe Ser Asp His Tyr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 365 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 365 
attagtaatg atggtggtac caaa 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 366 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 366 
Ile Ser Asn Asp Gly Gly Thr Lys 
1 5 
US 2010/0166768 A1 
119 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 367 
LENGTH: 63 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 367 
gcgagagatc agggatatat tggctacgac tcgtattatt actattccta cggtatggac 60 
gtc 63 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 368 
LENGTH: 21 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 368 
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser 
1 5 10 15 
Tyr Gly Met Asp Val 
20 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 369 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 369 
aaaattgtgt tgacgcagtc tccaggcacc ctgcctttgt ttccagggga aagagccacc 60 
ctctcctgta gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa 
tctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 
120 
180 
gacaggttca gtggcagtgg gtctgggacc gacttcactc tcaccatcag cggactggag 
cctgaagatt ttgaagtgta ttattgtcaa gtatatggta actcactcac tctcggcgga 
240 
300 
gggaccaagg tggagatcaa g 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 370 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 370 
Lys Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Pro Leu Phe Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys 
20 25 30 
Phe Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu 
35 40 45 
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
50 55 60 
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Glu 
US 2010/0166768 A1 
120 
JU1. 1, 2010 
-continued 
65 70 75 80 
Pro Glu Asp Phe Glu Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu 
85 90 95 
Thr Leu Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 371 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 371 
cagagtgtta acaacaaatt c 21 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 372 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 372 
Gln Ser Val Asn Asn Lys Phe 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 373 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 373 
ggtgcatcc 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 374 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 374 
Gly Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 375 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 375 
caagtatatg gtaactcact cact 24 
&210& 
&211& 
&212& 
&213& 
&220& 
SEQ ID NO 376 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
US 2010/0166768 A1 
121 
JU1. 1, 2010 
-continued 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 376 
Gln Val Tyr Gly Asn Ser Leu Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 377 
LENGTH: 384 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 377 
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60 
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct 
ccagggaagg ggctggagtg gatttcatac attagtaatg atggtggtac caaatactat 
120 
180 
gtggactctg tggagggccg attcatcatt tccagggaca acgccaagaa ctcattgtat 
ctacatatga acagcctcag agccgacgac acggccgtgt attactgtgc gagagatcag 
240 
300 
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctggggccaa 
gggaccacgg tcaccgtctc ctca 
360 
384 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 378 
LENGTH: 128 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 378 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His 
20 25 30 
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
35 40 45 
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Val Asp Ser Val 
50 55 60 
Glu Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu His Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser 
100 105 110 
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 379 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 379 
gaaattgtgt tgacgcagtc tccaggcacc ctgcctttgt ttccagggga aagagccacc 60 
US 2010/0166768 A1 
122 
JU1. 1, 2010 
-continued 
ctctcctgta gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa 120 
tctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 180 
gacaggttca gtggcagtgg gtctgggacc gacttcactc tcaccatcag cggactggag 240 
cctgaagatt ttgaagtgta ttattgtcaa gtatatggta actcactcac tctcggcgga 300 
gggaccaagg tggagatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 380 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 380 
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Pro Leu Phe Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys 
20 25 30 
Phe Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu 
35 40 45 
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
50 55 60 
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Glu 
65 70 75 80 
Pro Glu Asp Phe Glu Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu 
85 90 95 
Thr Leu Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 381 
LENGTH: 384 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 381 
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 60 
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct 
ccagggaagg ggctggagtg ggtttcatac attagtaatg atggtggtac caaatactac 
120 
180 
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat 240 
ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc gagagatcag 300 
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctgggggcaa 
gggaccacgg tcaccgtctc ctca 
360 
384 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 382 
LENGTH: 128 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 382 
US 2010/0166768 A1 
123 
JU1. 1, 2010 
-continued 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His 
20 25 30 
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser 
100 105 110 
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 383 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 383 
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60 
ctctcctgca gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa 120 
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 
gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag 
180 
240 
cctgaagatt ttgcagtgta ttactgtcaa gtatatggta actcactcac tttcggcgga 
gggaccaagg tggagatcaa a 
300 
321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 384 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 384 
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys 
20 25 30 
Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
35 40 45 
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
50 55 60 
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65 70 75 80 
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu 
85 90 95 
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 
US 2010/0166768 A1 
124 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 385 
LENGTH: 360 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 385 
gaggtgcaga aggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 
60 
120 
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240 
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 
300 
360 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 386 
LENGTH: 120 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 386 
Glu Val Gln Lys Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
20 25 30 
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln 
100 105 110 
Gly Thr Leu Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 387 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 387 
ggattcacct tcagtactta taac 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 388 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
125 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 388 
Gly Phe Thr Phe Ser Thr Tyr Asn 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 389 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 389 
attaggagta gtagtaatta cata 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 390 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 390 
Ile Arg Ser Ser Ser Asn Tyr Ile 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 391 
LENGTH: 39 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 391 
gcgagagatg gcagcagttg gtacgactac tctgactac 39 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 392 
LENGTH: 13 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 392 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 393 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 393 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 120 
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 
180 
240 
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 300 
US 2010/0166768 A1 
126 
JU1. 1, 2010 
-continued 
gggaccaagg tggaaatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 394 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 394 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 395 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 395 
cagagtatta gtagctgg 18 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 396 
LENGTH: 6 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 396 
Gln Ser Ile Ser Ser Trp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 397 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 397 
aaggcgtct 
&210& 
&211& 
&212& 
&213& 
&220& 
SEQ ID NO 398 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
US 2010/0166768 A1 
127 
JU1. 1, 2010 
-continued 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 398 
Lys Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 399 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 399 
caacagtata ttagttattc tcggacg 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 400 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 400 
Gln Gln Tyr Ile Ser Tyr Ser Arg Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 401 
LENGTH: 360 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 401 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 
60 
120 
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240 
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 
300 
360 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 402 
LENGTH: 120 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 402 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
20 25 30 
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
US 2010/0166768 A1 
128 
JU1. 1, 2010 
-continued 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln 
100 105 110 
Gly Thr Leu Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 403 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 403 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 
120 
180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 
240 
300 
gggaccaagg tggaaatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 404 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 404 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 405 
LENGTH: 360 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 405 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60 
US 2010/0166768 A1 
129 
JU1. 1, 2010 
-continued 
tcctgtgcag cctctggatt caccttcagt acttataaca tgaactgggt ccgccaggct 
ccagggaagg ggctggagtg ggtctcatcc attaggagta gtagtaatta catatactac 
120 
180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240 
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 300 
agcagttggt acgactactc tgactactgg ggccaaggaa ccctggtcac cgtctcctca 360 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 406 
LENGTH: 120 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 406 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
20 25 30 
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln 
100 105 110 
Gly Thr Leu Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 407 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 407 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120 
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 
180 
240 
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 300 
gggaccaagg tggaaatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 408 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 408 
US 2010/0166768 A1 
130 
JU1. 1, 2010 
-continued 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 409 
LENGTH: 360 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 409 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 
60 
120 
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240 
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 300 
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 410 
LENGTH: 120 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 410 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
20 25 30 
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln 
100 105 110 
Gly Thr Leu Val Thr Val Ser Ser 
US 2010/0166768 A1 
131 
JU1. 1, 2010 
-continued 
120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 411 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 411 
ggattcacct tcagtactta taac 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 412 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 412 
Gly Phe Thr Phe Ser Thr Tyr Asn 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 413 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 413 
attaggagta gtagtaatta cata 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 414 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 414 
Ile Arg Ser Ser Ser Asn Tyr Ile 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 415 
LENGTH: 39 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 415 
gcgagagatg gcagcagttg gtacgactac tctgactac 39 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 416 
LENGTH: 13 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 416 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr 
1 5 10 
US 2010/0166768 A1 
132 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 417 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 417 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 120 
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 
180 
240 
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 
gggaccaagg tggaaatcaa a 
300 
321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 418 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 418 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 419 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 419 
cagagtatta gtagctgg 18 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 420 
LENGTH: 6 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 420 
US 2010/0166768 A1 
133 
JU1. 1, 2010 
-continued 
Gln Ser Ile Ser Ser Trp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 421 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 421 
aaggcgtct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 422 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 422 
Lys Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 423 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 423 
caacagtata ttagttattc tcggacg 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 424 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 424 
Gln Gln Tyr Ile Ser Tyr Ser Arg Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 425 
LENGTH: 360 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 425 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60 
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 
120 
180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240 
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 300 
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360 
US 2010/0166768 A1 
134 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 426 
LENGTH: 120 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 426 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
20 25 30 
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln 
100 105 110 
Gly Thr Leu Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 427 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 427 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 120 
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 
180 
240 
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 
gggaccaagg tggaaatcaa a 
300 
321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 428 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 428 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
US 2010/0166768 A1 
135 
JU1. 1, 2010 
-continued 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 429 
LENGTH: 360 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 429 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 
tcctgtgcag cctctggatt caccttcagt acttataaca tgaactgggt ccgccaggct 
60 
120 
ccagggaagg ggctggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240 
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 
agcagttggt acgactactc tgactactgg ggccaaggaa ccctggtcac cgtctcctca 
300 
360 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 430 
LENGTH: 120 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 430 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
20 25 30 
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln 
100 105 110 
Gly Thr Leu Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 431 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 431 
US 2010/0166768 A1 
136 
JU1. 1, 2010 
-continued 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120 
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 
180 
240 
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 
gggaccaagg tggaaatcaa a 
300 
321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 432 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 432 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 433 
LENGTH: 360 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 433 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60 
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 
120 
180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagag ttcactgtat 240 
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 300 
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 434 
LENGTH: 120 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 434 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
US 2010/0166768 A1 
137 
JU1. 1, 2010 
-continued 
10 15 
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
20 25 30 
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln 
100 105 110 
Gly Thr Leu Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 435 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 435 
ggattcacct tcagtactta taac 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 436 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 436 
Gly Phe Thr Phe Ser Thr Tyr Asn 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 437 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 437 
attaggagta gtagtaatta cata 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 438 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 438 
Ile Arg Ser Ser Ser Asn Tyr Ile 
1 5 
&210& SEQ ID NO 439 
&211& LENGTH: 39 
US 2010/0166768 A1 
138 
JU1. 1, 2010 
-continued 
&212& TYPE: DNA 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 439 
gcgagagatg gcagcagttg gtacgactac tctgactac 39 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 440 
LENGTH: 13 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 440 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 441 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 441 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acaggtacca 120 
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 
240 
300 
gggaccaagg tggaaatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 442 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 442 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Val Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
US 2010/0166768 A1 
139 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 443 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 443 
cagagtatta gtagctgg 18 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 444 
LENGTH: 6 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 444 
Gln Ser Ile Ser Ser Trp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 445 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 445 
aaggcgtct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 446 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 446 
Lys Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 447 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 447 
caacagtata ttagttattc tcggacg 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 448 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 448 
Gln Gln Tyr Ile Ser Tyr Ser Arg Thr 
1 5 
&210& SEQ ID NO 449 
US 2010/0166768 A1 
140 
JU1. 1, 2010 
-continued 
&211& 
&212& 
&213& 
&220& 
&223& 
LENGTH: 360 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 449 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 
60 
120 
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagag ttcactgtat 240 
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 
300 
360 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 450 
LENGTH: 120 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 450 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
20 25 30 
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln 
100 105 110 
Gly Thr Leu Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 451 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 451 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acaggtacca 
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 
120 
180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 
240 
300 
gggaccaagg tggaaatcaa a 321 
US 2010/0166768 A1 
141 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 452 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 452 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Val Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 453 
LENGTH: 360 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 453 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt caccttcagt acttataaca tgaactgggt ccgccaggct 
ccagggaagg ggctggagtg ggtctcatcc attaggagta gtagtaatta catatactac 
120 
180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240 
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 300 
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 454 
LENGTH: 120 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 454 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
20 25 30 
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
US 2010/0166768 A1 
142 
JU1. 1, 2010 
-continued 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln 
100 105 110 
Gly Thr Leu Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 455 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 455 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 
120 
180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 
240 
300 
gggaccaagg tggaaatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 456 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 456 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 457 
LENGTH: 360 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 457 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60 
US 2010/0166768 A1 
143 
JU1. 1, 2010 
-continued 
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 
120 
180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240 
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 300 
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 458 
LENGTH: 120 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 458 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
20 25 30 
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln 
100 105 110 
Gly Thr Leu Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 459 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 459 
ggattcacct tcagtactta taac 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 460 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 460 
Gly Phe Thr Phe Ser Thr Tyr Asn 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 461 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
144 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 461 
attaggagta gtagtaatta cata 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 462 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 462 
Ile Arg Ser Ser Ser Asn Tyr Ile 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 463 
LENGTH: 39 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 463 
gcgagagatg gcagcagttg gtacgactac tctgactac 39 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 464 
LENGTH: 13 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 464 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 465 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 465 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 
120 
180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 
240 
300 
gggaccaagg tggaaatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 466 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 466 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
US 2010/0166768 A1 
145 
JU1. 1, 2010 
-continued 
10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 467 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 467 
cagagtatta gtagctgg 18 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 468 
LENGTH: 6 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 468 
Gln Ser Ile Ser Ser Trp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 469 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 469 
aaggcgtct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 470 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 470 
Lys Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
SEQ ID NO 471 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
US 2010/0166768 A1 
146 
JU1. 1, 2010 
-continued 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 471 
caacagtata ttagttattc tcggacg 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 472 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 472 
Gln Gln Tyr Ile Ser Tyr Ser Arg Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 473 
LENGTH: 360 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 473 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc cgggggggtc cctgagactc 60 
tcctgtacag cctctggatt caccttcagt acttataaca tgaattgggt ccgccaggct 
ccagggaagg gactggagtg ggtctcatcc attaggagta gtagtaatta catatactac 
120 
180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ttcactgtat 240 
ctgcaaatga acagcctgag agccgatgac acggctgtgt attactgtgc gagagatggc 300 
agcagttggt acgactactc tgactactgg ggccagggaa ccctggtcac cgtctcctca 360 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 474 
LENGTH: 120 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 474 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
20 25 30 
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln 
100 105 110 
Gly Thr Leu Val Thr Val Ser Ser 
115 120 
US 2010/0166768 A1 
147 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 475 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 475 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca acagatacca 
gggaaagccc ctaaactcct gatctataag gcgtctagtt tagaaaatgg ggtcccatca 
120 
180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca tcatcagcag cctgcagcct 
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 
240 
300 
gggaccaagg tggaaatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 476 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 476 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Ile Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Ile Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 477 
LENGTH: 360 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 477 
gaggtgcagc tggtggagtc tgggggaggc ctggtcaagc ctggggggtc cctgagactc 
tcctgtgcag cctctggatt caccttcagt acttataaca tgaactgggt ccgccaggct 
60 
120 
ccagggaagg ggctggagtg ggtctcatcc attaggagta gtagtaatta catatactac 180 
gcagactcag tgaagggccg attcaccatc tccagagaca acgccaagaa ctcactgtat 240 
ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatggc 
agcagttggt acgactactc tgactactgg ggccaaggaa ccctggtcac cgtctcctca 
300 
360 
&210& SEQ ID NO 478 
US 2010/0166768 A1 
148 
JU1. 1, 2010 
-continued 
&211& LENGTH: 120 
&212& TYPE: PRT 
&213& ORGANISM: Artific 
&220& FEATURE: 
&223& OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 478 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 
20 25 30 
Asn Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ser Ile Arg Ser Ser Ser Asn Tyr Ile Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gly Ser Ser Trp Tyr Asp Tyr Ser Asp Tyr Trp Gly Gln 
100 105 110 
Gly Thr Leu Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 479 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 479 
gacatccaga tgacccagtc tccttccacc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gagtattagt agctggttgg cctggtatca gcagaaacca 120 
gggaaagccc ctaagctcct gatctataag gcgtctagtt tagaaagtgg ggtcccatca 
aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct 
180 
240 
gatgattttg caacttatta ctgccaacag tatattagtt attctcggac gttcggccaa 
gggaccaagg tggaaatcaa a 
300 
321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 480 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 480 
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
US 2010/0166768 A1 
149 
JU1. 1, 2010 
-continued 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Tyr Ser Arg 
85 90 95 
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 481 
LENGTH: 354 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 481 
gaggtgcaac tagtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 
tcctgtgtag tctctggatt caccttcggt gactacgaca tgcactgggt ccgtcaagct 
60 
120 
acaggaagag gtctggagtg ggtctcaggt attgctcctg ctggtgacac atcctataca 
ggctccgtga agggccgatt caccatctcc agagagaatg ccaagaactc cttgcatctt 
180 
240 
caaatgaaca gcctgacaac cggggacacg gctatatatt attgtgctag agaggatata 
gcagtgcctg gttttgatta ctggggccag ggaaccctgg tcaccgtctc ctca 
300 
354 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 482 
LENGTH: 118 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 482 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Val Val Ser Gly Phe Thr Phe Gly Asp Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Ala Thr Gly Arg Gly Leu Glu Trp Val 
35 40 45 
Ser Gly Ile Ala Pro Ala Gly Asp Thr Ser Tyr Thr Gly Ser Val Lys 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu 
65 70 75 
His Leu 
80 
Gln Met Asn Ser Leu Thr Thr Gly Asp Thr Ala Ile Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Asp Ile Ala Val Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr 
100 105 110 
Leu Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 483 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 483 
ggattcacct tcggtgacta cgac 24 
US 2010/0166768 A1 
150 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 484 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 484 
Gly Phe Thr Phe Gly Asp Tyr Asp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 485 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 485 
attgctcctg ctggtgacac a 21 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 486 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 486 
Ile Ala Pro Ala Gly Asp Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 487 
LENGTH: 36 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 487 
gctagagagg atatagcagt gcctggtttt gattac 36 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 488 
LENGTH: 12 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 488 
Ala Arg Glu Asp Ile Ala Val Pro Gly Phe Asp Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 489 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 489 
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga acgaggcacc 60 
US 2010/0166768 A1 
151 
JU1. 1, 2010 
-continued 
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 
ggccaggctc ccagactcct catctatggt gcatccacga gggccactgg cttcccagcc 
120 
180 
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 
gaagattttg cagtttatta ctgtcagcag tataataagt ggcctccgtt cactttcggc 
240 
300 
cctgggacca aagtggattt caaa 324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 490 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 490 
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1 5 10 15 
Glu Arg Gly Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
35 40 45 
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Phe Pro Ala Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65 70 75 80 
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Lys Trp Pro Pro 
85 90 95 
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Phe Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 491 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 491 
cagagtgtta gcagcaac 18 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 492 
LENGTH: 6 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 492 
Gln Ser Val Ser Ser Asn 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 493 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 493 
US 2010/0166768 A1 
152 
JU1. 1, 2010 
-continued 
ggtgcatcc 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 494 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 494 
Gly Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 495 
LENGTH: 30 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 495 
cagcagtata ataagtggcc tccgttcact 30 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 496 
LENGTH: 10 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 496 
Gln Gln Tyr Asn Lys Trp Pro Pro Phe Thr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 497 
LENGTH: 354 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 497 
gaggtgcaac tagtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 
tcctgtgtag tctctggatt caccttcggt gactacgaca tgcactgggt ccgtcaagct 
60 
120 
acaggaagag gtctggagtg ggtctcaggt attgctcctg ctggtgacac atcctataca 
ggctccgtga agggccgatt caccatctcc agagagaatg ccaagaactc cttgcatctt 
180 
240 
caaatgaaca gcctgacaac cggggacacg gctatatatt attgtgctag agaggatata 
gcagtgcctg gttttgatta ctggggccag ggaaccctgg tcaccgtctc ctca 
300 
354 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 498 
LENGTH: 118 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 498 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Val Val Ser Gly Phe Thr Phe Gly Asp Tyr 
US 2010/0166768 A1 
153 
JU1. 1, 2010 
-continued 
20 25 30 
Asp Met His Trp Val Arg Gln Ala Thr Gly Arg Gly Leu Glu Trp Val 
35 40 45 
Ser Gly Ile Ala Pro Ala Gly Asp Thr Ser Tyr Thr Gly Ser Val Lys 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu His Leu 
65 70 75 80 
Gln Met Asn Ser Leu Thr Thr Gly Asp Thr Ala Ile Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Asp Ile Ala Val Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr 
100 105 110 
Leu Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 499 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 499 
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga acgaggcacc 60 
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 
ggccaggctc ccagactcct catctatggt gcatccacga gggccactgg cttcccagcc 
120 
180 
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 240 
gaagattttg cagtttatta ctgtcagcag tataataagt ggcctccgtt cactttcggc 
cctgggacca aagtggatat caaa 
300 
324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 500 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 500 
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1 5 10 15 
Glu Arg Gly Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
35 40 45 
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Phe Pro Ala Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65 70 75 80 
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Lys Trp Pro Pro 
85 90 95 
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& SEQ ID NO 501 
&211& LENGTH: 354 
US 2010/0166768 A1 
154 
JU1. 1, 2010 
-continued 
&212& TYPE: DNA 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 501 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt caccttcggt gactacgaca tgcactgggt ccgccaagct 120 
acaggaaaag gtctggagtg ggtctcagct attgctcctg ctggtgacac atactatcca 
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 
180 
240 
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgctag agaggatata 
gcagtgcctg gttttgatta ctggggccaa ggaaccctgg tcaccgtctc ctca 
300 
354 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 502 
LENGTH: 118 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 502 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Ala Pro Ala Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu 
65 70 75 80 
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Asp Ile Ala Val Pro Gly Phe Asp Tyr Trp Gly Gln Gly Thr 
100 105 110 
Leu Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 503 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 503 
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60 
ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct 
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 
120 
180 
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 
gaagattttg cagtttatta ctgtcagcag tataataagt ggcctccgtt cactttcggc 
240 
300 
cctgggacca aagtggatat caaa 324 
US 2010/0166768 A1 
155 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 504 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 504 
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
35 40 45 
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65 70 75 80 
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Lys Trp Pro Pro 
85 90 95 
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 505 
LENGTH: 378 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 505 
caaattctgc tggtgcaatc tggacctgag gtgaaggagc ctggggcctc agtgaaggtc 60 
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggtc 
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 
120 
180 
gcacatgaag tccagggcag agtcaccatg accacagaca catccacgac cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccatgt attactgtgc gagagggggt 300 
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg ccaagggacc 360 
acggtcaccg tctcctca 378 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 506 
LENGTH: 126 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 506 
Gln Ile Leu Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
20 25 30 
Ala Ile Ser Trp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala His Glu Val 
50 55 60 
US 2010/0166768 A1 
156 
JU1. 1, 2010 
-continued 
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys 
85 90 95 
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly 
100 105 110 
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 507 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 507 
ggttacacct ttaccaacta cgct 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 508 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 508 
Gly Tyr Thr Phe Thr Asn Tyr Ala 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 509 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 509 
gtcagcgctt acaatggtca caca 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 510 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 510 
Val Ser Ala Tyr Asn Gly His Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 511 
LENGTH: 57 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 511 
gcgagagggg gtgtagtcgt gccagttgct ccccacttct acaacggtat ggacgtc 57 
&210& SEQ ID NO 512 
US 2010/0166768 A1 
157 
JU1. 1, 2010 
-continued 
&211& 
&212& 
&213& 
&220& 
&223& 
LENGTH: 19 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 512 
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly 
1 5 10 15 
Met Asp Val 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 513 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 513 
gatattgtga tgactcagtt tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg 
60 
120 
tacctaaaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtc tattactgca tgcaagctct tcaaactccg 
tggacgttag gccaagggac caaggtggaa atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 514 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 514 
Asp Ile Val Met Thr Gln Phe Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile 
20 25 30 
Asn Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Lys Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Trp Thr Leu Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 515 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 515 
US 2010/0166768 A1 
158 
JU1. 1, 2010 
-continued 
cagagcctcc tgcatattaa tgaatacaac tat 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 516 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 516 
Gln Ser Leu Leu His Ile Asn Glu Tyr Asn Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 517 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 517 
ttgggtttt 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 518 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 518 
Leu Gly Phe 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 519 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 519 
atgcaagctc ttcaaactcc gtggacg 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 520 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 520 
Met Gln Ala Leu Gln Thr Pro Trp Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 521 
LENGTH: 378 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 521 
caggttcagc tggtgcagtc tggacctgag gtgaaggagc ctggggcctc agtgaaggtc 60 
US 2010/0166768 A1 
159 
JU1. 1, 2010 
-continued 
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggtc 
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 
120 
180 
gcacatgaag tccagggcag agtcaccatg accacagaca catccacgac cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccatgt attactgtgc gagagggggt 300 
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg ccaagggacc 360 
acggtcaccg tctcctca 378 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 522 
LENGTH: 126 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 522 
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
20 25 30 
Ala Ile Ser Trp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala His Glu Val 
50 55 60 
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys 
85 90 95 
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly 
100 105 110 
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 523 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 523 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 60 
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg 
tacctaaaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc 
120 
180 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 240 
agcagagtgg aggctgagga tgttggggtc tattactgca tgcaagctct tcaaactccg 
tggacgttag gccaagggac caaggtggaa atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 524 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
160 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 524 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile 
20 25 30 
Asn Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Lys Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Trp Thr Leu Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&211& 
&212& 
&213& 
&220& 
&223& 
&210& SEQ ID NO 525 
LENGTH: 378 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 525 
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggcc 120 
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 180 
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagggggt 
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg gcaagggacc 
300 
360 
acggtcaccg tctcctca 378 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 526 
LENGTH: 126 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 526 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
20 25 30 
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala Gln Lys Leu 
50 55 60 
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
US 2010/0166768 A1 
161 
JU1. 1, 2010 
-continued 
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly 
100 105 110 
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 527 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 527 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg 
60 
120 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct tcaaactccg 
tggacgttcg gccaagggac caaggtggaa atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 528 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 528 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile 
20 25 30 
Asn Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 529 
LENGTH: 351 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 529 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagca 
60 
120 
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactataca 180 
ggctccgtga tgggccgatt caccatctcc agagacgctg ccaaaaactc cttctatctt 240 
US 2010/0166768 A1 
162 
JU1. 1, 2010 
-continued 
gaaatgaaca gcctgagagt cggggacacg gctgtatatt actgtgcaag agagggaata 300 
agaacaccct atgattattg gggccaggga gcccgggtca ccgtctcctc a 351 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 530 
LENGTH: 117 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 530 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Thr Gly Ser Val Met 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Asp Ala Ala Lys Asn Ser Phe Tyr Leu 
65 70 75 80 
Glu Met Asn Ser Leu Arg Val Gly Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Ala Arg 
100 105 110 
Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 531 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 531 
ggattcaccc taagtagcta cgac 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 532 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 532 
Gly Phe Thr Leu Ser Ser Tyr Asp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 533 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 533 
attggcagta ctggtgacac a 21 
US 2010/0166768 A1 
163 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 534 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 534 
Ile Gly Ser Thr Gly Asp Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 535 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 535 
gcaagagagg gaataagaac accctatgat tat 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 536 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 536 
Ala Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 537 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 537 
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60 
ctctcctgca gggccagtca gagtgttagc agcaatgtag cctggtacca gcagaaacct 
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 
120 
180 
aggttcagtg gcagtgggtc tgggacagaa ttcactctca ccatcagcag cctgcagtct 
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc 
240 
300 
cctgggacca aagtggatat caaa 324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 538 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 538 
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
20 25 30 
US 2010/0166768 A1 
164 
JU1. 1, 2010 
-continued 
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
35 40 45 
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65 70 75 80 
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro 
85 90 95 
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 539 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 539 
cagagtgtta gcagcaat 18 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 540 
LENGTH: 6 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 540 
Gln Ser Val Ser Ser Asn 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 541 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 541 
ggtgcatcc 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 542 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 542 
Gly Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 543 
LENGTH: 30 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 543 
cagcagtata ataattggcc tccattcact 30 
US 2010/0166768 A1 
165 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 544 
LENGTH: 10 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 544 
Gln Gln Tyr Asn Asn Trp Pro Pro Phe Thr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 545 
LENGTH: 351 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 545 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagca 
60 
120 
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactataca 180 
ggctccgtga tgggccgatt caccatctcc agagacgctg ccaaaaactc cttctatctt 240 
gaaatgaaca gcctgagagt cggggacacg gctgtatatt actgtgcaag agagggaata 
agaacaccct atgattattg gggccaggga accctggtca ccgtctcctc a 
300 
351 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 546 
LENGTH: 117 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 546 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Thr Gly Ser Val Met 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Asp Ala Ala Lys Asn Ser Phe Tyr Leu 
65 70 75 80 
Glu Met Asn Ser Leu Arg Val Gly Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Leu 
100 105 110 
Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
SEQ ID NO 547 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
US 2010/0166768 A1 
166 
JU1. 1, 2010 
-continued 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 547 
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 
ctctcctgca gggccagtca gagtgttagc agcaatgtag cctggtacca gcagaaacct 
60 
120 
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 
aggttcagtg gcagtgggtc tgggacagaa ttcactctca ccatcagcag cctgcagtct 
180 
240 
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc 
cctgggacca aagtggatat caaa 
300 
324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 548 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 548 
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
20 25 30 
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
35 40 45 
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65 70 75 80 
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro 
85 90 95 
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 549 
LENGTH: 351 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 549 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagct 
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactatcca 
120 
180 
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 240 
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agagggaata 300 
agaacaccct atgattattg gggccaagga accctggtca ccgtctcctc a 351 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 550 
LENGTH: 117 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
167 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 550 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu 
65 70 75 80 
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Leu 
100 105 110 
Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 551 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 551 
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60 
ctctcctgca gggccagtca gagtgttagc agcaatttag cctggtacca gcagaaacct 
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 
120 
180 
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc 
240 
300 
cctgggacca aagtggatat caaa 324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 552 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 552 
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
35 40 45 
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65 70 75 80 
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro 
85 90 95 
US 2010/0166768 A1 
168 
JU1. 1, 2010 
-continued 
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 553 
LENGTH: 351 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 553 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagca 
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactataca 
120 
180 
ggctccgtga tgggccgatt caccatctcc agagacgctg ccaaaaactc cttctatctt 240 
gaaatgaaca gcctgagagt cggggacacg gctgtatatt actgtgcaag agagggaata 300 
agaacaccct atgattattg gggccaggga gcccgggtca ccgtctcctc a 351 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 554 
LENGTH: 117 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 554 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Thr Gly Ser Val Met 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Asp Ala Ala Lys Asn Ser Phe Tyr Leu 
65 70 75 80 
Glu Met Asn Ser Leu Arg Val Gly Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Ala Arg 
100 105 110 
Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 555 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 555 
ggattcaccc taagtagcta cgac 24 
&210& SEQ ID NO 556 
&211& LENGTH: 8 
&212& TYPE: PRT 
US 2010/0166768 A1 
169 
JU1. 1, 2010 
-continued 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 556 
Gly Phe Thr Leu Ser Ser Tyr Asp 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 557 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 557 
attggcagta ctggtgacac a 21 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 558 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 558 
Ile Gly Ser Thr Gly Asp Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 559 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 559 
gcaagagagg gaataagaac accctatgat tat 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 560 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 560 
Ala Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 561 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 561 
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 
ctctcctgca gggccagtca gagtgttagc agcaatgtag cctggtacca gcagaaacct 
60 
120 
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 
aggttcagtg gcagtgggtc tgggacagaa ttcactctca ccatcagcag cctgcagtct 
180 
240 
US 2010/0166768 A1 
170 
JU1. 1, 2010 
-continued 
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc 300 
cctgggacca aagtggatat caaa 324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 562 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 562 
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
20 25 30 
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
35 40 45 
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65 70 75 80 
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro 
85 90 95 
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 563 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 563 
cagagtgtta gcagcaat 18 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 564 
LENGTH: 6 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 564 
Gln Ser Val Ser Ser Asn 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 565 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 565 
ggtgcatcc 
&210& SEQ ID NO 566 
&211& LENGTH: 3 
US 2010/0166768 A1 
171 
JU1. 1, 2010 
-continued 
&212& TYPE: PRT 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 566 
Gly Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 567 
LENGTH: 30 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 567 
cagcagtata ataattggcc tccattcact 30 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 568 
LENGTH: 10 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 568 
Gln Gln Tyr Asn Asn Trp Pro Pro Phe Thr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 569 
LENGTH: 351 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 569 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagca 
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactataca 
120 
180 
ggctccgtga tgggccgatt caccatctcc agagacgctg ccaaaaactc cttctatctt 240 
gaaatgaaca gcctgagagt cggggacacg gctgtatatt actgtgcaag agagggaata 300 
agaacaccct atgattattg gggccaggga accctggtca ccgtctcctc a 351 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 570 
LENGTH: 117 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 570 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
US 2010/0166768 A1 
172 
JU1. 1, 2010 
-continued 
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Thr Gly Ser Val Met 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Asp Ala Ala Lys Asn Ser Phe Tyr Leu 
65 70 75 80 
Glu Met Asn Ser Leu Arg Val Gly Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Leu 
100 105 110 
Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 571 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 571 
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 60 
ctctcctgca gggccagtca gagtgttagc agcaatgtag cctggtacca gcagaaacct 
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 
120 
180 
aggttcagtg gcagtgggtc tgggacagaa ttcactctca ccatcagcag cctgcagtct 
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc 
240 
300 
cctgggacca aagtggatat caaa 324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 572 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 572 
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
20 25 30 
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
35 40 45 
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65 70 75 80 
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro 
85 90 95 
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 573 
LENGTH: 351 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
173 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 573 
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60 
tcctgtgcag cctctggatt caccctaagt agctacgaca tgcactgggt ccgccaagct 
acaggaaaag gtctggagtg ggtctcagct attggcagta ctggtgacac atactatcca 
120 
180 
ggctccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctt 
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agagggaata 
240 
300 
agaacaccct atgattattg gggccaagga accctggtca ccgtctcctc a 351 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 574 
LENGTH: 117 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 574 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr 
20 25 30 
Asp Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Gly Ser Thr Gly Asp Thr Tyr Tyr Pro Gly Ser Val Lys 
50 55 60 
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu 
65 70 75 80 
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala 
85 90 95 
Arg Glu Gly Ile Arg Thr Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Leu 
100 105 110 
Val Thr Val Ser Ser 
115 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 575 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 575 
gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc 
ctctcctgca gggccagtca gagtgttagc agcaatttag cctggtacca gcagaaacct 
60 
120 
ggccaggctc ccaggctcct catctatggt gcatccacca gggccactgg tatcccagcc 
aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct 
180 
240 
gaagattttg cagtttatta ctgtcagcag tataataatt ggcctccatt cactttcggc 
cctgggacca aagtggatat caaa 
300 
324 
&210& 
&211& 
&212& 
&213& 
&220& 
SEQ ID NO 576 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
US 2010/0166768 A1 
174 
JU1. 1, 2010 
-continued 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 576 
Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
35 40 45 
Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 
65 70 75 80 
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro 
85 90 95 
Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 577 
LENGTH: 363 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 577 
gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc 
tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagct 
60 
120 
ccagggaagg gcctggagtg ggtctcaggt attaattgga acagtggtag cataggctat 180 
gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagca ctccctgtat 240 
ctgcaaatga acagtctgag acctgaggac acggccttgt attactgtgt aaaagaggtg 
actacgggat actactacgg tatggacgtc tggggccaag ggaccacggt caccgtctcc 
300 
360 
tca 363 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 578 
LENGTH: 121 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 578 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
20 25 30 
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Gly Ile Asn Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys His Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys 
85 90 95 
US 2010/0166768 A1 
175 
JU1. 1, 2010 
-continued 
Val Lys Glu Val Thr Thr Gly Tyr Tyr Tyr Gly Met Asp Val Trp Gly 
100 105 110 
Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 579 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 579 
ggattcacct ttgatgatta tgcc 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 580 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 580 
Gly Phe Thr Phe Asp Asp Tyr Ala 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 581 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 581 
attaattgga acagtggtag cata 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 582 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 582 
Ile Asn Trp Asn Ser Gly Ser Ile 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 583 
LENGTH: 42 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 583 
gtaaaagagg tgactacggg atactactac ggtatggacg tc 42 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 584 
LENGTH: 14 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
176 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 584 
Val Lys Glu Val Thr Thr Gly Tyr Tyr Tyr Gly Met Asp Val 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 585 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 585 
gacatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgct gggccagtca gggcattagc agttatttag cctggtatca gaaaaaacca 120 
gggaaagccc ctaacctcct gatctatgat gcatccactt tgcaaagtgg ggtcccatca 
aggttcagcg gcagtggatc tgggacagaa ttcactctca cactcagcag cctgcagcct 
180 
240 
gaagattttg caacttatta ctgtcaacag cttaatattt acccattcac tttcggccct 300 
gggaccaaag tggatatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 586 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 586 
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Trp Ala Ser Gln Gly Ile Ser Ser Tyr 
20 25 30 
Leu Ala Trp Tyr Gln Lys Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile 
35 40 45 
Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Leu Ser Ser Leu Gln Pro 
65 70 75 80 
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ile Tyr Pro Phe 
85 90 95 
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 587 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 587 
cagggcatta gcagttat 18 
&210& SEQ ID NO 588 
&211& LENGTH: 6 
&212& TYPE: PRT 
&213& ORGANISM: Artificial Sequence 
US 2010/0166768 A1 
177 
JU1. 1, 2010 
-continued 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 588 
Gln Gly Ile Ser Ser Tyr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 589 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 589 
gatgcatcc 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 590 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 590 
Asp Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 591 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 591 
caacagctta atatttaccc attcact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 592 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 592 
Gln Gln Leu Asn Ile Tyr Pro Phe Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 593 
LENGTH: 363 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 593 
gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc 60 
tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagct 
ccagggaagg gcctggagtg ggtctcaggt attaattgga acagtggtag cataggctat 
120 
180 
gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagca ctccctgtat 240 
US 2010/0166768 A1 
178 
JU1. 1, 2010 
-continued 
ctgcaaatga acagtctgag acctgaggac acggccttgt attactgtgt aaaagaggtg 300 
actacgggat actactacgg tatggacgtc tggggccaag ggaccacggt caccgtctcc 360 
tca 363 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 594 
LENGTH: 121 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 594 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
20 25 30 
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Gly Ile Asn Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys His Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys 
85 90 95 
Val Lys Glu Val Thr Thr Gly Tyr Tyr Tyr Gly Met Asp Val Trp Gly 
100 105 110 
Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 595 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 595 
gacatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgct gggccagtca gggcattagc agttatttag cctggtatca gaaaaaacca 120 
gggaaagccc ctaacctcct gatctatgat gcatccactt tgcaaagtgg ggtcccatca 
aggttcagcg gcagtggatc tgggacagaa ttcactctca cactcagcag cctgcagcct 
180 
240 
gaagattttg caacttatta ctgtcaacag cttaatattt acccattcac tttcggccct 300 
gggaccaaag tggatatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 596 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 596 
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Trp Ala Ser Gln Gly Ile Ser Ser Tyr 
US 2010/0166768 A1 
179 
JU1. 1, 2010 
-continued 
20 25 30 
Leu Ala Trp Tyr Gln Lys Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile 
35 40 45 
Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Leu Ser Ser Leu Gln Pro 
65 70 75 80 
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ile Tyr Pro Phe 
85 90 95 
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 597 
LENGTH: 363 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 597 
gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc 
tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagct 
60 
120 
ccagggaagg gcctggagtg ggtctcaggt attaattgga acagtggtag cataggctat 180 
gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa ctccctgtat 240 
ctgcaaatga acagtctgag agctgaggac acggccttgt attactgtgt aaaagaggtg 
actacgggat actactacgg tatggacgtc tgggggcaag ggaccacggt caccgtctcc 
300 
360 
tca 363 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 598 
LENGTH: 121 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 598 
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
20 25 30 
Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Gly Ile Asn Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 
85 90 95 
Val Lys Glu Val Thr Thr Gly Tyr Tyr Tyr Gly Met Asp Val Trp Gly 
100 105 110 
Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 
US 2010/0166768 A1 
180 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 599 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 599 
gacatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc 60 
atcacttgcc gggccagtca gggcattagc agttatttag cctggtatca gcaaaaacca 
gggaaagccc ctaagctcct gatctatgat gcatccactt tgcaaagtgg ggtcccatca 
120 
180 
aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240 
gaagattttg caacttatta ctgtcaacag cttaatattt acccattcac tttcggccct 300 
gggaccaaag tggatatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 600 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 600 
Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 
1 5 10 15 
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr 
20 25 30 
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
35 40 45 
Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
50 55 60 
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65 70 75 80 
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ile Tyr Pro Phe 
85 90 95 
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 601 
LENGTH: 366 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 601 
gaggtgcagt tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 
tcctgtgcag cctctggatt cacgtttagt agctatgcca tgaactgggt ccgccaggct 
60 
120 
ccagggaagg ggctggattg ggtctcaggt atcagtggta atggtggtag cacctactac 
gcagactccg tgaagggccg gttcaccatc tccagagaca tttccaagaa cacgctgtat 
180 
240 
gtgcaaatgc acagcctgag agtcgaggac acggccgttt actactgtgc gaaagcccgt 
tattacgatt tttggggggg gaatttcgat ctctggggcc gtggcaccca ggtcactgtc 
300 
360 
tcctca 366 
US 2010/0166768 A1 
181 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 602 
LENGTH: 122 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 602 
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val 
35 40 45 
Ser Gly Ile Ser Gly Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Ile Ser Lys Asn Thr Leu Tyr 
65 70 75 80 
Val Gln Met His Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Lys Ala Arg Tyr Tyr Asp Phe Trp Gly Gly Asn Phe Asp Leu Trp 
100 105 110 
Gly Arg Gly Thr Gln Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 603 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 603 
ggattcacgt ttagtagcta tgcc 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 604 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 604 
Gly Phe Thr Phe Ser Ser Tyr Ala 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 605 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 605 
atcagtggta atggtggtag cacc 24 
&210& SEQ ID NO 606 
&211& LENGTH: 8 
&212& TYPE: PRT 
&213& ORGANISM: Artificial Sequence 
US 2010/0166768 A1 
182 
JU1. 1, 2010 
-continued 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 606 
Ile Ser Gly Asn Gly Gly Ser Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 607 
LENGTH: 45 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 607 
gcgaaagccc gttattacga tttttggggg gggaatttcg atctc 45 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 608 
LENGTH: 15 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 608 
Ala Lys Ala Arg Tyr Tyr Asp Phe Trp Gly Gly Asn Phe Asp Leu 
1 5 10 15 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 609 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 609 
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 
ctctcctgca gggccagtca gagtgttagc atcaggtact tagcctggta tcagcagaaa 
60 
120 
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 
gacaggttca gtgtcagtgt gtctgggaca gacttcactc tcaccatcac tagactggag 
180 
240 
cctgaagatt ttgcagtcta ttactgtcag caatatggta gttcaccgct cactttcggc 
ggagggacca aggtggagat caaa 
300 
324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 610 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 610 
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ile Arg 
20 25 30 
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
35 40 45 
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
50 55 60 
US 2010/0166768 A1 
183 
JU1. 1, 2010 
-continued 
Val Ser Val Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu 
65 70 75 80 
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 
85 90 95 
Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 611 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 611 
cagagtgtta gcatcaggta c 21 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 612 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 612 
Gln Ser Val Ser Ile Arg Tyr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 613 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 613 
ggtgcatcc 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 614 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 614 
Gly Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 615 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 615 
cagcaatatg gtagttcacc gctcact 27 
&210& SEQ ID NO 616 
&211& LENGTH: 9 
&212& TYPE: PRT 
US 2010/0166768 A1 
184 
JU1. 1, 2010 
-continued 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 616 
Gln Gln Tyr Gly Ser Ser Pro Leu Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 617 
LENGTH: 366 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 617 
gaggtgcagt tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 
tcctgtgcag cctctggatt cacgtttagt agctatgcca tgaactgggt ccgccaggct 
60 
120 
ccagggaagg ggctggattg ggtctcaggt atcagtggta atggtggtag cacctactac 
gcagactccg tgaagggccg gttcaccatc tccagagaca tttccaagaa cacgctgtat 
180 
240 
gtgcaaatgc acagcctgag agtcgaggac acggccgttt actactgtgc gaaagcccgt 
tattacgatt tttggggggg gaatttcgat ctctggggcc gtggcaccct ggtcactgtc 
300 
360 
tcctca 366 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 618 
LENGTH: 122 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 618 
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val 
35 40 45 
Ser Gly Ile Ser Gly Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Ile Ser Lys Asn Thr Leu Tyr 
65 70 75 80 
Val Gln Met His Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Lys Ala Arg Tyr Tyr Asp Phe Trp Gly Gly Asn Phe Asp Leu Trp 
100 105 110 
Gly Arg Gly Thr Leu Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 619 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 619 
US 2010/0166768 A1 
185 
JU1. 1, 2010 
-continued 
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 
ctctcctgca gggccagtca gagtgttagc atcaggtact tagcctggta tcagcagaaa 
60 
120 
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 
gacaggttca gtgtcagtgt gtctgggaca gacttcactc tcaccatcac tagactggag 
180 
240 
cctgaagatt ttgcagtcta ttactgtcag caatatggta gttcaccgct cactttcggc 300 
ggagggacca aggtggagat caaa 324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 620 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 620 
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ile Arg 
20 25 30 
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
35 40 45 
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
50 55 60 
Val Ser Val Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu 
65 70 75 80 
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 
85 90 95 
Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 621 
LENGTH: 366 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 621 
gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 
tcctgtgcag cctctggatt cacgtttagt agctatgcca tgagctgggt ccgccaggct 
60 
120 
ccagggaagg ggctggagtg ggtctcagct atcagtggta atggtggtag cacctactac 180 
gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240 
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagcccgt 
tattacgatt tttggggggg gaatttcgat ctctggggcc gtggcaccct ggtcactgtc 
300 
360 
tcctca 366 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 622 
LENGTH: 122 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
186 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 622 
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 
20 25 30 
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Ala Ile Ser Gly Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Lys Ala Arg Tyr Tyr Asp Phe Trp Gly Gly Asn Phe Asp Leu Trp 
100 105 110 
Gly Arg Gly Thr Leu Val Thr Val Ser Ser 
115 120 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 623 
LENGTH: 324 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 623 
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60 
ctctcctgca gggccagtca gagtgttagc atcaggtact tagcctggta ccagcagaaa 
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 
120 
180 
gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag 
cctgaagatt ttgcagtgta ttactgtcag caatatggta gttcaccgct cactttcggc 
240 
300 
ggagggacca aggtggagat caaa 324 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 624 
LENGTH: 108 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 624 
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ile Arg 
20 25 30 
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
35 40 45 
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
50 55 60 
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65 70 75 80 
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 
85 90 95 
US 2010/0166768 A1 
187 
JU1. 1, 2010 
-continued 
Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 625 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 625 
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60 
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 
120 
180 
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300 
ttagtagtac cacctgccct ttattattcc tactacgtta tggacgtctg gggccaaggg 360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 626 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 626 
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe 
50 55 60 
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys 
85 90 95 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Ser Tyr Tyr 
100 105 110 
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 627 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 627 
ggttacacct ttaccaccta tggt 24 
&210& SEQ ID NO 628 
&211& LENGTH: 8 
US 2010/0166768 A1 
188 
JU1. 1, 2010 
-continued 
&212& TYPE: PRT 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 628 
Gly Tyr Thr Phe Thr Thr Tyr Gly 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 629 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 629 
atcagcggtt acaatggtaa aaca 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 630 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 630 
Ile Ser Gly Tyr Asn Gly Lys Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 631 
LENGTH: 60 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 631 
tcgagagatc gtttagtagt accacctgcc ctttattatt cctactacgt tatggacgtc 60 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 632 
LENGTH: 20 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 632 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Ser Tyr Tyr 
1 5 10 15 
Val Met Asp Val 
20 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 633 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 633 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 
60 
120 
US 2010/0166768 A1 
189 
JU1. 1, 2010 
-continued 
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 
180 
240 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 
tacacttttg gccaggggac caagctggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 634 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 634 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
85 90 95 
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 635 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 635 
caaagcctcg tatacagtga tggaaacacc tac 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 636 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 636 
Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 637 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 637 
aaggtttct 
US 2010/0166768 A1 
190 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 638 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 638 
Lys Val Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 639 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 639 
atgcaaggta cacactggcc gtacact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 640 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 640 
Met Gln Gly Thr His Trp Pro Tyr Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 641 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 641 
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60 
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 
120 
180 
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300 
ttagtagtac cacctgccct ttattattcc tactacgtta tggacgtctg gggccaaggg 360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 642 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 642 
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala 
1 5 10 15 
US 2010/0166768 A1 
191 
JU1. 1, 2010 
-continued 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe 
50 55 60 
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys 
85 90 95 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Ser Tyr Tyr 
100 105 110 
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 643 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 643 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 
60 
120 
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 
180 
240 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 
tacacttttg gccaggggac caagctggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 644 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 644 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
85 90 95 
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 110 
&210& SEQ ID NO 645 
US 2010/0166768 A1 
192 
JU1. 1, 2010 
-continued 
&211& 
&212& 
&213& 
&220& 
&223& 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 645 
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 
tcctgcaagg cttctggtta cacctttacc acctatggta tcagctgggt gcgacaggcc 
60 
120 
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaactat 180 
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccgtgt attactgttc gagagatcgt 
ttagtagtac cacctgccct ttattattcc tactacgtta tggacgtctg ggggcaaggg 
300 
360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 646 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 646 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Tyr Ala Gln Lys Leu 
50 55 60 
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Ser Tyr Tyr 
100 105 110 
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 647 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 647 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 
60 
120 
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 
180 
240 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 300 
US 2010/0166768 A1 
193 
JU1. 1, 2010 
-continued 
tacacttttg gccaggggac caagctggag atcaaa 336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 648 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 648 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
85 90 95 
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 649 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 649 
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 
60 
120 
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 180 
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 
ttagtagtac cacctgccct taattattac tactacgtta tggacgtctg gggccaaggg 
300 
360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 650 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 650 
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
US 2010/0166768 A1 
194 
JU1. 1, 2010 
-continued 
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe 
50 55 60 
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys 
85 90 95 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Tyr Tyr Tyr 
100 105 110 
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 651 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 651 
ggttacacct ttaccaccta tggt 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 652 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 652 
Gly Tyr Thr Phe Thr Thr Tyr Gly 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 653 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 653 
atcagcggtt acaatggtaa aaca 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 654 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 654 
Ile Ser Gly Tyr Asn Gly Lys Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 655 
LENGTH: 60 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 655 
tcgagagatc gtttagtagt accacctgcc cttaattatt actactacgt tatggacgtc 60 
US 2010/0166768 A1 
195 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 656 
LENGTH: 20 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 656 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Tyr Tyr Tyr 
1 5 10 15 
Val Met Asp Val 
20 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 657 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 657 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 
60 
120 
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 
180 
240 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 
tacacttttg gccaggggac caagctggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 658 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 658 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
85 90 95 
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
SEQ ID NO 659 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
US 2010/0166768 A1 
196 
JU1. 1, 2010 
-continued 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 659 
caaagcctcg tatacagtga tggaaacacc tac 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 660 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 660 
Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 661 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 661 
aaggtttct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 662 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 662 
Lys Val Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 663 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 663 
atgcaaggta cacactggcc gtacact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 664 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 664 
Met Gln Gly Thr His Trp Pro Tyr Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 665 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
197 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 665 
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60 
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 
120 
180 
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 
ttagtagtac cacctgccct taattattac tactacgtta tggacgtctg gggccaaggg 
300 
360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 666 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 666 
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe 
50 55 60 
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys 
85 90 95 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Tyr Tyr Tyr 
100 105 110 
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 667 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 667 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 120 
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 
180 
240 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 
tacacttttg gccaggggac caagctggag atcaaa 
300 
336 
&210& SEQ ID NO 668 
&211& LENGTH: 112 
US 2010/0166768 A1 
198 
JU1. 1, 2010 
-continued 
&212& TYPE: PRT 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 668 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
85 90 95 
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 669 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 669 
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 
tcctgcaagg cttctggtta cacctttacc acctatggta tcagctgggt gcgacaggcc 
60 
120 
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaactat 180 
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccgtgt attactgttc gagagatcgt 
ttagtagtac cacctgccct taattattac tactacgtta tggacgtctg ggggcaaggg 
300 
360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 670 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 670 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Tyr Ala Gln Lys Leu 
50 55 60 
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
US 2010/0166768 A1 
199 
JU1. 1, 2010 
-continued 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Asn Tyr Tyr Tyr Tyr 
100 105 110 
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 671 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 671 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 
60 
120 
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 
180 
240 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 
tacacttttg gccaggggac caagctggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 672 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 672 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
85 90 95 
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 673 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 673 
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 
60 
120 
US 2010/0166768 A1 
200 
JU1. 1, 2010 
-continued 
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 180 
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 
ttagtagtac cacctgccct ttattattac tactacgtta tggacgtctg gggccaaggg 
300 
360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 674 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 674 
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe 
50 55 60 
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys 
85 90 95 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Tyr Tyr Tyr 
100 105 110 
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 675 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 675 
ggttacacct ttaccaccta tggt 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 676 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 676 
Gly Tyr Thr Phe Thr Thr Tyr Gly 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
SEQ ID NO 677 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
US 2010/0166768 A1 
201 
JU1. 1, 2010 
-continued 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 677 
atcagcggtt acaatggtaa aaca 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 678 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 678 
Ile Ser Gly Tyr Asn Gly Lys Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 679 
LENGTH: 60 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 679 
tcgagagatc gtttagtagt accacctgcc ctttattatt actactacgt tatggacgtc 60 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 680 
LENGTH: 20 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 680 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Tyr Tyr Tyr 
1 5 10 15 
Val Met Asp Val 
20 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 681 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 681 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 60 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 
120 
180 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 240 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 
tacacttttg gccaggggac caagctggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 682 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
202 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 682 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
85 90 95 
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 683 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 683 
caaagcctcg tatacagtga tggaaacacc tac 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 684 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 684 
Gln Ser Leu Val Tyr Ser Asp Gly Asn Thr Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 685 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 685 
aaggtttct 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 686 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 686 
Lys Val Ser 
1 
&210& SEQ ID NO 687 
US 2010/0166768 A1 
203 
JU1. 1, 2010 
-continued 
&211& 
&212& 
&213& 
&220& 
&223& 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 687 
atgcaaggta cacactggcc gtacact 27 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 688 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 688 
Met Gln Gly Thr His Trp Pro Tyr Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 689 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 689 
caggttcagc tggtgcagtc tggacctgag gtgaagaacc ctggggcctc agtgaaggtc 60 
tcctgcaagg cttctggtta cacctttacc acctatggta tcagttgggt acgacaggcc 
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaacgat 
120 
180 
gcacagaagt tccaggacag agtcgccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccattt attactgttc gagagatcgt 300 
ttagtagtac cacctgccct ttattattac tactacgtta tggacgtctg gggccaaggg 360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 690 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 690 
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Asn Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Asp Ala Gln Lys Phe 
50 55 60 
Gln Asp Arg Val Ala Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Ile Tyr Tyr Cys 
85 90 95 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Tyr Tyr Tyr 
US 2010/0166768 A1 
204 
JU1. 1, 2010 
-continued 
100 105 110 
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 691 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 691 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 
60 
120 
tttcagcaga ggccaggtca atctccaagg cgcctaattt ataaggtttc taaccgggac 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 
180 
240 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 
tacacttttg gccaggggac caagctggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 692 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 692 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
20 25 30 
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
85 90 95 
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 693 
LENGTH: 381 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 693 
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 
tcctgcaagg cttctggtta cacctttacc acctatggta tcagctgggt gcgacaggcc 
cctggacaag ggcttgagtg gatgggatgg atcagcggtt acaatggtaa aacaaactat 
120 
180 
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240 
US 2010/0166768 A1 
205 
JU1. 1, 2010 
-continued 
atggagctga ggagcctgag atctgacgac acggccgtgt attactgttc gagagatcgt 300 
ttagtagtac cacctgccct ttattattac tactacgtta tggacgtctg ggggcaaggg 360 
accacggtca ccgtctcctc a 381 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 694 
LENGTH: 127 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 694 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
20 25 30 
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Ile Ser Gly Tyr Asn Gly Lys Thr Asn Tyr Ala Gln Lys Leu 
50 55 60 
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ser Arg Asp Arg Leu Val Val Pro Pro Ala Leu Tyr Tyr Tyr Tyr Tyr 
100 105 110 
Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 695 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 695 
gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc 
atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg 
60 
120 
tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc taaccgggac 
tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc 
180 
240 
agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg 
tacacttttg gccaggggac caagctggag atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 696 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 696 
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 
1 5 10 15 
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 
US 2010/0166768 A1 
206 
JU1. 1, 2010 
-continued 
20 25 30 
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 
35 40 45 
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly 
85 90 95 
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 697 
LENGTH: 384 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 697 
caggtgcacc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct 
60 
120 
ccagggaagg ggctggagtg gatttcatac attagtaatg atggtggtac caaatactat 
gtggactctg tggagggccg attcatcatt tccagggaca acgccaagaa ctcattgtat 
180 
240 
ctacatatga acagcctcag agccgacgac acggccgtgt attactgtgc gagagatcag 
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctggggccaa 
300 
360 
gggaccacgg tcaccgtcgc ctca 384 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 698 
LENGTH: 128 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 698 
Gln Val His Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His 
20 25 30 
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
35 40 45 
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Val Asp Ser Val 
50 55 60 
Glu Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu His Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser 
100 105 110 
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ala Ser 
115 120 125 
US 2010/0166768 A1 
207 
JU1. 1, 2010 
-continued 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 699 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 699 
ggattcacct tcagtgacca ctac 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 700 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 700 
Gly Phe Thr Phe Ser Asp His Tyr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 701 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 701 
attagtaatg atggtggtac caaa 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 702 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 702 
Ile Ser Asn Asp Gly Gly Thr Lys 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 703 
LENGTH: 63 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 703 
gcgagagatc agggatatat tggctacgac tcgtattatt actattccta cggtatggac 60 
gtc 63 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 704 
LENGTH: 21 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 704 
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser 
1 5 10 15 
US 2010/0166768 A1 
208 
JU1. 1, 2010 
-continued 
Tyr Gly Met Asp Val 
20 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 705 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 705 
aaaattgtgt tgacgcagtc tccaggcacc ctgcctttgt ttccagggga aagagccacc 60 
ctctcctgta gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa 
tctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 
120 
180 
gacaggttca gtggcagtgg gtctgggacc gacttcactc tcaccatcag cggactggag 
cctgaagatt ttgaagtgta ttattgtcaa gtatatggta actcactcac tttcggcgga 
240 
300 
gggaccaagg tggagatcaa g 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 706 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 706 
Lys Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Pro Leu Phe Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys 
20 25 30 
Phe Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu 
35 40 45 
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
50 55 60 
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Glu 
65 70 75 80 
Pro Glu Asp Phe Glu Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu 
85 90 95 
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 707 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 707 
cagagtgtta acaacaaatt c 21 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 708 
LENGTH: 7 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
209 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 708 
Gln Ser Val Asn Asn Lys Phe 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 709 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 709 
ggtgcatcc 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 710 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 710 
Gly Ala Ser 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 711 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 711 
caagtatatg gtaactcact cact 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 712 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 712 
Gln Val Tyr Gly Asn Ser Leu Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 713 
LENGTH: 384 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 713 
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct 
60 
120 
ccagggaagg ggctggagtg gatttcatac attagtaatg atggtggtac caaatactat 
gtggactctg tggagggccg attcatcatt tccagggaca acgccaagaa ctcattgtat 
180 
240 
ctacatatga acagcctcag agccgacgac acggccgtgt attactgtgc gagagatcag 
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctggggccaa 
300 
360 
US 2010/0166768 A1 
210 
JU1. 1, 2010 
-continued 
gggaccacgg tcaccgtctc ctca 384 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 714 
LENGTH: 128 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 714 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His 
20 25 30 
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 
35 40 45 
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Val Asp Ser Val 
50 55 60 
Glu Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu His Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser 
100 105 110 
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 715 
LENGTH: 321 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 715 
gaaattgtgt tgacgcagtc tccaggcacc ctgcctttgt ttccagggga aagagccacc 
ctctcctgta gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa 
60 
120 
tctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 
gacaggttca gtggcagtgg gtctgggacc gacttcactc tcaccatcag cggactggag 
180 
240 
cctgaagatt ttgaagtgta ttattgtcaa gtatatggta actcactcac tttcggcgga 
gggaccaagg tggagatcaa a 
300 
321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 716 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 716 
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Pro Leu Phe Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys 
20 25 30 
Phe Leu Ala Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Arg Leu Leu 
US 2010/0166768 A1 
211 
JU1. 1, 2010 
-continued 
35 40 45 
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
50 55 60 
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Glu 
65 70 75 80 
Pro Glu Asp Phe Glu Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu 
85 90 95 
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 717 
LENGTH: 384 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 717 
caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc 
tcctgtgcag cctctggatt caccttcagt gaccactaca tgagctggat ccgccaggct 
60 
120 
ccagggaagg ggctggagtg ggtttcatac attagtaatg atggtggtac caaatactac 180 
gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat 240 
ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc gagagatcag 
ggatatattg gctacgactc gtattattac tattcctacg gtatggacgt ctgggggcaa 
300 
360 
gggaccacgg tcaccgtctc ctca 384 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 718 
LENGTH: 128 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 718 
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 
1 5 10 15 
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His 
20 25 30 
Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
35 40 45 
Ser Tyr Ile Ser Asn Asp Gly Gly Thr Lys Tyr Tyr Ala Asp Ser Val 
50 55 60 
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65 70 75 80 
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Asp Gln Gly Tyr Ile Gly Tyr Asp Ser Tyr Tyr Tyr Tyr Ser 
100 105 110 
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& SEQ ID NO 719 
&211& LENGTH: 321 
&212& TYPE: DNA 
US 2010/0166768 A1 
212 
JU1. 1, 2010 
-continued 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 719 
gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60 
ctctcctgca gggccagtca gagtgttaac aacaaattct tagcctggta ccagcagaaa 120 
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 180 
gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag 
cctgaagatt ttgcagtgta ttactgtcaa gtatatggta actcactcac tttcggcgga 
240 
300 
gggaccaagg tggagatcaa a 321 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 720 
LENGTH: 107 
TYPE: PRT 
ORGANISM: Artific 
FEATURE: 
OTHER INFORMATION 
ial Sequence 
Synthetic 
&400& SEQUENCE: 720 
Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1 5 10 15 
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Asn Lys 
20 25 30 
Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 
35 40 45 
Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 
50 55 60 
Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 
65 70 75 80 
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Val Tyr Gly Asn Ser Leu 
85 90 95 
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
100 105 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 721 
LENGTH: 378 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 721 
caaattctgc tggtgcaatc tggacctgag gtgaaggagc ctggggcctc agtgaaggtc 
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggtc 
60 
120 
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 180 
gcacatgaag tccagggcag agtcaccatg accacagaca catccacgac cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccatgt attactgtgc gagagggggt 300 
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg ccaagggacc 360 
acggtcaccg tctcctca 378 
&210& SEQ ID NO 722 
&211& LENGTH: 126 
US 2010/0166768 A1 
213 
JU1. 1, 2010 
-continued 
&212& TYPE: PRT 
&213& ORGANISM: Artificial Sequence 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 722 
Gln Ile Leu Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
20 25 30 
Ala Ile Ser Trp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala His Glu Val 
50 55 60 
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys 
85 90 95 
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly 
100 105 110 
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 723 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 723 
ggttacacct ttaccaacta cgct 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 724 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 724 
Gly Tyr Thr Phe Thr Asn Tyr Ala 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 725 
LENGTH: 24 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 725 
gtcagcgctt acaatggtca caca 24 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 726 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
US 2010/0166768 A1 
214 
JU1. 1, 2010 
-continued 
&400& SEQUENCE: 726 
Val Ser Ala Tyr Asn Gly His Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 727 
LENGTH: 57 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 727 
gcgagagggg gtgtagtcgt gccagttgct ccccacttct acaacggtat ggacgtc 57 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 728 
LENGTH: 19 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 728 
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly 
1 5 10 15 
Met Asp Val 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 729 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 729 
gatattgtga tgactcagtt tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg 
60 
120 
tacctaaaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtc tattactgca tgcaagctct tcaaactccg 
tggacgttcg gccaagggac caaggtggaa atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 730 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 730 
Asp Ile Val Met Thr Gln Phe Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile 
20 25 30 
Asn Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Lys Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro 
50 55 60 
US 2010/0166768 A1 
215 
JU1. 1, 2010 
-continued 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 731 
LENGTH: 33 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 731 
cagagcctcc tgcatattaa tgaatacaac tat 33 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 732 
LENGTH: 11 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 732 
Gln Ser Leu Leu His Ile Asn Glu Tyr Asn Tyr 
1 5 10 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 733 
LENGTH: 9 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 733 
ttgggtttt 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 734 
LENGTH: 3 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 734 
Leu Gly Phe 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 735 
LENGTH: 27 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 735 
atgcaagctc ttcaaactcc gtggacg 27 
&210& SEQ ID NO 736 
&211& LENGTH: 9 
&212& TYPE: PRT 
&213& ORGANISM: Artificial Sequence 
US 2010/0166768 A1 
216 
JU1. 1, 2010 
-continued 
&220& FEATURE: 
&223& OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 736 
Met Gln Ala Leu Gln Thr Pro Trp Thr 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 737 
LENGTH: 378 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 737 
caggttcagc tggtgcagtc tggacctgag gtgaaggagc ctggggcctc agtgaaggtc 60 
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggtc 
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 
120 
180 
gcacatgaag tccagggcag agtcaccatg accacagaca catccacgac cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccatgt attactgtgc gagagggggt 300 
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg ccaagggacc 360 
acggtcaccg tctcctca 378 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 738 
LENGTH: 126 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 738 
Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
20 25 30 
Ala Ile Ser Trp Val Arg Gln Val Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala His Glu Val 
50 55 60 
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys 
85 90 95 
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly 
100 105 110 
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 739 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 739 
US 2010/0166768 A1 
217 
JU1. 1, 2010 
-continued 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg 
60 
120 
tacctaaaga agccagggca gtctccacag ctcctgatct atttgggttt taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtc tattactgca tgcaagctct tcaaactccg 
tggacgttcg gccaagggac caaggtggaa atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 740 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 740 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile 
20 25 30 
Asn Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Lys Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Phe Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 741 
LENGTH: 378 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 741 
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60 
tcctgcaagg cttctggtta cacctttacc aactacgcta tcagctgggt gcgacaggcc 
cctggacaag ggcttgagtg gatgggatgg gtcagcgctt acaatggtca cacaaactat 
120 
180 
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagcctac 240 
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagggggt 300 
gtagtcgtgc cagttgctcc ccacttctac aacggtatgg acgtctgggg gcaagggacc 360 
acggtcaccg tctcctca 378 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 742 
LENGTH: 126 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 742 
US 2010/0166768 A1 
218 
JU1. 1, 2010 
-continued 
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 
1 5 10 15 
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 
20 25 30 
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
35 40 45 
Gly Trp Val Ser Ala Tyr Asn Gly His Thr Asn Tyr Ala Gln Lys Leu 
50 55 60 
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 
65 70 75 80 
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 
85 90 95 
Ala Arg Gly Gly Val Val Val Pro Val Ala Pro His Phe Tyr Asn Gly 
100 105 110 
Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
115 120 125 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 743 
LENGTH: 336 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 743 
gatattgtga tgactcagtc tccactctcc ctgcccgtca cccctggaga gccggcctcc 
atctcctgca ggtctagtca gagcctcctg catattaatg aatacaacta tttggattgg 
60 
120 
tacctgcaga agccagggca gtctccacag ctcctgatct atttgggttc taatcgggcc 
tccggggtcc ctgacaggtt cagtggcagt ggatcaggca cagattttac actgaaaatc 
180 
240 
agcagagtgg aggctgagga tgttggggtt tattactgca tgcaagctct tcaaactccg 
tggacgttcg gccaagggac caaggtggaa atcaaa 
300 
336 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 744 
LENGTH: 112 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 744 
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1 5 10 15 
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ile 
20 25 30 
Asn Glu Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
35 40 45 
Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro 
50 55 60 
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65 70 75 80 
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala 
85 90 95 
Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
US 2010/0166768 A1 
219 
JU1. 1, 2010 
-continued 
100 105 110 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
&220& 
&221& 
&222& 
&223& 
SEQ ID NO 745 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
FEATURE: 
NAME)KEY: VARIANT 
LOCATION: (1) . . . (8) 
OTHER INFORMATION: Xaa = Any amino acid 
&400& SEQUENCE: 745 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
&220& 
&221& 
&222& 
&223& 
SEQ ID NO 746 
LENGTH: 8 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
FEATURE: 
NAME)KEY: VARIANT 
LOCATION: (1) . . . (8) 
OTHER INFORMATION: Xaa — Any amino acid 
&400& SEQUENCE: 746 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
&220& 
&221& 
&222& 
&223& 
SEQ ID NO 747 
LENGTH: 20 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
FEATURE: 
NAME)KEY: VARIANT 
LOCATION: (1) . . . (20) 
OTHER INFORMATION: Xaa = Any amino acid 
&400& SEQUENCE: 747 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1 5 10 15 
Xaa Xaa Xaa Xaa 
20 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
&220& 
&221& 
&222& 
&223& 
SEQ ID NO 748 
LENGTH: 12 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
FEATURE: 
NAME)KEY: VARIANT 
LOCATION: (1) . . . (12) 
OTHER INFORMATION: Xaa = Any amino acid 
&400& SEQUENCE: 748 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1 5 10 
&210& SEQ ID NO 749 
&211& LENGTH: 3 
US 2010/0166768 A1 
220 
JU1. 1, 2010 
-continued 
&212& 
&213& 
&220& 
&223& 
&220& 
&221& 
&222& 
&223& 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
FEATURE: 
NAME)KEY: VARIANT 
LOCATION: (1) . . . (3) 
OTHER INFORMATION: Xaa = Any amino acid 
&400& SEQUENCE: 749 
Xaa Xaa Xaa 
1 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
&220& 
&221& 
&222& 
&223& 
SEQ ID NO 750 
LENGTH: 9 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
FEATURE: 
NAME)KEY: VARIANT 
LOCATION: (1) . . . (9) 
OTHER INFORMATION: Xaa = Any amino acid 
&400& SEQUENCE: 750 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1 5 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 751 
LENGTH: 330 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 751 
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 
1 5 10 15 
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
20 25 30 
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
35 40 45 
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
50 55 60 
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 
65 70 75 80 
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 
85 90 95 
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 
100 105 110 
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
115 120 125 
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
130 135 140 
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
145 150 155 160 
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
165 170 175 
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
180 185 190 
US 2010/0166768 A1 
221 
JU1. 1, 2010 
-continued 
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
195 200 205 
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
210 215 220 
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 
225 230 235 240 
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
245 250 255 
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 
260 265 270 
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 
275 280 285 
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 
290 295 300 
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 
305 310 315 320 
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
325 330 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 752 
LENGTH: 327 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 752 
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 
1 5 10 15 
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
20 25 30 
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
35 40 45 
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
50 55 60 
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 
65 70 75 80 
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 
85 90 95 
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro 
100 105 110 
Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 
115 120 125 
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 
130 135 140 
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 
145 150 155 160 
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 
165 170 175 
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 
180 185 190 
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 
195 200 205 
US 2010/0166768 A1 
222 
JU1. 1, 2010 
-continued 
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 
210 215 220 
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 
225 230 235 240 
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 
245 250 255 
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 
260 265 270 
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 
275 280 285 
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 
290 295 300 
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 
305 310 315 320 
Leu Ser Leu Ser Leu Gly Lys 
325 
&210& 
&211& 
&212& 
&213& 
&220& 
&223& 
SEQ ID NO 753 
LENGTH: 327 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic 
&400& SEQUENCE: 753 
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 
1 5 10 15 
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 
20 25 30 
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 
35 40 45 
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 
50 55 60 
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 
65 70 75 80 
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 
85 90 95 
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro 
100 105 110 
Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 
115 120 125 
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 
130 135 140 
Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 
145 150 155 160 
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 
165 170 175 
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 
180 185 190 
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 
195 200 205 
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 
210 215 220 
US 2010/0166768 A1 
223 
JU1. 1, 2010 
-continued 
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 
225 230 235 240 
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 
245 250 255 
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 
260 265 270 
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 
275 280 285 
Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 
290 295 300 
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 
305 310 315 320 
Leu Ser Leu Ser Leu Gly Lys 
325 
&210& SEQ ID NO 754 
&211& LENGTH: 2076 
&212& TYPE: DNA 
&213& ORGANISM: Homo sapiens 
&400& SEQUENCE: 754 
atgggcaccg tcagctccag gcggtcctgg tggccgctgc cactgctgct gctgctgctg 60 
ctgctcctgg gtcccgcggg cgcccgtgcg caggaggacg aggacggcga ctacgaggag 120 
ctggtgctag ccttgcgttc cgaggaggac ggcctggccg aagcacccga gcacggaacc 180 
acagccacct tccaccgctg cgccaaggat ccgtggaggt tgcctggcac ctacgtggtg 240 
gtgctgaagg aggagaccca cctctcgcag tcagagcgca ctgcccgccg cctgcaggcc 300 
caggctgccc gccggggata cctcaccaag atcctgcatg tcttccatgg ccttcttcct 360 
ggcttcctgg tgaagatgag tggcgacctg ctggagctgg ccttgaagtt gccccatgtc 420 
gactacatcg aggaggactc ctctgtcttt gcccagagca tcccgtggaa cctggagcgg 480 
attacccctc cacggtaccg ggcggatgaa taccagcccc ccgacggagg cagcctggtg 540 
gaggtgtatc tcctagacac cagcatacag agtgaccacc gggaaatcga gggcagggtc 600 
atggtcaccg acttcgagaa tgtgcccgag gaggacggga cccgcttcca cagacaggcc 660 
agcaagtgtg acagtcatgg cacccacctg gcaggggtgg tcagcggccg ggatgccggc 720 
gtggccaagg gtgccagcat gcgcagcctg cgcgtgctca actgccaagg gaagggcacg 780 
gttagcggca ccctcatagg cctggagttt attcggaaaa gccagctggt ccagcctgtg 840 
gggccactgg tggtgctgct gcccctggcg ggtgggtaca gccgcgtcct caacgccgcc 900 
tgccagcgcc tggcgagggc tggggtcgtg ctggtcaccg ctgccggcaa cttccgggac 960 
gatgcctgcc tctactcccc agcctcagct cccgaggtca tcacagttgg ggccaccaat 1020 
gcccaggacc agccggtgac cctggggact ttggggacca actttggccg ctgtgtggac 1080 
ctctttgccc caggggagga catcattggt gcctccagcg actgcagcac ctgctttgtg 1140 
tcacagagtg ggacatcaca ggctgctgcc cacgtggctg gcattgcagc catgatgctg 1200 
tctgccgagc cggagctcac cctggccgag ttgaggcaga gactgatcca cttctctgcc 1260 
aaagatgtca tcaatgaggc ctggttccct gaggaccagc gggtactgac ccccaacctg 1320 
gtggccgccc tgccccccag cacccatggg gcaggttggc agctgttttg caggactgtg 1380 
US 2010/0166768 A1 
224 
JU1. 1, 2010 
-continued 
tggtcagcac actcggggcc tacacggatg gccacagcca tcgcccgctg cgccccagat 1440 
gaggagctgc tgagctgctc cagtttctcc aggagtggga agcggcgggg cgagcgcatg 1500 
gaggcccaag ggggcaagct ggtctgccgg gcccacaacg cttttggggg tgagggtgtc 1560 
tacgccattg ccaggtgctg cctgctaccc caggccaact gcagcgtcca cacagctcca 1620 
ccagctgagg ccagcatggg gacccgtgtc cactgccacc aacagggcca cgtcctcaca 1680 
ggctgcagct cccactggga ggtggaggac cttggcaccc acaagccgcc tgtgctgagg 1740 
ccacgaggtc agcccaacca gtgcgtgggc cacagggagg ccagcatcca cgcttcctgc 1800 
tgccatgccc caggtctgga atgcaaagtc aaggagcatg gaatcccggc ccctcaggag 1860 
caggtgaccg tggcctgcga ggagggctgg accctgactg gctgcagtgc cctccctggg 1920 
acctcccacg tcctgggggc ctacgccgta gacaacacgt gtgtagtcag gagccgggac 1980 
gtcagcacta caggcagcac cagcgaagag gccgtgacag ccgttgccat ctgctgccgg 2040 
agccggcacc tggcgcaggc ctcccaggag ctccag 2076 
&210& SEQ ID NO 755 
&211& LENGTH: 692 
&212& TYPE: PRT 
&213& ORGANISM: Homo sapiens 
&400& SEQUENCE: 755 
Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp Pro Leu Pro Leu Leu 
1 5 10 15 
Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Gln Glu 
20 25 30 
Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu 
35 40 45 
Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr Ala Thr Phe 
50 55 60 
His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val 
65 70 75 80 
Val Leu Lys Glu Glu Thr His Leu Ser Gln Ser Glu Arg Thr Ala Arg 
85 90 95 
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu 
100 105 110 
His Val Phe His Gly Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly 
115 120 125 
Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr Ile Glu 
130 135 140 
Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg 
145 150 155 160 
Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Asp Gly 
165 170 175 
Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp 
180 185 190 
His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Asn Val 
195 200 205 
Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp 
210 215 220 
Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly 
225 230 235 240 
US 2010/0166768 A1 
225 
JU1. 1, 2010 
-continued 
Val P. la Lys Gly P. la Ser Met Prg Ser Leu Prg Val Leu P. sn Cys Gln 
245 250 255 
Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile P. rg 
260 265 270 
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro 
275 280 285 
Leu P. la Gly Gly Tyr Ser P. rg Val Leu P. sn P. la P. la Cys Gln P. rg Leu 
290 295 300 
P. la P. rg P. la Gly Val Val Leu Val Thr P. la P. la Gly P. sn Phe P. rg P. sp 
305 310 315 320 
P. sp P. la Cys Leu Tyr Ser Pro P. la Ser P. la Pro Glu Val Ile Thr Val 
325 330 335 
Gly P. la Thr P. sn P. la Gln P. sp Gln Pro Val Thr Leu Gly Thr Leu Gly 
340 345 350 
Thr P. sn Phe Gly P. rg Cys Val P. sp Leu Phe P. la Pro Gly Glu P. sp Ile 
355 360 365 
Ile Gly P. la Ser Ser P. sp Cys Ser Thr Cys Phe Val Ser Gln Ser Gly 
370 375 380 
Thr Ser Gln P. la P. la P. la His Val P. la Gly Ile P. la P. la Met Met Leu 
385 390 395 400 
Ser P. la Glu Pro Glu Leu Thr Leu P. la Glu Leu P. rg Gln P. rg Leu Ile 
405 410 415 
His Phe Ser P. la Lys P. sp Val Ile P. sn Glu P. la Trp Phe Pro Glu P. sp 
420 425 430 
Gln P. rg Val Leu Thr Pro P. sn Leu Val P. la P. la Leu Pro Pro Ser Thr 
435 440 445 
His Gly P. la Gly Trp Gln Leu Phe Cys P. rg Thr Val Trp Ser P. la His 
450 455 460 
Ser Gly Pro Thr P. rg Met P. la Thr P. la Ile P. la P. rg Cys P. la Pro P. sp 
465 470 475 480 
Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Prg Ser Gly Lys Prg Prg 
485 490 495 
Gly Glu P. rg Met Glu P. la Gln Gly Gly Lys Leu Val Cys P. rg P. la His 
500 505 510 
P. sn P. la Phe Gly Gly Glu Gly Val Tyr P. la Ile P. la P. rg Cys Cys Leu 
515 520 525 
Leu Pro Gln P. la P. sn Cys Ser Val His Thr P. la Pro Pro P. la Glu P. la 
530 535 540 
Ser Met Gly Thr P. rg Val His Cys His Gln Gln Gly His Val Leu Thr 
545 550 555 560 
Gly Cys Ser Ser His Trp Glu Val Glu P. sp Leu Gly Thr His Lys Pro 
565 570 575 
Pro Val Leu P. rg Pro P. rg Gly Gln Pro P. sn Gln Cys Val Gly His P. rg 
580 585 590 
Glu P. la Ser Ile His P. la Ser Cys Cys His P. la Pro Gly Leu Glu Cys 
595 600 605 
Lys Val Lys Glu His Gly Ile Pro P. la Pro Gln Glu Gln Val Thr Val 
610 615 620 
P. la Cys Glu Glu Gly Trp Thr Leu Thr Gly Cys Ser P. la Leu Pro Gly 
625 630 635 640 
US 2010/0166768 A1 
226 
JU1. 1, 2010 
-continued 
Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val 
645 650 655 
Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Glu Ala Val 
660 665 670 
Thr Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln Ala Ser 
675 680 685 
Gln Glu Leu Gln 
690 
&210& SEQ ID NO 756 
&211& LENGTH: 692 
&212& TYPE: PRT 
&213& ORGANISM: Macaca mulata 
&400& SEQUENCE: 756 
Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp Pro Leu Pro Leu Pro 
1 5 10 15 
Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Gln Glu 
20 25 30 
Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu 
35 40 45 
Glu Asp Gly Leu Ala Asp Ala Pro Glu His Gly Ala Thr Ala Thr Phe 
50 55 60 
His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val 
65 70 75 80 
Val Leu Lys Glu Glu Thr His Arg Ser Gln Ser Glu Arg Thr Ala Arg 
85 90 95 
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu 
100 105 110 
His Val Phe His His Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly 
115 120 125 
Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr Ile Glu 
130 135 140 
Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg 
145 150 155 160 
Ile Thr Pro Ala Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro Lys Gly 
165 170 175 
Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Asp 
180 185 190 
His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Ser Val 
195 200 205 
Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp 
210 215 220 
Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly 
225 230 235 240 
Val Ala Lys Gly Ala Gly Leu Arg Ser Leu Arg Val Leu Asn Cys Gln 
245 250 255 
Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg 
260 265 270 
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro 
275 280 285 
Leu Ala Gly Gly Tyr Ser Arg Val Phe Asn Ala Ala Cys Gln Arg Leu 
290 295 300 
US 2010/0166768 A1 
227 
JU1. 1, 2010 
-continued 
P. la P. rg P. la Gly Val Val Leu Val Thr P. la P. la Gly P. sn Phe P. rg P. sp 
305 310 315 320 
P. sp P. la Cys Leu Tyr Ser Pro P. la Ser P. la Pro Glu Val Ile Thr Val 
325 330 335 
Gly P. la Thr P. sn P. la Gln P. sp Gln Pro Val Thr Leu Gly Thr Leu Gly 
340 345 350 
Thr P. sn Phe Gly P. rg Cys Val P. sp Leu Phe P. la Pro Gly Glu P. sp Ile 
355 360 365 
Ile Gly P. la Ser Ser P. sp Cys Ser Thr Cys Phe Val Ser Prg Ser Gly 
370 375 380 
Thr Ser Gln P. la P. la P. la His Val P. la Gly Ile P. la P. la Met Met Leu 
385 390 395 400 
Ser P. la Glu Pro Glu Leu Thr Leu P. la Glu Leu P. rg Gln P. rg Leu Ile 
405 410 415 
His Phe Ser P. la Lys P. sp Val Ile P. sn Glu P. la Trp Phe Pro Glu P. sp 
420 425 430 
Gln P. rg Val Leu Thr Pro P. sn Leu Val P. la P. la Leu Pro Pro Ser Thr 
435 440 445 
His P. rg P. la Gly Trp Gln Leu Phe Cys P. rg Thr Val Trp Ser P. la His 
450 455 460 
Ser Gly Pro Thr P. rg Met P. la Thr P. la Val P. la P. rg Cys P. la Gln P. sp 
465 470 475 480 
Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Prg Ser Gly Lys Prg Prg 
485 490 495 
Gly Glu P. rg Ile Glu P. la Gln Gly Gly Lys P. rg Val Cys P. rg P. la His 
500 505 510 
P. sn P. la Phe Gly Gly Glu Gly Val Tyr P. la Ile P. la P. rg Cys Cys Leu 
515 520 525 
Leu Pro Gln Val P. sn Cys Ser Val His Thr P. la Pro Pro P. la Gly P. la 
530 535 540 
Ser Met Gly Thr P. rg Val His Cys His Gln Gln Gly His Val Leu Thr 
545 550 555 560 
Gly Cys Ser Ser His Trp Glu Val Glu P. sp Leu Gly Thr His Lys Pro 
565 570 575 
Pro Val Leu P. rg Pro P. rg Gly Gln Pro P. sn Gln Cys Val Gly His P. rg 
580 585 590 
Glu P. la Ser Ile His P. la Ser Cys Cys His P. la Pro Gly Leu Glu Cys 
595 600 605 
Lys Val Lys Glu His Gly Ile Pro P. la Pro Gln Glu Gln Val Ile Val 
610 615 620 
P. la Cys Glu P. sp Gly Trp Thr Leu Thr Gly Cys Ser Pro Leu Pro Gly 
625 630 635 640 
Thr Ser His Val Leu Gly P. la Tyr P. la Val P. sp P. sn Thr Cys Val Val 
645 650 655 
P. rg Ser Prg P. sp Val Ser Thr Thr Gly Ser Thr Ser Lys Glu P. la Val 
660 665 670 
P. la P. la Val P. la Ile Cys Cys Prg Ser Prg His Leu Val Gln P. la Ser 
675 680 685 
Gln Glu Leu Gln 
690 
US 2010/0166768 A1 
228 
JU1. 1, 2010 
-continued 
&210& SEQ ID NO 757 
&211& LENGTH: 694 
&212& TYPE: PRT 
&213& ORGANISM: Mus muscular 
&400& SEQUENCE: 757 
Met Gly Thr His Cys Ser Ala Trp Leu Arg Trp Pro Leu Leu Pro Leu 
1 5 10 15 
Leu Pro Pro Leu Leu Leu Leu Leu Leu Leu Leu Cys Pro Thr Gly Ala 
20 25 30 
Gly Ala Gln Asp Glu Asp Gly Asp Tyr Glu Glu Leu Met Leu Ala Leu 
35 40 45 
Pro Ser Gln Glu Asp Gly Leu Ala Asp Glu Ala Ala His Val Ala Thr 
50 55 60 
Ala Thr Phe Arg Arg Cys Ser Lys Glu Ala Trp Arg Leu Pro Gly Thr 
65 70 75 80 
Tyr Ile Val Val Leu Met Glu Glu Thr Gln Arg Leu Gln Ile Glu Gln 
85 90 95 
Thr Ala His Arg Leu Gln Thr Arg Ala Ala Arg Arg Gly Tyr Val Ile 
100 105 110 
Lys Val Leu His Ile Phe Tyr Asp Leu Phe Pro Gly Phe Leu Val Lys 
115 120 125 
Met Ser Ser Asp Leu Leu Gly Leu Ala Leu Lys Leu Pro His Val Glu 
130 135 140 
Tyr Ile Glu Glu Asp Ser Phe Val Phe Ala Gln Ser Ile Pro Trp Asn 
145 150 155 160 
Leu Glu Arg Ile Ile Pro Ala Trp His Gln Thr Glu Glu Asp Arg Ser 
165 170 175 
Pro Asp Gly Ser Ser Gln Val Glu Val Tyr Leu Leu Asp Thr Ser Ile 
180 185 190 
Gln Gly Ala His Arg Glu Ile Glu Gly Arg Val Thr Ile Thr Asp Phe 
195 200 205 
Asn Ser Val Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser 
210 215 220 
Lys Cys Asp Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg 
225 230 235 240 
Asp Ala Gly Val Ala Lys Gly Thr Ser Leu His Ser Leu Arg Val Leu 
245 250 255 
Asn Cys Gln Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu 
260 265 270 
Phe Ile Arg Lys Ser Gln Leu Ile Gln Pro Ser Gly Pro Leu Val Val 
275 280 285 
Leu Leu Pro Leu Ala Gly Gly Tyr Ser Arg Ile Leu Asn Ala Ala Cys 
290 295 300 
Arg His Leu Ala Arg Thr Gly Val Val Leu Val Ala Ala Ala Gly Asn 
305 310 315 320 
Phe Arg Asp Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val 
325 330 335 
Ile Thr Val Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly 
340 345 350 
Thr Leu Gly Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly 
355 360 365 
US 2010/0166768 A1 
229 
JU1. 1, 2010 
-continued 
Lys Asp Ile Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Met Ser 
370 375 380 
Gln Ser Gly Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Val Ala 
385 390 395 400 
Arg Met Leu Ser Arg Glu Pro Thr Leu Thr Leu Ala Glu Leu Arg Gln 
405 410 415 
Arg Leu Ile His Phe Ser Thr Lys Asp Val Ile Asn Met Ala Trp Phe 
420 425 430 
Pro Glu Asp Gln Gln Val Leu Thr Pro Asn Leu Val Ala Thr Leu Pro 
435 440 445 
Pro Ser Thr His Glu Thr Gly Gly Gln Leu Leu Cys Arg Thr Val Trp 
450 455 460 
Ser Ala His Ser Gly Pro Thr Arg Thr Ala Thr Ala Thr Ala Arg Cys 
465 470 475 480 
Ala Pro Glu Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly 
485 490 495 
Arg Arg Arg Gly Asp Trp Ile Glu Ala Ile Gly Gly Gln Gln Val Cys 
500 505 510 
Lys Ala Leu Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Val Ala Arg 
515 520 525 
Cys Cys Leu Val Pro Arg Ala Asn Cys Ser Ile His Asn Thr Pro Ala 
530 535 540 
Ala Arg Ala Gly Leu Glu Thr His Val His Cys His Gln Lys Asp His 
545 550 555 560 
Val Leu Thr Gly Cys Ser Phe His Trp Glu Val Glu Asp Leu Ser Val 
565 570 575 
Arg Arg Gln Pro Ala Leu Arg Ser Arg Arg Gln Pro Gly Gln Cys Val 
580 585 590 
Gly His Gln Ala Ala Ser Val Tyr Ala Ser Cys Cys His Ala Pro Gly 
595 600 605 
Leu Glu Cys Lys Ile Lys Glu His Gly Ile Ser Gly Pro Ser Glu Gln 
610 615 620 
Val Thr Val Ala Cys Glu Ala Gly Trp Thr Leu Thr Gly Cys Asn Val 
625 630 635 640 
Leu Pro Gly Ala Ser Leu Thr Leu Gly Ala Tyr Ser Val Asp Asn Leu 
645 650 655 
Cys Val Ala Arg Val His Asp Thr Ala Arg Ala Asp Arg Thr Ser Gly 
660 665 670 
Glu Ala Thr Val Ala Ala Ala Ile Cys Cys Arg Ser Arg Pro Ser Ala 
675 680 685 
Lys Ala Ser Trp Val Gln 
690 
&210& SEQ ID NO 758 
&211& LENGTH: 653 
&212& TYPE: PRT 
&213& ORGANISM: Homo sapiens 
&400& SEQUENCE: 758 
Glu Phe Arg Cys His Asp Gly Lys Cys Ile Ser Arg Gln Phe Val Cys 
1 5 10 15 
Asp Ser Asp Arg Asp Cys Leu Asp Gly Ser Asp Glu Ala Ser Cys Pro 
US 2010/0166768 A1 
230 
JU1. 1, 2010 
-continued 
20 25 30 
Val Leu Thr Cys Gly Pro P. la Ser Phe Gln Cys P. sn Ser Ser Thr Cys 
35 40 45 
Ile Pro Gln Leu Trp P. la Cys P. sp P. sn P. sp Pro P. sp Cys Glu P. sp Gly 
50 55 60 
Ser P. sp Glu Trp Pro Gln P. rg Cys P. rg Gly Leu Tyr Val Phe Gln Gly 
65 70 75 80 
P. sp Ser Ser Pro Cys Ser P. la Phe Glu Phe His Cys Leu Ser Gly Glu 
85 90 95 
Cys Ile His Ser Ser Trp Prg Cys Psp Gly Gly Pro P. sp Cys Lys Psp 
100 105 110 
Lys Ser P. sp Glu Glu P. sn Cys P. la Val P. la Thr Cys P. rg Pro P. sp Glu 
115 120 125 
Phe Gln Cys Ser P. sp Gly P. sn Cys Ile His Gly Ser Prg Gln Cys Psp 
130 135 140 
P. rg Glu Tyr P. sp Cys Lys P. sp Met Ser P. sp Glu Val Gly Cys Val P. sn 
145 150 155 160 
Val Thr Leu Cys Glu Gly Pro P. sn Lys Phe Lys Cys His Ser Gly Glu 
165 170 175 
Cys Ile Thr Leu P. sp Lys Val Cys P. sn Met P. la P. rg P. sp Cys P. rg P. sp 
180 185 190 
Trp Ser P. sp Glu Pro Ile Lys Glu Cys Gly Thr P. sn Glu Cys Leu P. sp 
195 200 205 
P. sn P. sn Gly Gly Cys Ser His Val Cys P. sn P. sp Leu Lys Ile Gly Tyr 
210 215 220 
Glu Cys Leu Cys Pro P. sp Gly Phe Gln Leu Val P. la Gln P. rg P. rg Cys 
225 230 235 240 
Glu P. sp Ile P. sp Glu Cys Gln P. sp Pro P. sp Thr Cys Ser Gln Leu Cys 
245 250 255 
Val P. sn Leu Glu Gly Gly Tyr Lys Cys Gln Cys Glu Glu Gly Phe Gln 
260 265 270 
Leu P. sp Pro His Thr Lys P. la Cys Lys P. la Val Gly Ser Ile P. la Tyr 
275 280 285 
Leu Phe Phe Thr P. sn P. rg His Glu Val P. rg Lys Met Thr Leu P. sp P. rg 
290 295 300 
Ser Glu Tyr Thr Ser Leu Ile Pro P. sn Leu Prg P. sn Val Val P. la Leu 
305 310 315 320 
P. sp Thr Glu Val P. la Ser P. sn P. rg Ile Tyr Trp Ser P. sp Leu Ser Gln 
325 330 335 
P. rg Met Ile Cys Ser Thr Gln Leu P. sp Prg P. la His Gly Val Ser Ser 
340 345 350 
Tyr P. sp Thr Val Ile Ser P. rg P. sp Ile Gln P. la Pro P. sp Gly Leu P. la 
355 360 365 
Val P. sp Trp Ile His Ser P. sn Ile Tyr Trp Thr P. sp Ser Val Leu Gly 
370 375 380 
Thr Val Ser Val P. la P. sp Thr Lys Gly Val Lys P. rg Lys Thr Leu Phe 
385 390 395 400 
P. rg Glu P. sn Gly Ser Lys Pro P. rg P. la Ile Val Val P. sp Pro Val His 
405 410 415 
Gly Phe Met Tyr Trp Thr P. sp Trp Gly Thr Pro P. la Lys Ile Lys Lys 
420 425 430 
US 2010/0166768 A1 
231 
JU1. 1, 2010 
-continued 
Gly Gly Leu Asn Gly Val Asp Ile Tyr Ser Leu Val Thr Glu Asn Ile 
435 440 445 
Gln Trp Pro Asn Gly Ile Thr Leu Asp Leu Leu Ser Gly Arg Leu Tyr 
450 455 460 
Trp Val Asp Ser Lys Leu His Ser Ile Ser Ser Ile Asp Val Asn Gly 
465 470 475 480 
Gly Asn Arg Lys Thr Ile Leu Glu Asp Glu Lys Arg Leu Ala His Pro 
485 490 495 
Phe Ser Leu Ala Val Phe Glu Asp Lys Val Phe Trp Thr Asp Ile Ile 
500 505 510 
Asn Glu Ala Ile Phe Ser Ala Asn Arg Leu Thr Gly Ser Asp Val Asn 
515 520 525 
Leu Leu Ala Glu Asn Leu Leu Ser Pro Glu Asp Met Val Leu Phe His 
530 535 540 
Asn Leu Thr Gln Pro Arg Gly Val Asn Trp Cys Glu Arg Thr Thr Leu 
545 550 555 560 
Ser Asn Gly Gly Cys Gln Tyr Leu Cys Leu Pro Ala Pro Gln Ile Asn 
565 570 575 
Pro His Ser Pro Lys Phe Thr Cys Ala Cys Pro Asp Gly Met Leu Leu 
580 585 590 
Ala Arg Asp Met Arg Ser Cys Leu Thr Glu Ala Glu Ala Ala Val Ala 
595 600 605 
Thr Gln Glu Thr Ser Thr Val Arg Leu Lys Val Ser Ser Thr Ala Val 
610 615 620 
Arg Thr Gln His Thr Thr Thr Arg Pro Val Pro Asp Thr Ser Arg Leu 
625 630 635 640 
Pro Gly Ala Thr Pro Gly Leu Thr Thr Val Glu Ile Val 
645 650 
&210& SEQ ID NO 759 
&211& LENGTH: 753 
&212& TYPE: PRT 
&213& ORGANISM: Homo sapiens 
&400& SEQUENCE: 759 
Met Glu Arg Arg Ala Trp Ser Leu Gln Cys Thr Ala Phe Val Leu Phe 
1 5 10 15 
Cys Ala Trp Cys Ala Leu Asn Ser Ala Lys Ala Lys Arg Gln Phe Val 
20 25 30 
Asn Glu Trp Ala Ala Glu Ile Pro Gly Gly Pro Glu Ala Ala Ser Ala 
35 40 45 
Ile Ala Glu Glu Leu Gly Tyr Asp Leu Leu Gly Gln Ile Gly Ser Leu 
50 55 60 
Glu Asn His Tyr Leu Phe Lys His Lys Asn His Pro Arg Arg Ser Arg 
65 70 75 80 
Arg Ser Ala Phe His Ile Thr Lys Arg Leu Ser Asp Asp Asp Arg Val 
85 90 95 
Ile Trp Ala Glu Gln Gln Tyr Glu Lys Glu Arg Ser Lys Arg Ser Ala 
100 105 110 
Leu Arg Asp Ser Ala Leu Asn Leu Phe Asn Asp Pro Met Trp Asn Gln 
115 120 125 
Gln Trp Tyr Leu Gln Asp Thr Arg Met Thr Ala Ala Leu Pro Lys Leu 
US 2010/0166768 A1 
232 
JU1. 1, 2010 
-continued 
130 135 140 
P. sp Leu His Val I le Pro Val Trp Gln Lys Gly I le Thr Gly Lys Gly 
145 150 155 160 
Val Val Ile Thr Val Leu P. sp P. sp Gly Leu Glu Trp P. sn His Thr P. sp 
165 170 175 
Ile Tyr P. la P. sn Tyr P. sp Pro Glu P. la Ser Tyr P. sp Phe P. sn P. sp P. sn 
180 185 190 
P. sp His P. sp Pro Phe Pro P. rg Tyr P. sp Pro Thr P. sn Glu P. sn Lys His 
195 200 205 
Gly Thr P. rg Cys P. la Gly Glu Ile P. la Met Gln P. la P. sn P. sn His Lys 
210 215 220 
Cys Gly Val Gly Val P. la Tyr P. sn Ser Lys Val Gly Gly Ile P. rg Met 
225 230 235 240 
Leu P. sp Gly Ile Val Thr P. sp P. la Ile Glu P. la Ser Ser Ile Gly Phe 
245 250 255 
P. sn Pro Gly His Val P. sp Ile Tyr Ser P. la Ser Trp Gly Pro P. sn P. sp 
260 265 270 
P. sp Gly Lys Thr Val Glu Gly Pro Gly P. rg Leu P. la Gln Lys P. la Phe 
275 280 285 
Glu Tyr Gly Val Lys Gln Gly P. rg Gln Gly Lys Gly Ser Ile Phe Val 
290 295 300 
Trp P. la Ser Gly P. sn Gly Gly P. rg Gln Gly P. sp P. sn Cys P. sp Cys P. sp 
305 310 315 320 
Gly Tyr Thr P. sp Ser Ile Tyr Thr Ile Ser Ile Ser Ser P. la Ser Gln 
325 330 335 
Gln Gly Leu Ser Pro Trp Tyr P. la Glu Lys Cys Ser Ser Thr Leu P. la 
340 345 350 
Thr Ser Tyr Ser Ser Gly P. sp Tyr Thr P. sp Gln P. rg Ile Thr Ser P. la 
355 360 365 
P. sp Leu His P. sn P. sp Cys Thr Glu Thr His Thr Gly Thr Ser P. la Ser 
370 375 380 
P. la Pro Leu P. la P. la Gly Ile Phe P. la Leu P. la Leu Glu P. la P. sn Pro 
385 390 395 400 
P. sn Leu Thr Trp P. rg P. sp Met Gln His Leu Val Val Trp Thr Ser Glu 
405 410 415 
Tyr P. sp Pro Leu P. la P. sn P. sn Pro Gly Trp Lys Lys P. sn Gly P. la Gly 
420 425 430 
Leu Met Val P. sn Ser P. rg Phe Gly Phe Gly Leu Leu P. sn P. la Lys P. la 
435 440 445 
Leu Val P. sp Leu P. la P. sp Pro P. rg Thr Trp P. rg Ser Val Pro Glu Lys 
450 455 460 
Lys Glu Cys Val Val Lys P. sp P. sn P. sp Phe Glu Pro P. rg P. la Leu Lys 
465 470 475 480 
P. la P. sn Gly Glu Val Ile Ile Glu Ile Pro Thr P. rg P. la Cys Glu Gly 
485 490 495 
Gln Glu P. sn P. la Ile Lys Ser Leu Glu His Val Gln Phe Glu P. la Thr 
500 505 510 
Ile Glu Tyr Ser P. rg P. rg Gly P. sp Leu His Val Thr Leu Thr Ser P. la 
515 520 525 
P. la Gly Thr Ser Thr Val Leu Leu P. la Glu P. rg Glu P. rg P. sp Thr Ser 
530 535 540 
US 2010/0166768 A1 
233 
JU1. 1, 2010 
-continued 
Pro Asn Gly Phe Lys Asn Trp Asp Phe Met Ser Val His Thr Trp Gly 
545 550 555 560 
Glu Asn Pro Ile Gly Thr Trp Thr Leu Arg Ile Thr Asp Met Ser Gly 
565 570 575 
Arg Ile Gln Asn Glu Gly Arg Ile Val Asn Trp Lys Leu Ile Leu His 
580 585 590 
Gly Thr Ser Ser Gln Pro Glu His Met Lys Gln Pro Arg Val Tyr Thr 
595 600 605 
Ser Tyr Asn Thr Val Gln Asn Asp Arg Arg Gly Val Glu Lys Met Val 
610 615 620 
Asp Pro Gly Glu Glu Gln Pro Thr Gln Glu Asn Pro Lys Glu Asn Thr 
625 630 635 640 
Leu Val Ser Lys Ser Pro Ser Ser Ser Ser Val Gly Gly Arg Arg Asp 
645 650 655 
Glu Leu Glu Glu Gly Ala Pro Ser Gln Ala Met Leu Arg Leu Leu Gln 
660 665 670 
Ser Ala Phe Ser Lys Asn Ser Pro Pro Lys Gln Ser Pro Lys Lys Ser 
675 680 685 
Pro Ser Ala Lys Leu Asn Ile Pro Tyr Glu Asn Phe Tyr Glu Ala Leu 
690 695 700 
Glu Lys Leu Asn Lys Pro Ser Gln Leu Lys Asp Ser Glu Asp Ser Leu 
705 710 715 720 
Tyr Asn Asp Tyr Val Asp Val Phe Tyr Asn Thr Lys Pro Tyr Lys His 
725 730 735 
Arg Asp Asp Arg Leu Leu Gln Ala Leu Val Asp Ile Leu Asn Glu Glu 
740 745 750 
Asn 
&210& SEQ ID NO 760 
&211& LENGTH: 785 
&212& TYPE: PRT 
&213& ORGANISM: Homo sapiens 
&400& SEQUENCE: 760 
Met Pro Lys Gly Arg Gln Lys Val Pro His Leu Asp Ala Pro Leu Gly 
1 5 10 15 
Leu Pro Thr Cys Leu Trp Leu Glu Leu Ala Gly Leu Phe Leu Leu Val 
20 25 30 
Pro Trp Val Met Gly Leu Ala Gly Thr Gly Gly Pro Asp Gly Gln Gly 
35 40 45 
Thr Gly Gly Pro Ser Trp Ala Val His Leu Glu Ser Leu Glu Gly Asp 
50 55 60 
Gly Glu Glu Glu Thr Leu Glu Gln Gln Ala Asp Ala Leu Ala Gln Ala 
65 70 75 80 
Ala Gly Leu Val Asn Ala Gly Arg Ile Gly Glu Leu Gln Gly His Tyr 
85 90 95 
Leu Phe Val Gln Pro Ala Gly His Arg Pro Ala Leu Glu Val Glu Ala 
100 105 110 
Ile Arg Gln Gln Val Glu Ala Val Leu Ala Gly His Glu Ala Val Arg 
115 120 125 
Trp His Ser Glu Gln Arg Leu Leu Arg Arg Ala Lys Arg Ser Val His 
130 135 140 
US 2010/0166768 A1 
234 
JU1. 1, 2010 
-continued 
Phe P. sn P. sp Pro Lys Tyr Pro Gln Gln Trp His Leu P. sn P. sn P. rg P. rg 
145 150 155 160 
Ser Pro Gly P. rg P. sp Ile P. sn Val Thr Gly Val Trp Glu P. rg P. sn Val 
165 170 175 
Thr Gly P. rg Gly Val Thr Val Val Val Val P. sp P. sp Gly Val Glu His 
180 185 190 
Thr Ile Gln P. sp Ile P. la Pro P. sn Tyr Ser Pro Glu Gly Ser Tyr P. sp 
195 200 205 
Leu P. sn Ser P. sn P. sp Pro P. sp Pro Met Pro His Pro P. sp Val Glu P. sn 
210 215 220 
Gly P. sn His His Gly Thr P. rg Cys P. la Gly Glu Ile P. la P. la Val Pro 
225 230 235 240 
P. sn P. sn Ser Phe Cys P. la Val Gly Val P. la Tyr Gly Ser Prg Ile P. la 
245 250 255 
Gly Ile P. rg Val Leu P. sp Gly Pro Leu Thr P. sp Ser Met Glu P. la Val 
260 265 270 
P. la Phe P. sn Lys His Tyr Gln Ile P. sn P. sp Ile Tyr Ser Cys Ser Trp 
275 280 285 
Gly Pro P. sp P. sp P. sp Gly Lys Thr Val P. sp Gly Pro His Gln Leu Gly 
290 295 300 
Lys P. la P. la Leu Gln His Gly Val Ile P. la Gly P. rg Gln Gly Phe Gly 
305 310 315 320 
Ser Ile Phe Val Val P. la Ser Gly P. sn Gly Gly Gln His P. sn P. sp P. sn 
325 330 335 
Cys P. sn Tyr P. sp Gly Tyr P. la P. sn Ser Ile Tyr Thr Val Thr Ile Gly 
340 345 350 
P. la Val P. sp Glu Glu Gly P. rg Met Pro Phe Tyr P. la Glu Glu Cys P. la 
355 360 365 
Ser Met Leu P. la Val Thr Phe Ser Gly Gly P. sp Lys Met Leu P. rg Ser 
370 375 380 
Ile Val Thr Thr P. sp Trp P. sp Leu Gln Lys Gly Thr Gly Cys Thr Glu 
385 390 395 400 
Gly His Thr Gly Thr Ser P. la P. la P. la Pro Leu P. la P. la Gly Met Ile 
405 410 415 
P. la Leu Met Leu Gln Val P. rg Pro Cys Leu Thr Trp P. rg P. sp Val Gln 
420 425 430 
His Ile Ile Val Phe Thr P. la Thr P. rg Tyr Glu P. sp P. rg P. rg P. la Glu 
435 440 445 
Trp Val Thr P. sn Glu P. la Gly Phe Ser His Ser His Gln His Gly Phe 
450 455 460 
Gly Leu Leu P. sn P. la Trp P. rg Leu Val P. sn P. la P. la Lys Ile Trp Thr 
465 470 475 480 
Ser Val Pro Tyr Leu P. la Ser Tyr Val Ser Pro Val Leu Lys Glu P. sn 
485 490 495 
Lys P. la Ile Pro Gln Ser Pro Prg Ser Leu Glu Val Leu Trp P. sn Val 
500 505 510 
Ser P. rg Met P. sp Leu Glu Met Ser Gly Leu Lys Thr Leu Glu His Val 
515 520 525 
P. la Val Thr Val Ser Ile Thr His Pro Prg Prg Gly Ser Leu Glu Leu 
530 535 540 
US 2010/0166768 A1 
235 
JU1. 1, 2010 
-continued 
Lys Leu Phe Cys Pro Ser Gly Met Met Ser Leu Ile Gly Ala Pro Arg 
545 550 555 560 
Ser Met Asp Ser Asp Pro Asn Gly Phe Asn Asp Trp Thr Phe Ser Thr 
565 570 575 
Val Arg Cys Trp Gly Glu Arg Ala Arg Gly Thr Tyr Arg Leu Val Ile 
580 585 590 
Arg Asp Val Gly Asp Glu Ser Phe Gln Val Gly Ile Leu Arg Gln Trp 
595 600 605 
Gln Leu Thr Leu Tyr Gly Ser Val Trp Ser Ala Val Asp Ile Arg Asp 
610 615 620 
Arg Gln Arg Leu Leu Glu Ser Ala Met Ser Gly Lys Tyr Leu His Asp 
625 630 635 640 
Asp Phe Ala Leu Pro Cys Pro Pro Gly Leu Lys Ile Pro Glu Glu Asp 
645 650 655 
Gly Tyr Thr Ile Thr Pro Asn Thr Leu Lys Thr Leu Val Leu Val Gly 
660 665 670 
Cys Phe Thr Val Phe Trp Thr Val Tyr Tyr Met Leu Glu Val Tyr Leu 
675 680 685 
Ser Gln Arg Asn Val Ala Ser Asn Gln Val Cys Arg Ser Gly Pro Cys 
690 695 700 
His Trp Pro His Arg Ser Arg Lys Ala Lys Glu Glu Gly Thr Glu Leu 
705 710 715 720 
Glu Ser Val Pro Leu Cys Ser Ser Lys Asp Pro Asp Glu Val Glu Thr 
725 730 735 
Glu Ser Arg Gly Pro Pro Thr Thr Ser Asp Leu Leu Ala Pro Asp Leu 
740 745 750 
Leu Glu Gln Gly Asp Trp Ser Leu Ser Gln Asn Lys Ser Ala Leu Asp 
755 760 765 
Cys Pro His Gln His Leu Asp Val Pro His Gly Lys Glu Glu Gln Ile 
770 775 780 
Cys 
785 
&210& SEQ ID NO 761 
&211& LENGTH: 692 
&212& TYPE: PRT 
&213& ORGANISM: Macaca fascicularis 
&400& SEQUENCE: 761 
Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp Pro Leu Pro Leu Pro 
1 5 10 15 
Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Gln Glu 
20 25 30 
Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg Ser Glu 
35 40 45 
Glu Asp Gly Leu Ala Asp Ala Pro Glu His Gly Ala Thr Ala Thr Phe 
50 55 60 
His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val 
65 70 75 80 
Val Leu Lys Glu Glu Thr His Arg Ser Gln Ser Glu Arg Thr Ala Arg 
85 90 95 
Arg Leu Gln Ala Gln Ala Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu 
100 105 110 
US 2010/0166768 A1 
236 
JU1. 1, 2010 
-continued 
His Val Phe His His Leu Leu Pro Gly Phe Leu Val Lys Met Ser Gly 
115 120 125 
P. sp Leu Leu Glu Leu P. la Leu Lys Leu Pro His Val P. sp Tyr Ile Glu 
130 135 140 
Glu P. sp Ser Ser Val Phe P. la Gln Ser Ile Pro Trp P. sn Leu Glu Prg 
145 150 155 160 
Ile Thr Pro P. la P. rg Tyr P. rg P. la P. sp Glu Tyr Gln Pro Pro Lys Gly 
165 170 175 
Gly Ser Leu Val Glu Val Tyr Leu Leu P. sp Thr Ser Ile Gln Ser P. sp 
180 185 190 
His P. rg Glu Ile Glu Gly P. rg Val Met Val Thr P. sp Phe Glu Ser Val 
195 200 205 
Pro Glu Glu P. sp Gly Thr P. rg Phe His P. rg Gln P. la Ser Lys Cys P. sp 
210 215 220 
Ser His Gly Thr His Leu P. la Gly Val Val Ser Gly P. rg P. sp P. la Gly 
225 230 235 240 
Val P. la Lys Gly P. la Gly Leu P. rg Ser Leu P. rg Val Leu P. sn Cys Gln 
245 250 255 
Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile P. rg 
260 265 270 
Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu Leu Pro 
275 280 285 
Leu P. la Gly Gly Tyr Ser P. rg Val Phe P. sn P. la P. la Cys Gln P. rg Leu 
290 295 300 
P. la P. rg P. la Gly Val Val Leu Val Thr P. la P. la Gly P. sn Phe P. rg P. sp 
305 310 315 320 
P. sp P. la Cys Leu Tyr Ser Pro P. la Ser P. la Pro Glu Val Ile Thr Val 
325 330 335 
Gly P. la Thr P. sn P. la Gln P. sp Gln Pro Val Thr Leu Gly Thr Leu Gly 
340 345 350 
Thr P. sn Phe Gly P. rg Cys Val P. sp Leu Phe P. la Pro Gly Glu P. sp Ile 
355 360 365 
Ile Gly P. la Ser Ser P. sp Cys Ser Thr Cys Phe Val Ser Prg Ser Gly 
370 375 380 
Thr Ser Gln P. la P. la P. la His Val P. la Gly Ile P. la P. la Met Met Leu 
385 390 395 400 
Ser P. la Glu Pro Glu Leu Thr Leu P. la Glu Leu P. rg Gln P. rg Leu Ile 
405 410 415 
His Phe Ser P. la Lys P. sp Val Ile P. sn Glu P. la Trp Phe Pro Glu P. sp 
420 425 430 
Gln P. rg Val Leu Thr Pro P. sn Leu Val P. la P. la Leu Pro Pro Ser Thr 
435 440 445 
His P. rg P. la Gly Trp Gln Leu Phe Cys P. rg Thr Val Trp Ser P. la His 
450 455 460 
Ser Gly Pro Thr P. rg Met P. la Thr P. la Val P. la P. rg Cys P. la Gln P. sp 
465 470 475 480 
Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Prg Ser Gly Lys Prg Prg 
485 490 495 
Gly Glu P. rg Ile Glu P. la Gln Gly Gly Lys P. rg Val Cys P. rg P. la His 
500 505 510 
US 2010/0166768 A1 
237 
JU1. 1, 2010 
-continued 
Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu 
515 520 525 
Leu Pro Gln Val Asn Cys Ser Val His Thr Ala Pro Pro Ala Gly Ala 
530 535 540 
Ser Met Gly Thr Arg Val His Cys His Gln Gln Gly His Val Leu Thr 
545 550 555 560 
Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His Lys Pro 
565 570 575 
Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly His Arg 
580 585 590 
Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu Glu Cys 
595 600 605 
Lys Val Lys Glu His Gly Ile Pro Ala Pro Gln Glu Gln Val Ile Val 
610 615 620 
Ala Cys Glu Asp Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu Pro Gly 
625 630 635 640 
Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val 
645 650 655 
Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Glu Ala Val 
660 665 670 
Ala Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Val Gln Ala Ser 
675 680 685 
Gln Glu Leu Gln 
690 
&210& SEQ ID NO 762 
&211& LENGTH: 698 
&212& TYPE: PRT 
&213& ORGANISM: Mesocricetus auratus 
&400& SEQUENCE: 762 
Met Gly Thr Ser Cys Ser Ala Arg Pro Arg Trp Leu Leu Ser Pro Leu 
1 5 10 15 
Leu Leu Leu Leu Leu Leu Leu Arg Tyr Met Gly Ala Ser Ala Gln Asp 
20 25 30 
Glu Asp Ala Glu Tyr Glu Glu Leu Met Leu Thr Leu Gln Ser Gln Asp 
35 40 45 
Asp Gly Leu Ala Asp Glu Thr Asp Glu Ala Pro Gln Gly Ala Thr Ala 
50 55 60 
Ala Phe His Arg Cys Pro Glu Glu Ala Trp Arg Val Pro Gly Thr Tyr 
65 70 75 80 
Ile Val Met Leu Ala Glu Glu Ala Gln Trp Val His Ile Glu Gln Thr 
85 90 95 
Met His Arg Leu Gln Thr Gln Ala Ala Arg Arg Gly Tyr Val Ile Lys 
100 105 110 
Ile Gln His Ile Phe Tyr Asp Phe Leu Pro Ala Phe Val Val Lys Met 
115 120 125 
Ser Ser Asp Leu Leu Asp Leu Ala Leu Lys Leu Pro His Val Lys Tyr 
130 135 140 
Ile Glu Glu Asp Ser Leu Val Phe Ala Gln Ser Ile Pro Trp Asn Leu 
145 150 155 160 
Asp Arg Ile Ile Pro Ala Gly Arg Gln Ala Gln Glu Tyr Ser Ser Ser 
165 170 175 
US 2010/0166768 A1 
238 
JU1. 1, 2010 
-continued 
P. rg Lys Val Pro Ser Gly Ser Gly Gln Val Glu Val Tyr Leu Leu P. sp 
180 185 190 
Thr Ser Ile Gln Ser P. sp His Prg Glu Ile Glu Gly P. rg Val Thr Val 
195 200 205 
Thr P. sp Phe P. sn Ser Val Pro Glu Glu P. sp Gly Thr P. rg Phe His P. rg 
210 215 220 
Gln P. la Ser Lys Cys P. sp Ser His Gly Thr His Leu P. la Gly Val Val 
225 230 235 240 
Ser Gly P. rg P. sp P. la Gly Val P. la Lys Gly Thr Ile Leu His Gly Leu 
245 250 255 
P. rg Val Leu P. sn Cys Gln Gly Lys Gly Ile Val Ser Gly Ile Leu Thr 
260 265 270 
Gly Leu Glu Phe Ile Trp Lys Ser Gln Leu Met Gln Pro Ser Gly Pro 
275 280 285 
Gln Val Val Leu Leu Pro Leu P. la Gly Prg Tyr Ser P. rg Val Leu P. sn 
290 295 300 
Thr P. la Cys Gln His Leu P. la Prg Thr Gly Val Val Leu Val P. la P. la 
305 310 315 320 
P. la Gly P. sn Phe P. rg P. sp P. sp P. la Cys Leu Tyr Ser Pro P. la Ser P. la 
325 330 335 
Pro Glu Val Ile Thr Val Gly P. la Thr P. sp Val Gln P. sp Gln Pro Val 
340 345 350 
Thr Leu Gly Thr Leu Gly Thr P. sn Phe Gly P. rg Cys Val P. sp Leu Phe 
355 360 365 
P. la Pro Gly Lys P. sp Ile Ile Gly P. la Ser Ser P. sp Cys Ser P. la Cys 
370 375 380 
Phe Met Ser Gln Ser Gly Thr Ser Gln P. la P. la P. la His Val P. la Gly 
385 390 395 400 
Ile Val P. la Met Met Leu Thr Leu Glu Pro Glu Leu Thr Leu Thr Glu 
405 410 415 
Leu P. rg Gln P. rg Leu Ile His Phe Ser Thr Lys P. sp P. la Ile P. sn Met 
420 425 430 
P. la Trp Phe Pro Glu P. sp Gln P. rg Val Leu Thr Pro P. sn Leu Val P. la 
435 440 445 
Thr Leu Pro Pro Ser Thr His Gly Thr Gly Gly Gln Leu Leu Cys P. rg 
450 455 460 
Thr Val Trp Ser P. la His Ser Gly Pro Thr P. rg P. la P. la Thr P. la Thr 
465 470 475 480 
P. la Prg Cys P. la Pro Gly Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser 
485 490 495 
P. rg Ser Gly P. rg P. rg P. rg Gly P. sp P. rg Ile Glu P. la P. la Gly Thr Gln 
500 505 510 
Gln Val Cys Lys P. la Leu P. sn P. la Phe Gly Gly Glu Gly Val Tyr P. la 
515 520 525 
Val P. la Prg Cys Cys Leu Leu Pro Prg P. la P. sn Cys Ser Ile His Thr 
530 535 540 
Thr Pro P. la P. la P. rg Thr Ser Leu Glu Thr His P. la His Cys His Gln 
545 550 555 560 
Lys P. sp His Val Leu Thr Gly Cys Ser Leu His Trp Glu Val Glu Gly 
565 570 575 
US 2010/0166768 A1 
239 
JU1. 1, 2010 
-continued 
Ile Gly Val Gln Pro Leu Ala Val Leu Arg Ser Arg His Gln Pro Gly 
580 585 590 
Gln Cys Thr Gly His Arg Glu Ala Ser Val His Ala Ser Cys Cys His 
595 600 605 
Ala Pro Gly Leu Glu Cys Lys Ile Lys Glu His Gly Ile Ser Gly Pro 
610 615 620 
Ala Glu Gln Val Thr Val Ala Cys Glu Ala Gly Trp Thr Leu Thr Gly 
625 630 635 640 
Cys Asn Val Leu Pro Gly Ala Phe Ile Thr Leu Gly Ala Tyr Ala Val 
645 650 655 
Asp Asn Thr Cys Val Ala Arg Ser Arg Val Thr Asp Thr Ala Gly Arg 
660 665 670 
Thr Gly Glu Glu Ala Thr Val Ala Ala Ala Ile Cys Cys Arg Asn Arg 
675 680 685 
Pro Ser Ala Lys Ala Ser Trp Val His Gln 
690 695 
&210& SEQ ID NO 763 
&211& LENGTH: 691 
&212& TYPE: PRT 
&213& ORGANISM: Rattus norvegicus 
&400& SEQUENCE: 763 
Met Gly Ile Arg Cys Ser Thr Trp Leu Arg Trp Pro Leu Ser Pro Gln 
1 5 10 15 
Leu Leu Leu Leu Leu Leu Leu Cys Pro Thr Gly Ser Arg Ala Gln Asp 
20 25 30 
Glu Asp Gly Asp Tyr Glu Glu Leu Met Leu Ala Leu Pro Ser Gln Glu 
35 40 45 
Asp Ser Leu Val Asp Glu Ala Ser His Val Ala Thr Ala Thr Phe Arg 
50 55 60 
Arg Cys Ser Lys Glu Ala Trp Arg Leu Pro Gly Thr Tyr Val Val Val 
65 70 75 80 
Leu Met Glu Glu Thr Gln Arg Leu Gln Val Glu Gln Thr Ala His Arg 
85 90 95 
Leu Gln Thr Trp Ala Ala Arg Arg Gly Tyr Val Ile Lys Val Leu His 
100 105 110 
Val Phe Tyr Asp Leu Phe Pro Gly Phe Leu Val Lys Met Ser Ser Asp 
115 120 125 
Leu Leu Gly Leu Ala Leu Lys Leu Pro His Val Glu Tyr Ile Glu Glu 
130 135 140 
Asp Ser Leu Val Phe Ala Gln Ser Ile Pro Trp Asn Leu Glu Arg Ile 
145 150 155 160 
Ile Pro Ala Trp Gln Gln Thr Glu Glu Asp Ser Ser Pro Asp Gly Ser 
165 170 175 
Ser Gln Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gln Ser Gly His 
180 185 190 
Arg Glu Ile Glu Gly Arg Val Thr Ile Thr Asp Phe Asn Ser Val Pro 
195 200 205 
Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys Cys Asp Ser 
210 215 220 
His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp Ala Gly Val 
225 230 235 240 
US 2010/0166768 A1 
240 
JU1. 1, 2010 
-continued 
P. la Lys Gly Thr Ser Leu His Ser Leu P. rg Val Leu P. sn Cys Gln Gly 
245 250 255 
Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile P. rg Lys 
260 265 270 
Ser Gln Leu Ile Gln Pro Ser Gly Pro Leu Val Val Leu Leu Pro Leu 
275 280 285 
P. la Gly Gly Tyr Ser P. rg Ile Leu P. sn Thr P. la Cys Gln P. rg Leu P. la 
290 295 300 
P. rg Thr Gly Val Val Leu Val P. la P. la P. la Gly P. sn Phe P. rg P. sp P. sp 
305 310 315 320 
P. la Cys Leu Tyr Ser Pro P. la Ser P. la Pro Glu Val Ile Thr Val Gly 
325 330 335 
P. la Thr P. sn P. la Gln P. sp Gln Pro Val Thr Leu Gly Thr Leu Gly Thr 
340 345 350 
P. sn Phe Gly P. rg Cys Val P. sp Leu Phe P. la Pro Gly Lys P. sp Ile Ile 
355 360 365 
Gly P. la Ser Ser P. sp Cys Ser Thr Cys Tyr Met Ser Gln Ser Gly Thr 
370 375 380 
Ser Gln P. la P. la P. la His Val P. la Gly Ile Val P. la Met Met Leu P. sn 
385 390 395 400 
P. rg P. sp Pro P. la Leu Thr Leu P. la Glu Leu P. rg Gln P. rg Leu Ile Leu 
405 410 415 
Phe Ser Thr Lys P. sp Val Ile P. sn Met P. la Trp Phe Pro Glu P. sp Gln 
420 425 430 
P. rg Val Leu Thr Pro P. sn P. rg Val P. la Thr Leu Pro Pro Ser Thr Gln 
435 440 445 
Glu Thr Gly Gly Gln Leu Leu Cys P. rg Thr Val Trp Ser P. la His Ser 
450 455 460 
Gly Pro Thr P. rg Thr P. la Thr P. la Thr P. la P. rg Cys P. la Pro Glu Glu 
465 470 475 480 
Glu Leu Leu Ser Cys Ser Ser Phe Ser P. rg Ser Gly P. rg P. rg P. rg Gly 
485 490 495 
P. sp P. rg Ile Glu P. la Ile Gly Gly Gln Gln Val Cys Lys P. la Leu P. sn 
500 505 510 
P. la Phe Gly Gly Glu Gly Val Tyr P. la Val P. la P. rg Cys Cys Leu Leu 
515 520 525 
Pro P. rg Val P. sn Cys Ser Ile His P. sn Thr Pro P. la P. la P. rg P. la Gly 
530 535 540 
Pro Gln Thr Pro Val His Cys His Gln Lys P. sp His Val Leu Thr Gly 
545 550 555 560 
Cys Ser Phe His Trp Glu Val Glu P. sn Leu P. rg P. la Gln Gln Gln Pro 
565 570 575 
Leu Leu P. rg Ser P. rg His Gln Pro Gly Gln Cys Val Gly His Gln Glu 
580 585 590 
P. la Ser Val His P. la Ser Cys Cys His P. la Pro Gly Leu Glu Cys Lys 
595 600 605 
Ile Lys Glu His Gly Ile P. la Gly Pro P. la Glu Gln Val Thr Val P. la 
610 615 620 
Cys Glu P. la Gly Trp Thr Leu Thr Gly Cys P. sn Val Leu Pro Gly P. la 
625 630 635 640 
US 2010/0166768 A1 
241 
JU1. 1, 2010 
-continued 
Ser Leu Pro Leu Gly P. la Tyr Ser Val P. ep P. en Val Cye Val P. la Prg 
648 680 688 
Ile P. rg P. ep P. la Gly P. rg P. la P. ep P. rg Thr Ser Glu Glu P. la Thr Val 
660 668 670 
P. la P. la P. la Ile Cye Cye P. rg Ser P. rg Pro Ser P. la Lye P. la Ser Trp 
678 680 688 
Val Hie Gln 
690 
We claim: 
1. An antibody or antigen-binding fragment of an antibody 
that specifically binds hPCSK9 and is characterized by at 
least one of: 
(I) capable of reducing serum total cholesterol at least 
about 25-35% and sustaining the reduction over at least 
a 24 day period relative to a predose level; 
(ii) capable of reducing serum LDL cholesterol at least 
about 65-80% and sustaining the reduction over at least 
a 24 day period relative to a predose level; 
(iii) capable of reducing serum LDL cholesterol at least 
about 40-70% and sustaining the reduction over at least 
a 60 or 90 day period relative to a predose level; 
(iv) capable of reducing serum triglyceride at least about 
25-40% relative to predose level; 
(v) does not reduce serum HDL cholesterol or reduces 
serum HDL cholesterol no more than 5% relative to 
predose level. 
2. The antibody or antigen-binding fragment of claim 1, 
characterized as binding an epitope comprising amino acid 
residue 238 or 366 of hPCSK9 (SEQ ID NO:755). 
3. The antibody or antigen-binding fragment of claim 1, 
wherein the binding of the antibody or fragment thereof to a 
variant PCSK9 protein is less than 50% of the binding 
between the antibody or fragment thereof and the PCSK9 
protein of SEQ ID NO:755. 
4. The antibody or antigen-binding fragment of claim 3, 
wherein the variant PCSK9 protein comprises at least one 
mutation of a residue at a position selected from the group 
consisting of S153, E159, D238, and D343. 
5. The antibody or antigen-binding fragment of claim 3, 
wherein the variant PCSK9 protein comprises at least one 
mutation of a residue at a position selected from the group 
consisting of S147. E366 and V380. 
6. An antibody or antigen-binding fragment of an antibody 
that specifically binds hPCSK9, characterized as binding an 
epitope comprising amino acid residue 238 or 366 of 
hPCSK9 (SEQ ID NO:755), wherein the binding of the anti- 
body or fragment thereof to a variant PCSK9 protein is less 
than 50% of the binding between the antibody or fragment 
thereof and the PCSK9 protein of SEQ ID NO:755. 
7. An antibody or antigen-binding fragment of an antibody 
that specifically binds hPCSK9, comprising 
a heavy chain CDR3 (HCDR3) domain selected from the 
group consisting of SEQ ID NO:8, 32, 56, 80, 104, 128, 
152, 176, 200, 224, 248, 272, 296, 320, 344, 368, 392, 
416, 440, 464, 488, 512, 536, 560, 584, 608, 632, 656, 
680, 704 and 728; and 
a light chain CDR3 (LCDR3) domain selected from the 
group consisting of SEQ ID NO:16, 40, 64, 88, 112, 136, 
160, 184, 208, 232, 256, 280, 304, 328, 352, 376, 400, 
424, 448, 472, 496, 520, 544, 568, 592, 616, 639, 664, 
688, 712 and 736. 
S. The antibody or antigen-binding fragment of an anti- 
body of claim 7, further comprising 
a heavy chain CDRI (HCDRI) domain selected from the 
group consisting of SEQ ID NO:4, 28, 52, 76, 100, 124, 
148, 172, 196, 220, 244, 268, 292, 316, 340, 364, 388, 
412, 436, 460, 484, 508, 532, 556, 580, 604, 628, 652, 
676, 7000 and 724; 
a heavy chain CDR2 (HCDR2) domain selected from the 
group consisting of SEQ ID NO:6, 30, 54, 78, 102, 126, 
150, 174, 198, 222, 246, 270, 294, 318, 342, 366, 390, 
414, 438, 462, 486, 510, 534, 558, 582, 606, 630, 654, 
678, 702 and 726; 
a light chain CDRI (LCDRI) domain selected from the 
group consisting of SEQ ID NO: 12, 36, 60, 84, 108, 132, 
156, 180, 204, 228, 252, 276, 300, 324, 348, 372, 396, 
420, 444, 468, 492, 516, 540, 564, 588, 612, 636, 660, 
684, 708 and 732; and 
a light chain CDR2 (LCDR2) domain selected from the 
group consisting of SEQ ID NO: 14, 38, 62, 86, 110, 134, 
158, 182, 206, 230, 254, 278, 302, 326, 350, 374, 398, 
422, 446, 470, 494, 518, 542, 566, 590, 614, 638, 662, 
686, 710 and 734. 
9. The antibody or antigen-binding fragment of an anti- 
body of claim S, wherein the light and heavy chain CDR 
sequences are selected from the group consisting of 
SEQ ID NO:52, 54, 56, 60, 62, 64; 
SEQ ID NO:76, 78, 80, 84, 86, 88; 
SEQ ID NO:124, 126, 128, 132, 134, 136; 
SEQ ID NO:220, 222, 224, 228, 230, 232; 
SEQ ID NO:244, 246, 248, 252, 254, 256; Bnd 
SEQ ID NO:316, 318, 320, 324, 326, 328. 
10. An antibody or antigen-binding fragment of an anti- 
body which binds the same epitope as the antibody or antigen- 
binding fragment of the antibody of claim 9. 
11. An antibody or antigen-binding fragment of an anti- 
body which competes for binding to hPCSK9 with the anti- 
body or antigen-binding fragment of the antibody of claim 9. 
12. An antibody or antigen-binding fragment of an anti- 
body that specifically binds hPCSK9, comprising a heavy 
chain variable region (HCVR) selected from the group con- 
sisting of 66, 90, 138 and 218. 
13. An antibody or antigen-binding fragment of an anti- 
body that specifically binds hPCSK9, comprising a light 
chain variable region (LCVR) selected from the group con- 
sisting of SEQ ID NO:68, 92, 140 and 226. 
US 2010/0166768 A1 
242 
JU1. 1, 2010 
14. An antibody or antigen-binding fragment of an anti- 
body that specifically binds hPCSK9, comprising heavy and 
light chain CDR sequences from HCVR and LCVR sequence 
pairs 90/92 or 218/226. 
15. A human anti-PCSK9 antibody or antigen-binding 
fragment thereof, comprising a heavy chain variable region 
(HCVR) encoded by nucleotide sequence segments derived 
from V~, Demand J~germline gene segments, and a light chain 
variable region (LCVR) encoded by nucleotide sequence seg- 
ments derived from V~ and J~ germline gene segments, 
wherein the germline sequences are: 
a) V~ gene 3-23. D~ gene 7-27. J~ gene 2. V~ gene 4-1. J~ 
gene 2, or 
b) V~ gene 3-7. D~ gene 2-8, J~ gene 6. V~ gene 2-28. J~ 
gene 4. 
16. An isolated nucleic acid molecule encoding the anti- 
body or antigen-binding fragment of an antibody of claim 1. 
17. An expression vector comprising the nucleic acid mol- 
ecule of claim 16. 
1S. A method of producing an anti-human PCSK9 anti- 
body or antigen-binding fragment of an antibody comprising 
the steps of introducing the expression vector of claim 17 into 
an isolated host cell, growing the cell under conditions per- 
mitting production of the antibody or fragment thereof, and 
recovering the antibody or fragment so produced. 
19. An antibody or antigen-binding fragment of an anti- 
body that specifically binds human PCSK9, comprising a 
HCDR3 and a LCDR3, wherein the HCDR3 comprises an 
amino acid sequence of the formula X' X X X 
X X X X X X' X" X' X' X' 
X' X' X' X' X' X (SEQ ID NO747) 
whereinXisAla, X isArgorLys, X isAsp, X is SerorIle, 
X isAsnorVal, X is Leu or Trp, X is Gly or Met, X isAsn 
orVal, X is Pheor Tyr, X' isAsp, X" is Leuor Met, X' is 
Asp or absent. X' is Tyr or absent, X' is Tyr or absent, X' 
is Tyrorabsent, X' is Tyrorabsent, X' is Glyorabsent, X' 
Met or absent, X' isAsp or absent, andX is Val orabsent; 
and 
the LCDR3 comprises an amino acid sequence of the form 
X' X X X X X X -X X (SEQ ID 
NO:750) wherein X' is Gln or Met, X is Gln, X is Tyr 
or Thr, X is Tyr or Leu. X is Thr or Gln, X is Thr, X 
is Pro. X is Tyror Leu, andX is Thr. 
20. The antibody or antigen-binding fragment of claim 19, 
further comprising a HCDRI, HCDR2, LCDRI and LCDR2, 
wherein 
the HCDRI comprises an amino acid sequence of the for- 
mula X' X X X X X X-X (SEQ ID 
NO:745), whereinX' is Gly, X is Phe, X is Thr. X is 
Phe, X is SerorAsn, X is SerorAsn, X is Tyror His, 
and X isAla or Trp; 
the HCDR2 comprises an amino acid sequence of the for- 
mula X' X X X X X X-X (SEQ ID 
NO:746), wherein X' is Ile. X is Ser orAsn, X is Gly or 
Gln. X isAsp or Ser, X is Gly. X is Ser or Gly, X is 
ThrorGlu, and X is ThrorLys; 
the LCDRI comprises an amino acid sequence of the for- 
mula X' X X X X X X -X X 
X' X" X' (SEQ ID NO:748) wherein X' is Gln. 
X is Ser. X isValorLeu, X isLeu. X isHisor Tyr, X 
isArgorSer. X isSerorAsn, X isAsnorGly. X isAsn, 
X' isArg orAsn, X" is Asn or Tyr, and X' is Phe or 
absent; 
the LCDR2 comprises an amino acid sequence of the for- 
mulaX' X X (SEQIDNO:749) whereinX'is Trp 
or Leu, X is Ala or Gly, and X is Ser. 
21. A pharmaceutical composition comprising the human 
antibody or fragment thereof of claim 1 and a pharmaceuti- 
cally acceptable carrier. 
22. The pharmaceutical composition of claim 21, further 
comprising a second therapeutic agent, wherein the second 
therapeutic agent is selected from an inhibitor of 3-hydroxy- 
3-methylglutaryl (HMG)-coenzyme A (CoA) reductase, an 
inhibitor of cholesterol uptake and or bile acid re-absorption, 
an agent which increases lipoprotein catabolism, or an acti- 
vator of LXR transcription factor. 
23. The pharmaceutical composition of claim 22, wherein 
the second therapeutic agent is a statin. 
24. A method for treating a disease or condition which is 
ameliorated, improved, inhibited or prevented with a PCSK9 
antagonist, comprising administering a therapeutic amount o f 
the pharmaceutical composition of claim 21 to a subject in 
need thereof. 
25. The method o f claim 24, wherein the subj ect is a human 
subject suffering from hypercholesterolemia, hyperlipi- 
demia, indicated for LDL apheresis, identified as heterozy- 
gous for Familial Hypercholesterolemia, statin intolerant. 
statin uncontrolled, at risk for developing hypercholester- 
olemia, dyslipidemia, cholestatic liver disease, nephrotic syn- 
drome, hypothyroidism, obesity, atherosclerosis and cardio- 
vascular diseases. 

